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The purpose of this study is to improve the solubility, dissolution rate and permeability 
of poorly water-soluble drugs by investigating the dissolution and permeation properties 
of flufenamic acid cocrystals in the presence of polymers. This study was separated into 
four tasks: 
(1) Formation of pharmaceutical cocrystals: 
Two pharmaceutical cocrystals of poorly water soluble active pharmaceutical ingredient 
(API) flufenamic acid (FFA) were synthesized, including 1:1 flufenamic 
acid-nicotinamide cocrystal (FFA-NIC CO) and 1:1 flufenamic acid-theophylline 
cocrystal (FFA-TP CO). The results of infrared spectroscopy (IR), differential scanner 
calorimetry (DSC) and x-ray powder diffraction (XRPD) confirmed the formation of 
cocrystals.  
(2) Effect of polymers on cocrystals supersaturated solution: 
The influence of three polymers (polyethylene glycol (PEG), polyvinylpyrrolidone 
(PVP), and a copolymer of N-vinly-2-pyrrolidone (60%) and vinyl acetate (40%) 
(PVP-VA)) on FFA crystallization from FFA and FFA cocrystals supersaturated 
solutions was studied by measuring the nucleation induction time and desupersaturation 
rates of the supersaturated solutions in the absence or presence of crystals seeds. It was 
found that the competition of intermolecular hydrogen bonding among drug/coformer, 
drug/polymer and coformer/polymer was the key factor for maintaining the 
supersaturated state in cocrystal solution.  
(3) Study the mechanism of cocrystals dissolution: 
The dissolution mechanism of cocrystals in absence or presence of polymers was 
investigated by carrying out different dissolution experiments of both single and 
powdered cocrystals at multiple length scales, including molecular level, macroscopic 
level and bulk experiment. According to the results, FFA-NIC CO and FFA-TP CO 
have different dissolution mechanisms. The addition of polymers can alter the 





(4) Investigation of permeation property of cocrystals: 
The key processes (kinetics of FFA cocrystals supersaturation and subsequent drug 
permeation) during cocrystals dissolution in the absence or presence of different 
concentration of polymers (PVP and PVP-VA) were systematically evaluated by using 
dissolution/permeation system in a side-by-side cell. Furthermore, the insight 
mechanism of the supersaturated solution and permeation behavior was explored by 1H 
NMR. We found that the permeation property of cocrystals is highly depended on the 
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Chapter 1 Introduction 
1.1 Research Background 
In systemic circulation, the desired (anticipated) pharmacological response could be 
achieved when the desired drug concentration reached [1]. The reality in pharmaceutical 
industries is that 99% Active Pharmaceutical Ingredients (API) failed to develop as a 
commercial drugs because of their poor water solubility [2], which limit the applications 
of the highly potent drugs [3, 4]. Hence, it is essential to improve the solubility of the 
poorly water-soluble drugs to maximize their therapeutic values. Many techniques have 
emerged to enhance the solubility and dissolution rate of poorly water-soluble drugs, 
such as particle size reduction, solid dispersion, hot-melt extrusion and nanomaterials 
[1]. These approaches have shown the benefits on increasing solubility and dissolution 
rate of APIs [5-8].  
Recently, cocrystals have attracted numerous attention due to its ability to improve the 
bioavailability of poorly water-soluble APIs by combining them with coformers at a 
specific stoichiometric ratio [2, 9, 10]. Cocrystals are physicochemically stable at room 
temperature and have been proved to be highly potential methods to modulate the 
physicochemical properties of APIs for overcoming the insufficient bioavailability of 
drugs [2, 11-15]. 
For cocrystal formulations, the ability to generate and maintain the supersaturated state 
in solution is the key factor of oral drug delivery [16, 17]. Nevertheless, crystallization 
of the stable form from the supersaturation would simultaneously occur during 
cocrystals dissolution, which would diminish the dissolution and solubility advantages 
of cocrystals. Especially, the surface of dissolving cocrystal could be covered when the 
crystallization happens on the cocrystal surface [18-20]. This problem of crystallization 
also causes no effective permeation of drugs [16]. Based on the literatures, the addition 
of crystallization inhibitor (e.g. polymers) in a solubility-enable formulation can 
maintain the supersaturation state by preventing the crystallization, subsequently for 
adequate drugs absorption. The reported polymers include PVP, PVP-VA, HPMC and 




polymer can maintain the supersaturated solution of carbamazepine-cinnamic acid 
cocrystals [10]. The effect of the polymeric crystallization inhibitors on supersaturated 
state in other systems have been extensively studied, in particular amorphous solid 
dispersions [23, 24]. However, such studies are still rare for cocrystal based 
formulations. Therefore, a full understanding of the polymers influence on cocrystal 
products is significant. Firstly, the effect of polymers on the key processes (kinetics of 
nucleation and crystal growth) of crystallization in supersaturated solution needs to be 
considered. Furthermore, the additional polymers in solution not only impact the 
crystallization process of APIs but also influence the dissolution behaviors of cocrystals 
during dissolution. Hence, revealing the dissolution mechanism of cocrystal in solution 
in the absence and presence of pre-dissolved polymers is essential. The therapeutic 
effect of oral administration drug products is strongly depended on both dissolution and 
permeation steps. If the drug molecules in the gastrointestinal (GI) tract cannot across 
the, the drug would fail to be absorbed by the body. Furthermore, based on solid 
dispersion systems, the introduced polymers would influence the supersaturated state 
and reduce or enhance the capability of drug molecules to permeate across the 
membrane [25]. Other work also showed that polymers can reduce the permeability of 
drug, such as cyclodextrins, micellar solubilization [26, 27], because the drug 
encapsulated in the solubilizing agent reduces free fraction of the drug available for 
membrane permeation. For a cocrystal formulation, it has been reported that cocrystal 
can alter the permeability property of API due to the API-coformer interaction [28-30]. 
Thus, to successfully develop a cocrystal formulation, the underlying relationship 
between the supersaturated solution and drug permeation in the presence of polymers 
during cocrystals dissolution need to be discreetly considered. 
1.2. Research Aim and Objectives 
The aim of this study is to improve the water solubility of flufenamic acid by using 
cocrystal method and investigate the dissolution and permeation properties of 
corresponding cocrystals in the presence of polymers. The properties of cocrystals can 
be disclosed by studying the crystallization process of cocrystal supersaturated solution, 
investigating the dissolution mechanism of cocrystals and examining the permeation 




Objective 1: review the pharmaceutical cocrystals definition, synthesis methods, 
characterization techniques, advantages and disadvantages of cocrystals and find out 
methods of avoiding cocrystals drawbacks. 
Objective 2: synthesize two cocrystals of 1:1 flufenamic acid-nicotinamide cocrystal 
(FFA-NIC CO) and 1:1 flufenamic acid-theophylline cocrystal (FFA-TP CO) in both 
powdered and single crystal form and characterize these two cocrystals by using FTIR, 
Raman, DSC and XRPD.   
Objective 3: investigate the influence of polymers on supersaturated FFA cocrystals 
solutions by studying the crystallization kinetics of both nucleation and crystal growth 
of supersaturated solution in the absence or presence of polymers.  
Objective 4: understand the dissolution mechanisms of cocrystals in solution in the 
absence and presence of pre-dissolved polymers by examining dissolution properties of 
cocrystal in different dissolution experiments of both single and powdered cocrystals at 
multiple length scales, including the molecular level, macroscopic level and bulk 
experiments in both sink and nonsink condition. 
Objective 5: study the polymers influence on the kinetics of cocrystals supersaturation 
and subsequent drug permeation during dissolution by using dissolution/permeation 
system in side-by-side cell and explore the insight mechanism of the supersaturated 
solution and permeation behavior by applying one dimensional proton nuclear magnetic 
resonance (1H NMR) to study the interaction between API, coformers and polymers in 
solution. 
 1.3 Thesis Structure 
This thesis includes 8 chapters: 





Chapter 2: Literature reviews on pharmaceutical cocrystals, additives effect on 
recrystallization, dissolution and permeation properties of drugs. Brief introduction 
about FFA cocrystals, pharmaceutical coformers and polymers used in this study. 
Chapter 3: Description of the materials, analytical techniques, experimental methods, 
preparation methods and calculation equations that used in this research. 
Comprehensive introduction about analytical methods including principles, operation 
procedures and parameters setting.  
Chapter 4: Samples characterization of FFA I, NIC, TP, FFA-NIC CO and FFA-TP CO 
by using DSC, ATR and XRPD. The molecular structures of FFA-NIC CO and FFA-TP 
CO were displayed in this chapter.  
Chapter 5: The influence of polymers of polyethylene glycol (PEG), 
polyvinylpyrrolidone (PVP) and Copolymer of N-Vinyl-2-Pyrrolidone (60%) and Vinyl 
Acetate (40%) (PVP-VA) on recrystallization from cocrystals supersaturated solution 
was discussed in this chapter. The nucleation process and crystal growth of FFA stable 
form in FFA and FFA cocrystals supersaturated solution were fully examined. The 
molecular interactions among FFA, coformers and polymers were also investigated by 
applying liquid ATR-FTIR. 
Chapter 6: The dissolution mechanisms of FFA cocrystals in the presence of PEG, PVP 
and PVP-VA were disclosed in multiple length scales. At molecular level, atomic force 
microscopy (AFM) was used to detect the etching pattern of crystal surface to find out 
how polymers interact with crystal faces during dissolution. At macroscopic level, 
optical light microscopy (OLM) was employed to monitor the dissolution rate of the 
specific faces of single crystals. In bulk experiments, dissolution tests of pure FFA and 
FFA cocrystals were conducted in both sink and non-sink condition.  
Chapter 7: The permeation property of FFA cocrystals in the absence or presence of 
different concentration of polymers (PVP and PVP-VA) was investigated using 
dissolution and permeation system in side-by-side cell. The insight mechanism between 








Chapter 2 Literature Reviews 
2.1 Chapter Review 
Firstly, a brief introduction of current approaches for improving the bioavailability of 
poorly water-soluble drugs was given. Then, a comprehensive introduction of 
pharmaceutical cocrystals including cocrystals definition, cocrystals design strategies, 
cocrystals screening methods and physicochemical properties of cocrystals were 
presented. After that, detailed reviews about the problems of cocrystals and the 
additives effect on crystallization of drug stable form, dissolution behavior and 
permeation property of drugs were described. Finally, the basic information about 
materials used in this study was introduced, including FFA, FFA cocrystals, NIC, TP, 
PEG, PVP and PVP-VA.  
2.2 Biopharmaceutics Classification System (BCS) 
Biopharmaceutics Classification System (BCS) (Figure 2. 1) is a scientific approach to 
classify drug substances into different classes according to drug’s aqueous solubility 
and intestinal permeability [31]. Based on BCS system, drugs are classified into four 
classes: Class I: high solubility-high permeability; Class II: low solubility-high 
permeability; Class III: high solubility-low permeability; Class IV: low solubility-low 
permeability [32]. Most of newly developed APIs belong to BCS class II with the 
properties of low solubility but high permeability [33]. The low water solubility of APIs 
causes low drug dissolution and oral absorption. Therefore, it is important to improve 
the solubility of Class II drugs to achieve the drug therapeutic efficacy. Various 
techniques have been successfully used to conquer the solubility problem, such as 





Figure 2. 1 Biopharmaceutics Classification System (BCS) 
2.3 Enabling Formulations for Poorly Water-Soluble Drug 
Generally, improving the performance of dissolution and solubility of Class II drug can 
be obtained by three techniques including physical modifications (such as particle size 
reduction like micronization, crystal engineering like pharmaceutical cocrystal and 
amorphous like solid dispersion), chemical modifications (such as salt formation, pH 
modification) and miscellaneous methods (such as co-solvency and surfactant 
solubilization) [1]. 
2.3.1 Micronization 
Micronization is a conventional approach of particle size reduction, which can rise the 
dissolution rate of API by increasing the surface area, but cannot increase the 
equilibrium solubility of API [37]. Micronization of a drug can be achieved by 
employing jet mill, rotor stator colloid mills et al. Micronization has been widely used 
to improve the bioavailability of poorly water-soluble drugs, such as griseofulvin 
[38-43], progesterone [44-47], danazol [48] and digoxin [49]. For example, micronized 
danazol showed around 16-fold (5.1% to 82.3%) increasing bioavailability. The 
problems of micronized particles are the reduced wettability and their handling [50]. 
2.3.2 Salt Formation 
Salt formation has been commonly used to enhance the properties of solubility and 





the difference of pKa between base and acid is greater than 3 [52].In early 1950s, salt 
formation had been employed to improve the dissolution rate of several weakly acidic 
compounds [53, 54]. Different absorption rates and extents of novobiocin [55] and 
tolbutamide [56] were found with a combination of sodium salt formation. An enhanced 
dissolution rate and oral bioavailability were observed for celecoxib-sodium salt with 
respect to pure celecoxib [57]. 
2.3.3 Solid Dispersion 
Solid dispersion is an effective pharmaceutical approach for increasing the solubility, 
dissolution and bioavailability of drugs by loading the hydrophobic drug into a 
hydrophilic polymer matrix. Enormous studies have shown that solid dispersion can 
enhance the drug release rate [58-62]. Chiou and Riegelman found that insoluble 
griseofulvin would be almost completely absorbed by man and dog by using solid 
dispersion [63]. 
2.3.4 Cyclodextrin Complexation 
Cyclodextrins (CD) are oligosaccharides, formed as a hydrophobic cavity interior with a 
hydrophilic exterior surface [64]. Cyclodextrins have shown its potential ability to 
increase the oral absorption of poorly water-soluble API by forming inclusion 
complexes [65-68]. Examples of such formation include acetazolamide, [69] 
carbamazepine [70], cyclosporine [71], finasteride [72], oxazepam [73] and propofol 
[74]. Tonnesen et al used cyclodextrin complex to increase the solubility of curcumin 
by a factor of at least 104 under pH 5 buffer [75]. The solubility of camptothecin 
was171-fold higher compared with crystalline camptothecin by applying cyclodextrin 
method in 0.02M HCl at 25°C [36]. Currently, around 35 commercial formulations of 
cyclodextrin have appeared into the market [76], including pansporin T, opalmon, 
meiact, transillium and more [76]. 
2.3.5 Pharmaceutical Cocrystals 
Historically, the first reported cocrystal was described as a “complex” or “compound” 
in 1844 [77]. Quinhydrone is the earliest reported cocrystal, a 1:1 molar ratio compound 




To date, there is no universal and uniform definition of cocrystal based on the scientific 
literatures [79]. Most of the literatures defined cocrystals as crystals, which composes at 
least two components. A restrictive definition of cocrystals was introduced by Michael J. 
Zaworotko group [80], “a cocrystal is a multicomponent crystalline material at a 
defined stoichiometric ratio, which is solid under ambient temperature and all 
components are discrete neutral molecules”. The difference between a salt and a 
cocrystal is that there is proton transfer during salt formation but no proton transfer 
within a cocrystal formation. Compared with salts formation, there are at least two 
inherent benefit of cocrystal method: (1) all APIs including weakly ionizable and 
non-ionizable molecules can form cocrystal. But for salt, only strong ionizable 
molecules can form salt; (2) Due to toxicity issues, only about 12 basic or acidic 
counter-molecules can be used for salt screening but abundant potential counterions are 
explored in cocrystal formation [81]. 
For pharmaceutical cocrystals, one of the components is drug molecule. The early 
reported pharmaceutical cocrystals were sulphonamides cocrystals [82]. In the past 30 
years, pharmaceutical cocrystals have been effectively applied to improve the 
physicochemical property of poorly water soluble drugs, such as lamivudine [83], AMG 
517 [84], gabapentin [85], piroxicam [86], celecoxib [20] and norfloxacin [87]. 
Currently, 3 pharmaceutical cocrystals have been approved, Entresto® 
(sacubitril-valsartan), • Lexapro® (escitalopram oxalate) and Depakote® (valproate 
sodium cocrystal with valproic acid) [88].  
2.3.5.1 Cocrystals Design Strategies 
Cocrystal design and formation is based on the fundamental principle of crystal 
engineering, referring to construction or engineering of a new solid crystalline material 
with the desirable property of designed molecule based on the intermolecular 
interactions and non-covalent interactions (e.g. hydrogen bonding) between molecules, 
which control the supramolecular assemblies and molecular recognitions [89, 90]. The 
bioavailability and chemical stability of cocrystals are depended on the non-covalent 
interactions in the crystal structures, like hydrogen bonding, van der Waals interactions, 
π–π stacking and electrostatic interactions [90]. Among these mentioned non-covalent 




synthesis of cocrystal system due to its directionality and strength [2, 91, 92]. Three 
hydrogen bonding rules were introduced by Etter and Donohue [93-95]. 
(1) All good hydrogen bonding acceptors and donors can be used in hydrogen bonding; 
(2) Intramolecular hydrogen bonds are easier to form within six-membered-ring than 
intermolecular hydrogen bonds;  
(3) The best hydrogen bonding donors and acceptors still can form intermolecular 
hydrogen bonds with others after the formation of intramolecular hydrogen bonds. 
Based on these rules, synthon formation and hydrogen bonding between the functional 
groups can be predicted and cocrystal strategies can be proposed [96-98].Figure 2. 2 
shows the common hydrogen bonds used in crystals. 
 
Figure 2. 2 Common synthon used in crystals 
In order to get an ideal cocrystal, it is important to have a design strategy of cocrystal 
formation. There are several steps to design a pharmaceutical cocrystal [99], Figure 2. 3 
represents the diagram of stages for cocrystal design. 
 


















2.3.5.2 Coformer Selection 
For cocrystal formation, the first step is the coformer selection. In this process, the 
formation of supramolecular synthons or non-covalent bonds between molecules is a 
crucial parameter [100]. Before starting coformer selection, it is vital to understand 
structure and functional groups of APIs and determine which functional groups can 
form stable intermolecular interaction with the coformer. Then computational methods 
such as Cambridge Structural Database (CSD) can be applied to identify a stable and 
common supramolecular synthon for the APIs. Isostar search allows to discover the 
common arrangement of hydrogen bonding within crystals [101]. Coformers selection 
can base on the following standards [101]: 
(1) All coformers are commercial drug products and pharmaceutically acceptable; 
(2) All coformers are non-toxic; 
2.3.5.3 Cocrystal Screening Methodology 
At present, the main techniques that have been used for cocrystal screening are 
solution-based methods like antisolvent addition, solvent evaporation and cooling 
crystallization and solid-based methods like crystallization form melting, solvent drop 
grinding and neat grinding [102, 103]. Compared with solid-based methods, 
solution-based methods are more common to prepare cocrystals [104] and majority of 
the single cocrystals can only be prepared by solution-based method. 
2.3.5.3.1 Solution-Based Method  
In practice, cocrystal screening using solution-based method needs to follow one of 
following two strategies [105]: (1) application of solvents or co-solvents in which all 
starting components have similar solubility and the cocrystals congruently saturates; (2) 
reaching the cocrystal stability region in noncongruently saturating solvents by applying 
non-equivalent reactant concentration. For designing a successful cocrystal, it is useful 
to construct ternary phase diagrams to describe the three-phase behaviors of reactants, 
solvent and cocrystal, and predict the pathway of cocrystal formation [13]. Particularly, 




because differences would change the location of thermodynamically stable cocrystal 
phase regions. Two possible phase diagrams of cocrystal are illustrated in Figure 2. 4. In 
Figure 2. 4(a) the solubility of A and B is similar in solvent and solution crystallization 
with equimolar reactants results in 1:1 AB cocrystal from solvent evaporation. From 
Figure 2. 4(b) (components with non-equivalent solubility in solvent), cocrystal from 
solution by solvent evaporation may lead pure starting crystalline materials, or mixture 
of cocrystals and single component crystal. This situation can be developed by reaction 
crystallization, adding B into a component A saturated or nearly saturated solution 
cause a AB cocrystal supersaturated solution, which crystallization pathway would pass 
either through region 5 or 4. Therefore, a rational design of cocrystal method can be 
selected by using ternary phase diagram. 
Compared with other cocrystallization methods, there are several factors for popularity 
of solution-based method, including high yield, high purity, more easily evaluated 
surface features and crystal habit single crystal [106]. 
  
(a) (b) 
Figure 2. 4 Isothermal ternary phase diagram of cocrystal: (a) similar solubility of API and coformer in 
solvent; (b) different solubility of API and coformer in solvent; 1: A and solvent; 2: A and cocrystal; 3: 
cocrystal; 4: mixture of B and cocrystal; 5: B and solvent and 6: solution [13]. 
2.3.5.3.2 Solid-Based Method 
Solid-based method is alternative to solution-based method when the cocrystal 
components solubility in a given solvent is not concerned [106-109], which provided an 
significantly more efficient method for cocrystals screening and synthesis [110]. To 
date, a lot of cocrystals have been successfully formed by solid-based method, as listed 








Crystallization from melting using hot-melting microscopy is a thermal method for 
cocrystal screening by recognizing cocrystal phases then to determine the binary phase 
diagrams (composition–temperature plots) of molecular complexes [111]. In thermal 
method (Figure 2. 5): (1) Both higher melting point cocrystal component A and low 
melting point cocrystal component B melt; (2) Component A recrystallizes before 
component B encounters component A; (3) Liquid component B contacts and 
solubilizes a part of component A. Furthermore, all components solidify and form a 
mixing zone [112] where cocrystal can be possibly formed. 
Solid-state grinding can trigger chemical change (mechanochemical reaction) resulting 
in cocrystal formation [106]. Solid-state grinding method comprises neat and 
liquid-assisted grinding. In neat grinding method, the stoichiometric cocrystals 
components are mixed by using mortar and pestle or ball mill. Whereas, for 
liquid-assisted grinding, a small amount of solvent is added to the cocrystal components. 
Etter and coworkers suggested that there were two determined factors related to 
cocrystal formation by using solid-based grinding method, including (1) at least one of 
the cocrystal components have volatile property at the operating temperature of grinding 
process; (2) The intermolecular hydrogen bonding within cocrystals should be stronger 
than the hydrogen bonding with the starting materials [113]. 
 
Figure 2. 5 Diagram of crystallization from melting [112] 
Table 2. 1 Example of cocrystals synthesis by solid-state grinding 
Solid-based method Cocrystals Reference 
Neat grinding 4-aminobenzonic aicd-3,5-dinitrobenzoic acid cocrystal; 
Anhydrous theophylline-citric acid cocrystal, 













hydrate-citric acid cocrystal, 
Liquid-assisted grinding theophylline anhydrate-citric acid cocrystal, caffeine 
hydrate-citric acid cocrystal, adefovir dipovoxil-glutaric 
acid cocrystal 
[114, 115] 
Crystallization from melting Nicotinamide-ibuprofen cocrystal; salicylic 
acid-nicotinamide cocrystal, flurbiprofen-nicotinamide 




2.3.5.4 Cocrystal Characterization Techiniques 
It is important to understand the structural information and physiochemical properties of 
cocrystals. Various analytical apparatuses have been used to characterize cocrystals. For 
identifying the structure of cocrystals, analytical techniques like infrared spectroscopy 
(IR), Raman spectroscopy, single crystal X-ray diffraction (SXRD), X-ray powder 
diffraction (XRPD), and solid state nuclear magnetic resonance spectroscopy (SSNMR) 
has been broadly applied. For determining the thermal properties of cocrystal, 
differential scanning calorimetry (DSC) have been widely employed.  
X-ray diffraction is a useful technique to determine the crystal structure of the 
molecules in three dimensions and has been used to study the structure data from the 
twentieth century [117]. The electron density and periodic assembly of molecules or 
atoms of a crystal can be rebuilt according to the X-ray diffraction data. The data 
obtained from single crystal X-ray Diffraction (SXRD) can expose the regularly 
repeating arrangement of molecules and the packing pattern of the single crystal. SXRD 
can promise to provide very accurate parameters of cell dimensions if there are less than 
100 atoms in the asymmetric unit in the structures [118]. However, it is difficult to 
prepare a single crystal with sufficient size for SXRD testing. Therefore, X-ray powder 
diffraction (XRPD) has become an essential equipment for studying the structure of 
cocrystal. However, XRPD is not capable of differentiating between hydrates, 




Raman Spectroscopy is an effective technique for distinguishing polymorphs of APIs 
and isostructural phases based on bond vibrational energies of crystal structure [119]. 
Furthermore, the testing of Raman is rapid and non-destructive.  
IR spectroscopy is a common tool to confirm the cocrystal formation, especially when a 
carboxylic acid is involved in hydrogen bonding formation between an API and 
coformer because of the strong stretching at C=O band (~1700cm-1), C-O (~1200cm-1) 
and O-H (~3000cm-1) [120]. 
SSNMR is a helpful technique to provide detailed information about the cocrystal 
structure, especially for cocrystals synthesized by grinding methods. Hydrogen bonding, 
spin diffusion and intermolecular contacts can be studied by application of 1H-1H, 
1H-13C and 19F-13C experiments by SSNMR [121]. 
DSC is a particularly convenient method to characterize thermal properties of cocrystals, 
including melting point data, enthalpy of melting, heat of fusion and transition 
temperature [122], which can be compared with individual cocrystal components to 
confirm the formation of cocrystal. The only drawback of DSC is that the low heating 
rate would cause overlap of the melting event of metastable form and recrystallization 
of stable form in DSC graph [123].  
2.3.5.5 Physicochemical Properties of Cocrystals 
The key benefit of cocrystals is the ability to change physicochemical properties of 
APIs, for improving the solubility, bioavailability, dissolution rate and melting point. 
These properties would directly or indirectly impact the stability and efficacy of the API 
dosage form.  
Melting point 
Meting point is the temperature where the solid phase change to the liquid phase, 
depending on the crystal structure. Generally, cocrystals have a distinct melting point as 
compared to individual components because of the different intermolecular interactions, 
crystal structure and composition. Analysis of 50 cocrystals of different API shows that 
melting point of cocrystal can be higher, lower or between that of cocrystal formers 




the solubility behaviors of cocrystal, which is more related with solute-solvent 
interaction [124]. 
Stability  
Stability is a vital factor to evaluate the properties of a new chemical, which depend on 
the molecular arrangement in crystal lattice. In terms of hygroscopicity, cocrystals have 
shown a stable property under typical manufacturing and storage state and an improved 
stability compared with the individual components [11, 125, 126]. In the attempt to 
improve the physical stability of theophylline, cocrystallization of theophylline was 
investigated. Over 7-week study at 98% RH (relative humidity), cocrystal of 
theophylline-oxalic acid was stable while theophylline anhydrate was transferred to 
theophylline monohydrate [127]. Indomethacin-saccharin cocrystal sorbed negligible 
water (<0.05%), less than γ-form indomethacin at 95% RH at 25°C [128]. In order to 
evaluated the chemical stability of 2-[4-(4-chloro-2-fluorophenoxy)phenyl] 
pyrimidine-4-carboxamide cocrystal (glutaric acid as coformer), the samples was putted 
in a glass bottles at 40°C/75% RH and 60°C for 2 months. Cocrystal samples were 
measured by DSC, XRPD and HPLC after stored. The results of DS, XRPD and HPLC 
did not find out any know degradants during storage [11]. For analyzing the 
photochemical stability of crystalline carbamazepine (III), carbamazepine-saccharin 
cocrystal and carbamazepine-nicotinamide cocrystal, the samples were exposed at 98% 
RH at room temperature under fluorescent/ambient light up to 9 months. After 9 months, 
the samples were detected by HPLC, DSC and FTIR. The crystalline carbamazepine (III) 
transferred to carbamazepine (dihydrate) after absorbing moisture and slowly turned to 
yellow-orange after 4 months storage due to photochemical instability. Conversely, the 
carbamazepine cocrystals did not show degradation after 9 months [125].    
Solubility  
An improved solubility of poorly water-soluble drug is one of the two main reasons to 
study cocrystals. The potential application of cocrystal as a solubility improvement 
approach was realized since early 1900s and number of pharmaceutical application was 
reported in the late 20th century [77]. For instance, Kranz et al. disclosed that sodium 
theophyllinate-glycine cocrystal could enhance the solubility of theophylline in 1947 




solubility relative to sulfa drugs [130]. Additionally, other Japanese group revealed that 
glucuronic acid-caffeine cocrystal and glucuronic acid-theobromine cocrystal generated 
a higher solubility compared to caffeine and theobromine [77]. Aakeröy et al. found that 
five anticancer drug cocrystals formed with different dicarboxylic acids as coformers 
had enhanced or reduced aqueous solubility compared with the pure anticancer drug 
[131]. Based on these results, it can be realized that the solubility of cocrystal has a 
relationship with the molecular structure of coformers. 
Dissolution rate  
An enhanced dissolution rate is one of the key properties of cocrystals. Remenar’s 
research group found that itraconazole cocrystals with malic acid, succinic acid and 
tartaric acid showed 4-20 times enhanced drug concentration during dissolution testing 
as compared to the crystalline drug [132]. An 1:1 molar ratio cocrystal of a potential 
API with glutaric acid demonstrated an eighteen folds dissolution rate relative to pure 
crystalline API [11]. Thus, these studies indicated that cocrystals have the potential to 
increase the dissolution rate of API to achieve a therapeutic effect. 
Bioavailability 
Animal bioavailability is a method to evaluate the pharmacokinetic data of a new drug 
candidate by measuring the rate and amount of an API that reach the systemic 
circulation of animals. Various studies have exposed that cocrystals have the potential 
ability to develop the drug absorption. For example, about 10-fold bioavailability 
improvement of cocrystals of quercetin over pure quercetin [34]. Chen et al. studied the 
mean AUC0-24 of apixaban-oxalic acid cocrystal in beagle dogs, showing the cocrystal 
outperformed apixaban with a growth mean AUC0-24 up to 2.7 folds [133]. Other 
cocrystals also shown an enhanced bioavailability such as in danazol cocrystal [134], 
cilostazol cocrystal [17], AMG 517 sorbic acid cocrystal [135] and 




2.4 Development of Pharmaceutical Cocrystal Formulation 
2.4.1 Solution Mediated Phase Transformation (SMPT) 
Improving the solubility of poorly water-soluble drug is the key stage to successfully 
develop a new drug candidate and obtain the desired therapeutic performance. 
Pharmaceutical cocrystals have been demonstrated to be an effective tool for enhancing 
the solubility and create a supersaturated state of poorly water-soluble drugs [11, 137, 
138]. However, cocrystals is not thermodynamically stable in solution, leading to a 
phenomenon called solution-mediated phase transformation (SMPT) due to the 
crystallization of stable solid phase from the metastable phase from supersaturated 
condition in bulk solution or around the surface of dissolving solid during dissolution 
[128, 139-142]. Such transformation is a  challenge for cocrystals,  which may reduce 
the advantages of the cocrystals and consequently decrease the bioavailability [143]. In 
our group, this phenomenon on flufenamic acid cocrystals and carbamazepine 
cocrystals has been systematically investigated [9, 10, 144-146]. For instance, the 
intrinsic dissolution behaviors of carbamazepine-nicotinamide cocrystal were studied 
using UV-imaging techniques by Qiao et al [145]. The intrinsic dissolution rate of 
carbamazepine-nicotinamide cocrystal reached a maximum value of 0.0123 
mg/min/cm2 then slowly decreased during dissolution. The precipitation with lower free 
energy state, carbamazepine dihydrate, was found on the surface of sample compact 
after dissolution test and analyzed by Raman and SEM. Other groups also reported that 
the supersaturated state generated by cocrystal has the trend back to the equilibrium 
state of the stable form [20, 139, 140]. For example, the dissolution of fluoxetine 
hydrochloride-succinic acid cocrystal in water at 20°C shown that a maximum 
fluoxetine hydrochloride concentration with 1.7-fold higher with respect to pure API 
was achieved first, followed by a decreased concentration after 2 min. The results of 
solid residues obtained after dissolution indicated that recrystallization of fluoxetine 
hydrochloride from cocrystal occurred, which was confirmed by XRPD [139].  
There are several factors influencing the phase transformation of a cocrystal during 
dissolution, such as the type of coformers [144, 146], dissolution condition (e.g. pH and 




carbamazepine-cinnamic acid cocrystal was more stable than carbamazepine-saccharin 
cocrystal in 1% SLS aqueous solution [146]. For different dissolution conditions, the 
dissolution behaviors of indomethacin-saccharin cocrystal in 60mM and 200mM 
phosphate buffer (pH 7.4) at 26°C were different [128]. The results of 
indomethacin-saccharin cocrystal powder dissolution showed that the peak 
concentration of indomethacin was maintained for several hours in 200mM buffer with 
no evidence of precipitation from the dissolution profile. On the other hand, 
precipitation was found in 60mins in 60mM buffer because of the drop of the pH from 
7.4 to 6.8. Although no precipitation observed in 200mM buffer, the results of XRPD 
indicated that the solid residues were not cocrystal. Therefore, it is important to 
characterize the solid residues after dissolution to completely understand the SMPT 
phenomenon. 
In a SMPT process, there are three steps: (1) supersaturated condition created by 
dissolving metastable solid; (2) nucleation of stable form; and (3) crystal growth of the 
formed nucleus.  
2.4.1.1 Nucleation  
Nucleation is a process of formation of new crystal nuclei by self-association of the 
solute molecules, including primary nucleation (nuclei spontaneously from clear 
supersaturated solution) and secondary nucleation (nuclei from supersaturated solution 
in presence of seeded crystals). Therefore, it is significant to disturb the self-association 
of molecules for preventing nucleation. There are two nucleation types in primary 
nucleation: homogeneous and heterogeneous nucleation [148]. Homogenous nucleation 
happens randomly and spontaneously in a medium without any foreign bodies. 
However, it is rare to obtain homogenous nucleation because of its rigor requirements. 
Heterogeneous nucleation takes place in presence of foreign bodies in the 
supersaturated solution, such as residues or dust from last batch. The nucleation occurs 
in supersaturated solution in the presence of crystals, called secondary nucleation. The 
presence of extra substances (impurity or crystals) would promote the formation of the 
nuclei. Hence, secondary nucleation and heterogenous nucleation could happen in lower 




The size of the aggregates or clusters is one of the key factors in nucleation process. 
Stable aggregates or clusters can be formed only when the size of weak aggregates or 
clusters are larger than critical size. Otherwise, the unstable clusters would re-dissolve. 
The possibility of forming a stable aggregates or critical nuclei is dependent on the 
energy of the nucleus’ formation and the subsequent growth [149, 150]. 
2.4.1.2 Crystal Growth 
Crystal growth is the process of subsequent growth of the nuclei. The crystal growth of 
nucleus occurs if the rate of growth is greater than the rate of dissolving nuclei. In 
supersaturated solution, nucleation or crystal growth rate will be high if the ∆µ 
(chemical potential) is high and ∆G (the difference of free energy between solid-sate of 
solute and solution-state solute) is low. According to Hartman and Perdock theory [151], 
for a three dimensional crystal face, the capture of growth units can be classified into 
three types based on how many bond contacts formed between the absorbed growth unit 
and the crystal surface (Figure 2. 6), including kinked faces (three attachment), stepped 
faces (two attachment) and flat faces (one attachment). In general, the ranking of ∆G of 
three crystal faces is kinked<stepped<flat [152]. The more interaction sites free on the 
crystal face, the faster it will grow. Therefore, the growth rate of kinked faces is faster 
than stepped face while the flat face is the slowest. The crystal shape is mainly 
determined by the slow growing face. Therefore, it is important to block the interaction 




    
 
Step Kink Flat 




2.4.2 Additives Effect on SMPT 
A method called “spring and parachute” (Figure 2. 7) has been widely used on 
promoting and maintaining supersaturated state for poorly water-soluble drug in 
solution to improve the oral absorption [118]. “Spring” refers to the high energy form of 
the drug (cocrystals, crystalline salt or amorphous), which may rapidly dissolve and 
generate a supersaturated solution with a higher concentration than the equilibrium 
solubility of API and then cause the crystallization of API. In this condition, additives 
(parachute) can maintain the supersaturated solution for a physiologically relevant type 
period to allow adequate drug absorption in the body and improve the bioavailability. 
Vast of studies proved that additives could be effective crystallization inhibitors in high 
energy form formulations for delaying the crystallization of stable form [153]. 
 
Figure 2. 7 Spring and parachute approach 
2.4.2.1 Precipitation Inhibitors 
The ability of additives on slowing down the crystallization from supersaturated 
solution is mainly going through two aspects: (1) effect on the system’s thermodynamic 
(equilibrium state of API) properties; (2) effect on the kinetics of crystallization 
(nucleation and crystal growth) [153]. 
In terms of thermodynamic properties, massive works have been demonstrated that 






























polyvinylpyrrolidone (PVPK30), polyvinylpyrrolidone K90 (PVPK90), polyethylene 
glycol (PEG6000), polyethylene-polypropylene glycol 188 (F-68) and 
hydroxypropylmethyl cellulose (HPMC), have been reported to enhance the solubility 
of pioglitazone hydrochloride in water [154]. Surfactants also have been established to 
promote the drug solubility (e.g. Kolliphor TPGS and sodium Lauretha sulfate (SLES)) 
[134]. Generally, the mechanism of this solubilizing effect of additives is due to the 
formation of a micelle between the additive and API (Figure 2. 8) [155]. 
 
Figure 2. 8 Diagram of surfactant effect on supersaturation [155] 
The ability of additives on inhibiting crystallization by changing the kinetics of 
nucleation and crystal growth process is based on the specific intermolecular interaction 
between polymers and APIs in solution (hydrogen bonding or hydrophobic interaction) 
or steric hindrance of polymers on crystallization process [156]. The key factors 
influencing the inhibitory effect of additives include (1) hydrophobic level of additives 
[157, 158] and (2) the ability of the polymers to interact with drugs via hydrogen bonds 
[159]. In our group, Qiu et al. has enclosed the effect of polymers in carbamazepine 
cocrystals powder dissolution [10]. In the presence of 2mg/mL HPMCAS, 
carbamazepine-nicotinamide cocrystal and carbamazepine-cinnamic acid cocrystal 
showed about 8-fold increased drug release with respect to pure carbamazepine III in 
pH 6.8 phosphate buffer. In the meantime, HPMCAS showed a great stabilizing effect 
on carbamazepine-saccharin cocrystal and carbamazepine-cinnamic acid cocrystal with 
smallest eutectic constant (Keu=
𝐶𝑜𝑓𝑜𝑟𝑚𝑒𝑟𝑒𝑢
𝐴𝑃𝐼𝑒𝑢
, the ratio of concentrations of the coformer 
and drug at the eutectic point in dissolution medium). It suggested the significant effect 
of preventing crystallization of carbamazepine if Keu value is below the stoichiometric 








that the cocrystals are stable in dissolution medium [160]. The inhibition effect of 
HPMCAS is due to its dual role on inhibiting crystallization of carbamazepine, acted as 
a nucleation inhibitor and also a crystal growth retardant [161]. Ozaki et al. also 
exposed that amorphous griseofulvin and danazol had higher degree of supersaturated 
solution in the presence of PVP and HPMC compared to the polymers-free solution 
because of their inhibition effect on both kinetics of nucleation and crystal growth. 
Without polymers, only around 1.5-fold increased supersaturation for griseofulvin and 
3-fold increased supersaturation for danazol compared with crystalline materials, 
respectively. In contrast, amorphous griseofulvin showed about 8-fold and 3-fold 
increased supersaturation in the presence of HPMC and PVP. For danazol, 15-fold and 
9-fold increased supersaturation in the presence of HPMC and PVP, respectively [162]. 
Additives Effect on Nucleation  
The inhibition effect of additives on nucleation are mainly attributed to the 
intermolecular interactions between APIs and polymers during the embryo formation 
phase and then disturbs the self-assembly of solute molecules. In nucleation system, 
determination of the induction time is a useful method for evaluating the kinetics of 
nucleus formation. Induction time, also called nucleation time, is the time span from the 
creation of supersaturated solution to the first nuclei formed [163]. In the presence of 
additives, the length of induction time for the nucleation is depended on the strength of 
the interactions between drugs and additives, which is determined on both hydrogen 
bonding functional groups of drugs and additives [159]. For example, in the presence of 
HPMC, the induction time of hydrocortisone acetate nucleation was longer than that in 
the presence of PVP, due to stronger interactions between hydrocortisone acetate and 
HPMC as HPMC has more hydrogen bonding functional groups per monomer unit 
[159]. The polymers HPMCAS and HPMC significantly retarded the nucleation of 
acetaminophen due to the intermolecular interactions between APIs and polymers [164]. 
Similar effect of HPMC on nucleation of felodipine from felodipine supersaturated 
solution was reported [165]. HPMCAS HF suppressed the nucleation of supersaturated 






Additives Effect on Crystal Growth  
The additives can be absorbed on the growth site and act as a mechanical barrier and 
thus inhibit the crystal growth [166]. The de-supersaturated rate would be significantly 
reduced when the additive attaches on the faster growing faces [164]. There are two 
types of attachments on the crystal surface, including reversibly physical absorption 
(van der Waals forces and electrostatic force) and irreversibly chemical absorption 
(covalent bonding) [157]. The interactions of hydrophobic [167], electrostatic 
interaction [168] and hydrogen bonding [169] between polymers and crystal faces are 
the key factors in absorption process as these interaction can drive the polymer 
absorption on the crystal surface [169]. The electrostatic interaction would be 
considered only when the additive and absorbent bear groups have opposite charges 
[170]. For un-ionized components, hydrophobic interactions and intermolecular 
interactions (e.g. hydrogen bonding) are important for inhibiting crystal growth. For 
instance, the intermolecular interaction between drugs of celecoxib and efavirenz and 
polymer PVP-VA promoted the polymer to absorb on the crystal surface for preventing 
crystal growth [169]. It has been also reported that the absorption of HPMC on different 
crystal faces of hydrocortisone acetate can modify the crystal habit by forming 
hydrogen bonds with the functional groups of API which are exposed at the surface of 
crystal [159]. Cellulose derivatives inhibited the crystal growth of ritonavir, which was 
contributed by the following properties of polymers: moderate level hydrophobicity and  
rigidity of polymer structure [157]. The absorption of polymers on crystal surface also 
can be influenced by the solution properties. For example, HPMCAS has different 
conformation when it absorbed on the crystal surface of felodipine in different pH 
solutions [166]. HPMCAS unevenly absorbed on the crystal surface in pH 3 while 
HPMCAS uniformly adsorbed on the surface in pH 6.8 and effectively covered the 
crystal growth sites [166]. 
2.4.2.2 Additives Screening  
It is obviously significant for selecting effective additives to prevent nucleation and 
crystal growth for maximizing the period of the supersaturated state of high energy 
drugs. There are two steps for screening potential additives, including generation of 




Generation of Supersaturated Solution 
There are several techniques to generate a supersaturated solution, such as, solvent shift, 
pH change, temperature change, dissolving of high energy solid phases, and the addition 
of antisolvent that reduces the solubility of the solute [171]. The most commonly 
methods used are solvent shift [154, 163, 172] and dissolving a high energy solid form 
in solution [20, 134, 173, 174]. 
The solvent shift method is the most frequent technique to employ for polymer 
screening [175]. In this method, drug is dissolved in a water-miscible solvent as a stock 
solution, in which the drug has a high solubility. Supersaturated solution can be created 
by diffusing suitable fraction of stock solution of high drug concertation into dissolution 
media. The commonly used solvents included dimethyl sulfoxide (DMSO) [173, 176], 
methanol [154, 177], N,N-dimethylformamide (DMF) [178] and ethanol [179, 180]. For 
example, Sun and Lee used solvent shift method to create indomethacin, naproxen and 
piroxicam supersaturated solution [179]. Supersaturated loviride solutions with different 
supersaturation ratios were obtained via solvent shift method, for evaluating the 
inhibitory effect of HPMC-E5 on precipitation of loviride [181]. 
A supersaturated solution also can be formed by dissolving a high energy form in 
solution, such as amorphous forms, crystalline salts, or cocrystals. Many works has 
investigated the effect of additives on supersaturated solution by dissolving a metastable 
form, such as solid dispersion [156, 182]. 
Methods for De-Supersaturation Analysis 
To determine additives effect on supersaturated solution, induction time of nucleation, 
the changes of drug concentration with time, mass and morphology of the precipitates in 
pre-dissolved additive solution need to be analyzed. 
In general, for simply determine the overall effect of additives on inhibiting API 
crystallization kinetics (nucleation and crystal growth) from a supersaturated solution, 
the rate of de-supersaturation in unseeded de-supersaturation experiment is measured by 
detecting the changes of drug concentration [183]. As for determining the induction 
time, there are several apparatuses, such as optical microscopy, UV and turbidity 




acetaminophen was prepared in 10mM pH 6.8 sodium phosphate buffer at 70 °C with 
stirring rate of 700 rpm, followed by reduction of temperature to 20°C. When the new 
nucleus appeared, the laser transmission through sample decreased. The nucleation 
induction time was taken as the time difference between the initial decrease in 
transmission and the zero-time point [164]. The induction time of diprophylline during 
nucleation was detected by light transmission, which would be reduced once the nucleus 
appears [184]. Ozaki et al. used UV absorption to detect the induction time of danazol 
and griseofulvin. A supersaturated solution was firstly prepared by adding an aliquot of 
DMSO solution with high drug concentration into a 2ml fasted state simulated intestinal 
fluid (FaSSIF) in the absence or presence of polymers in a quartz cuvette at 300 rpm 
stirring rate. Finally, the induction time was detected by monitoring the UV absorption 
at 320nm (danazol) and 350nm (griseofulvin) and measuring the sharp change in the 
absorption-time curve. Different from laser or light transmission, a steep increased 
absorption happened when nucleus came out [173]. Furthermore, polarizing microscopy 
was also used to determine the induction time via detecting of firstly appeared crystals, 
such as nucleation of tripalmitin [185] and di- and metasilicate glasses [186]. In terms 
of crystal growth, the ability of additives can be determined by measuring the rate of 
de-supersaturation in presence of seed crystal using HPLC and UV to measure the 
changes of drug concentration with time [157].  
To evaluate the additives (polymers) effect on crystal habit (e.g. morphology and size of 
new growth crystals) during crystallization, optical microscopy [164, 187, 188] and 
scanning electron microscopy [10] are widely used. For example, the solid residuals of 
acetaminophen after seeded crystal growth experiment were observed by microscope 
with a 40x magnification and found that polymers altered the morphology of crystals. 
Without polymers, the crystals were thin, flat and elongated. However, the crystals were 




2.4.3 Additives Effect on Crystal Dissolution  
2.4.3.1 Methods for Determining Crystal Dissolution Mechanism in The Presence 
of Additives 
In cocrystals dissolution process, the pre-dissolved additives in solution not only 
influence the crystallization of supersaturated condition but also the dissolution 
properties of the solid crystals. The performance of cocrystal-based product is depended 
on additives effect and cocrystal dissolution behaviors. Therefore, it is essential to 
understand the dissolution rate and dissolution mechanism of cocrystals in the presence 
of additives, which can lead to strategies for developing cocrystal enabling formulations 
[189]. 
The process of crystal dissolution is a specific type of heterogeneous reaction between 
the solid and solvent, including three steps: (1) absorption: solvent molecules absorb on 
the surface of crystal; (2) interaction or reaction: the crystal molecules interact/react 
with absorbed solvent molecules; (3) detachment and diffusion: the molecules detach 
and diffuse away from the crystal surface [189]. 
Atomic force microscopy (AFM) has been widely used for observation of the crystal 
dissolution at molecular level by analyzing the etching pattern changes of crystal 
surface during dissolution. The etching pattern is impacted by the crystal interaction 
network and the interaction between the crystal molecules in the lattice and solvent 
molecules [190-196]. The presence of additives in solution, would form an absorbed 
additive layer on the dissolving crystal surface that affect the solute bulk diffusion and 
surface diffusion during dissolution [197]. There are many factors that would impact the 
absorption of polymers on crystal surface, including crystal structure (i.e. functional 
group exposed on face [198]), polymer properties (i.e. chain rigidity and chain length 
[199]) and attachment energy between polymer and crystal surface [199]. For example, 
Wen et al. investigated the hydrogen bonding interaction between polymers and crystal 
face (010) of acetaminophen through detecting the etching pattern changes by applying 
AFM [200]. The presence of hydroxypropyl cellulose (HPC), 2-hydroxyethyl cellulose 
(HEC), poly(vinyl alcohol) (PVA) and hydroxypropyl methylcellulose (HPMC) 




due to the formation of hydrogen bonds between polymers and crystal surface. However, 
in the case of dextran, poly(ethylene glycol) (PEG) and poly(propylene glycol) (PPG) 
did not change the etching pattern in the direction of a-axis (crystal cell edge) because 
no hydrogen bonding was formed between polymers and crystal face. 
As a crystal dissolves, the dissolution rate of each face is distinct because different 
function groups are exposed on each crystal face. Optical light microscopy (OLM) has 
been used to determine the dissolution rate of particular face of a single crystal by 
measuring the physical retreated velocities of different faces at a macroscopic scale [198, 
201-203]. Adobes-Vidal et al. measured the dissolution rate of (010) and (101) faces of 
furosemide in 4 mL KCl (50mM) aqueous solution in a Petri dish by measuring the 
displacement of the width and length of (001) face with time using optical microcopy 
[198]. 
2.4.4 Additives Effect on Permeability 
Based on the Biopharmaceutical Classification System, the ability of drug molecules to 
pass through the intestinal mucosa is a key factor for administrating the extent of oral 
absorption of a drug [26]. However, the enhanced drug concentration of solid form in 
gastrointestinal tract cannot always improve the drug absorption. Higuchi has 
mentioned that diffusion flux relies on thermodynamic activity/chemical potential 
instead of the concertation gradient [204]. In the presence of low concentration of 
polymers, enhanced permeation of drug could be obtained in supersaturated solutions 
due to polymers’ inhibition effect on crystallization of stable form [205-210]. For 
example, the permeation of fentanyl was improved in propylene glycol/ethanol 
formulation because of the enhanced drug thermodynamic activity of fentanyl [209]. 
However, an increasing equilibrium solubility of API due to the additives’ 
solubilization effect (i.e. surfactant), would reduce the permeation performance of API. 
This reduced permeability results from the formation of micelle between additive and 
drug, which would decrease the free fraction of drug available for membrane 
permeation [211, 212]. This observation is supported by the studies of Dahan et al [26], 
Miller et al [27, 213-215]. Raina et al [212] also showed that when additives 




felodipine and nifedipine decreased. Besides, there is a maximum value of flux of drug, 
which could be achieved in a supersaturated solution when liquid-liquid phase 
separation (LLPS) take place. 
The insight mechanism of stabilized and solubilized effect of additives on 
supersaturation and permeation behaviors can be revealed by using nuclear magnetic 
resonance (NMR) [216, 217]. For example, the mechanism underlying additives effect 
on permeation properties of carbamazepine were determined by NMR by observing the 
chemical shift and spin−lattice relaxation time (T1) over spin−spin relaxation time (T2) 
of carbamazepine in presence of HPMC-AS and P407 [216]. 
2.5 Flufenamic Acid Cocrystals Studies 
2.5.1 Introduction of Flufenamic Acid (FFA) 
In 1948, flufenamic acid (2-[[3-(trifluoromethyl)phenyl]amino] benzoic acid, FFA) was 
first synthesed by Wilkinson and Finar [218] and discovered it as a useful 
anti-inflammatory drug in 1963 [219]. Its anti-inflammatory property is due to the 
inhibition of the prostaglandin synthesis [220]. In 1996, FFA was used to treat the 
problems of arthritis and inflammation associated with muscular-skeletal [221]. Its 
acute (oral) potency was 16-folds as aspirin, 12-folds as aminopyrene, 3.2-folds as 
mefenamic acid and 1.6-folds as phenybutazole [222]. Furthermore, it has been 
discovered that FFA can act as an ion channel modulator where it not only impacts the 
non-selective cation channels and chloride channels but also modifies the potassium 
calcium and sodium channels [223]. Recently, it has been found that FFA has 
effect/activity on neuroprotection [224] and antitumor therapy [225]. There are nine 
reported polymorphs of FFA but only FFA I (white) and FFA III (yellow) has been used 
as commercial solid forms [226]. The transition point of FFA I and FFA III is 42°C: 
FFA III is the stable form and FFA I is the metastable form at room temperature [227]. 
It is a Class II drug with low water solubility (0.0067mg/mL in 22°C) and high 
permeability (logP =5.62) in BCS system [228, 229]. The poor water solubility leads to 
the low oral bioavailability of FFA, which restricts their applications on oral and 




the solubility of FFA, such as amorphous materials [230], solid dispersion with PVP 
[231] and Cyclodextrins [232].  
2.5.2 FFA Cocrystals Research 
As mentioned in Section 2.3.5, cocrystal is an effective approach to modulate the 
solubility, dissolution and other physiochemical properties of low water-soluble APIs 
via forming hydrogen bonds with high water-soluble components. Only 7 FFA 
cocrystals have been reported as summarized in Table 2. 2. 
Table 2. 2  Summary of known FFA cocrystals 
FFA cocrystal Reference 
FFA-transthyretin [233] 
1:1 FFA-nicotinamide (NIC) [229, 234, 235] 
1:1 FFA-Theophylline (TP), 1:1 FFA-2-Pyridone 
(PYR) and 1:0.5 FFA-4,4’-bipyridine (BP) 
[229] 
1:1 FFA- 2-chloro-4-nitrobenzoic acid (CNB) and 1:1 
FFA- ethenzamide (ETZ) 
[236] 
2.5.3 FFA Cocrystals Design Strategies and Synthesis 
To date, hydrogen bonds are the most frequently used strategy in FFA cocrystals design. 
The structure of FFA (Figure 2. 9a) composes of two aromatic rings with -NH bridge, 
CF3 and carboxylic acid that has a strong hydrogen bond donor and acceptor. Based on 
the hydrogen bonding pattern (Figure 2. 9) of 6 FFA cocrystals, there are two cocrystal 
design strategies for designing FFA cocrystals. One is to use both C=O and C-OH of 
carboxylic acid to from hydrogen bonds with other coformers, such as NIC (Figure 2. 
9b), PRY (Figure 2. 9d), CNB (Figure 2. 9f) and ETZ (Figure 2. 9g). The other strategy 
is to employ the OH of carboxylic acid to form hydrogen bonds with other coformers, 
such as TP (Figure 2. 9c), and BP (Figure 2. 9e). 
FFA cocrystals have been successfully prepared by both solution-based and solid-based 
methods. In a study by Fabian et al, FFA-nicotinamide cocrystal was synthesized by 




used solvent evaporation and liquid-assisted grinding to prepare FFA-theophylline 












Figure 2. 9 Structures of (a) FFA I; (b) FFA-NIC CO, (c) FFA-TP CO, (d) FFA-PRY CO; (e) FFA-BP CO; 




2.5.4 Introduction of Pharmaceutical Cocrystal Coformers: Nicotinamide and 
Theophylline 
Nicotinamide (NIC) (Figure 2. 10) is amide of niacin and belongs to vitamin B group 
(B3), which has ability to restore cognition in Alzheimer’s disease transgenic mice by 
employing sirtuin inhibition and selective reduction of Thr231-Phosphotau [237]. There 
are four reported polymorphs of NIC with different melting points, including NIC I 
(126-128°C), NIC II (112-117°C), NIC III (107-111°C) and NIC IV (101-103°C) [238]. 
Form I is the stable form at room temperature. NIC has been reported as a popular 
coformer in synthesis of pharmaceutical cocrystal [239], contributing to by its high 
water solubility and amide group for forming hydrogen bonding [235]. Table 2. 3 shows 
a list of cocrystals containing NIC.  
Theophylline (TP) (Figure 2. 10) is an active pharmaceutical ingredient for treating 
respiratory diseases (e.g. asthma) with melting point at around 271°C [240, 241]. TP 
(Figure 2. 10) has been reported as a coformer for cocrystals because it can act as both 
hydrogen-bonding donor (imidazole NH and CH group) and hydrogen-boning acceptor 
(two carbonyl oxygen atoms) [242]. The cocrystals containing APIs and theophylline 
are drug-drug cocrystals, which have potential for developing combination drugs [243, 




Figure 2. 10 Structures of NIC and TP 
Table 2. 3 list of cocrystals containing NIC and TP 
Coformer Cocrystal References 
NIC Flufenamic acid-NIC cocrystal, niflumic acid-NIC 
cocrystal, tolfenamic acid-NIC cocrystal and mefenamic 
acid-NIC cocrystal 
[234] 




Carbamazepine-NIC cocrystal [145] 
Celecoxib-NIC cocrystal [246] 
Baicalein-NIC cocrystal [247] 
Ibuprofen-NIC cocrystal [248] 
α-lipoic acid-NIC cocrystal [249] 
Simvastatin-NIC cocrystal [250] 
Flurbiprofen-NIC cocrystal [251] 
Salicylic acid-NIC cocrystal [252] 
Diflunisal-NIC cocrystal [253] 
Indomethacin-NIC cocrystal [254] 
Protocatechuic acid-NIC cocrystal [255] 
Curcumin-NIC cocrystal [256] 
Dasatinib-NIC cocrystal [257] 
Aspirin-NIC cocrystal [258] 
Furosemide-NIC cocrystal [259] 
P-coumaric acid-NIC cocrystal [260] 
Rebamipide-NIC cocrystal [261] 
Adefovir dipivoxil-NIC cocrystal [262]  
Olanzapine-NIC cocrystal [263] 
Propiconazole-NIC cocrystal [264] 
Theophylline-NIC cocrystal [265] 
TP Caffeine-TP cocrystal and  [266] 
Flufenamic acid-TP cocrystal [229] 
Acetaminophen-TP cocrystal  [267] 
Glibenclamide-TP cocrytsal [268] 
Sulfacetamide-TP cocrystal [269] 




2.5.5 Introduction of Polymers 
Polyethylene Glycol (PEG)  
PEG (Figure 2. 11) is a semi-crystalline polymer that contains different numbers of 
ethylene glycol unit with a molecular weight ranging from 200 to 300000. PEG is a 
non-toxic, colorless, odorless and non-irritating polymer. The viscosity of PEG would 
increase as increasing molecular weight. PEG 4000 is a frequently used polymer in 
pharmaceutical industry because of its high water solubility (50mg/mL at 25°C) and 
suitable melting point (50-58°C) [271]. It is a hydrophilic polymer that can improve 
dissolution, solubility and inhibit the crystallization of drug by forming hydrogen 
boning with drug [272],[273]. For example, PEG can reduce the crystallization rate of 
benzocaine and increase induction time for crystallization of ibuprofen and fenofibrate 
[273]. 
Polyvinylpyrrolidone (PVP)  
PVP (Figure 2. 11) is an amorphous polymer which contains varying number of 
vinylpyrrolidone units with molecular weights falling in the range of 2500-3000000. 
The average molecular weight of PVP K30 is 40000 with Tg at 165.03°C. An increase 
in molecular weight of PVP would increase the viscosity resulting in lower dissolution 
rate of drug due to the formation of diffusion boundary layer on the dissolving surface 
[271]. PVPs are widely applied in pharmaceutical manufacturing as excipients [271]. 
PVP has also been found to stabilize the supersaturated condition of drugs by forming 
hydrogen bonding, such as norethindrone acetate [274], bicalutamide [275], 
indomethacin [276] and ketoconazole [277]. There are two functional groups (=N- and 
C=O) that are likely to form hydrogen bonding in each PVP unit. The carbonyl group is 
preferred for hydrogen bonding because the steric hindrance interrupts the 
intermolecular interaction with nitrogen atom [278]. 
Plasdone S630 (PVP-VA) 
PVP-VA (Figure 2. 11) is an amorphous copolymer of N-vinyl-2-pyrrolidone (60%) and 
vinyl acetate (40%). It is white and odorless powder with an average molecular weight 
of 51000 [279]. PVP-VA is more hydrophobic than PVP but with a lower Tg (106°C) 




solvent. PVP-VA is a good binder for direct-compression tablet/drug 
granulation/coating materials of control release drug [280] and a stabilizer for drug 
crystallization. Each monomer unit of PVP-VA contains two strong hydrogen bonding 
acceptors of C=O of vinylpyrrolidone group and C=O vinyl acetate group. PVP-VA has 
been reported as an inhibitor of crystal growth rate of amorphous felodipine [281] and 





PEG   PVP PVP-VA 
Figure 2. 11 Molecular structures of polymers 
2.6 Chapter Conclusion 
In this chapter, a brief introduction about pharmaceutical cocrystals was given. Firstly, 
description and several key issues about cocrystals were presented, including cocrystal 
design strategies, coformer selection, cocrystal screening methods, cocrystal 
characterization techniques and cocrystal physicochemical properties. Secondly, the key 
problem of cocrystal during dissolution, solution media phase transformation, was 
mentioned. The additives effect on recrystallization, dissolution and permeation 
behaviors of cocrystals also was introduced in 2.4.2 and 2.4.3 section. The methods that 
applied for screening additives and determining the dissolution mechanism of cocrystals 
were discussed. Finally, some information about the materials that used in this study 




Chapter 3 Materials and Methods 
3.1 Chapter Overview 
The materials, analytical techniques and calculation methods used in this study were 
fully described in this chapter.  
Firstly, the formulas, purity and manufacturers of materials were mentioned. Then, the 
analytical techniques applied to characterize the cocrystals formation and determine the 
physicochemical properties of cocrystals were presented, including infrared 
spectroscopy (IR), Raman spectroscopy, differential scanner calorimetry (DSC), high 
performance liquid chromatography (HPLC), atomic force microscopy (AFM), optical 
light microscopy (OLM), X-ray diffraction (XRD) and nuclear magnetic resonance 
(NMR). The working principle, instrumental models, parameter setting and operation 
procedures of these analytical techniques were comprehensively discussed. Then, the 
experimental and preparation methods were also mentioned. The calculation methods 
were presented, containing the equation of solubility parameter (SP), supersaturated 
ratio (SSR), supersaturated parameter (SSP), cocrystal solubility, dissolution 
performance parameter (DPP) and flux rate.  
3.2 Materials 
All materials were used as received, without further processing. The details of materials 
were presented in Table 3. 1. 
Table 3. 1 Lists of raw materials for experiments 
Materials Formula Purity/grade Manufacturer 
Flufenamic 
Acid 
C14H10F3NO2 97% Sigma-Aldrich Company Ltd., 
Dorset, UK 
Nicotinamide C6H6N2O ≥99.5% Sigma-Aldrich Company Ltd., 
Dorset, UK 





Methanol CH3OH HPLC grade Fisher Scientific Loughborough, U.K. 
Ethanol CH3CH2OH Lab grade Fisher Scientific Loughborough, U.K. 
Acetonitrile CH3CN HPLC grade Fisher Scientific Loughborough, U.K. 






Lab made by Bi-Distiller 
(WSC044.MH3.7, Fistreem 









NaOH 0.2M Fisher Scientific Loughborough, U.K. 
PEG 4000 C2nH4n+2On+1 ` Sigma-Aldrich Company Ltd., 
Dorset, UK 
PVP K30 (C6H9NO) n  Ashland Inc. (Schaffhausen, 
Switzerland) 
PVP-VA (C6H9NO)n(C4H6O2)m  Ashland Inc. (Schaffhausen, 
Switzerland) 
3.3 Methods 
3.3.1 Analytical Techniques  
3.3.1.1 Vibrational Spectroscopy 
Vibrational spectroscopy is a useful and energy sensitive approach to identify the 
structure of organic chemicals via detecting the functional groups or finger print. Its 




(Raman) of samples because of the molecular vibration (stretching, blending). When the 
radiation shines on the sample, the electromagnetic radiation would be absorbed (IR) or 
scattered (Raman).  
3.3.1.1.1 Infrared (IR) Spectroscopy 
IR spectroscopy is an analytical method to identify chemical samples (solid, gas or 
liquid) by detecting the interaction between a molecule and radiation in the IR regions 
from 2.5μm to 25μm (4000 to 400cm-1). 
The underlying principle behind IR spectroscopy is the absorption will only take place 
in resonant frequencies, referring to the frequency (energy) of incident radiation/photon 
matches the frequency of the molecular vibration or the energy gap from the ground 
state to excited state. The samples could be motivated to an excited state by absorbing 
energy from incident radiation, causing the radiation loses energy. There are three 
factors impact the energy gap including shape of the molecular potential energy surface, 
the associate vibronic coupling and masses of the atoms. 
Fourier transform infrared (FTIR) spectroscopy is for recording the infrared spectra 
based on the emission or absorption of radiation when the radiation hits a solid or liquid 
sample. All wavelengths would be simultaneously measured by FTIR via applying a 
Michelson interferometer (Figure 3. 1) In Michelson interferometer, the source radiation 
passes through a beamsplitter, which splits the source into two separated beams and 
send them to two mirrors. One beam is reflected from the fixed mirror and the other 
from movable mirror. The total path length of movable beam is different compared with 
the fixed mirror beam, this because of the movement of movable mirror. Then two 
beams recombine when they meet again at the beamsplitter and the different in path 
length creates a destructive and constructive interference, called interferogram. The 
recombined beam then passes through the sample, in which the beam will be absorbed, 
reflected, transmitted or scattered. The variation of the transmitted light is a function of 
the position of the moving mirror. Only transmitted light would be detected and 
reported as a signal of variation in transmitted light versus time. Then a mathematical 
Fourier-transform is used to convert the raw data (intensity vs time) into desired result 




In this study, the spectra of solid and liquid sample were determined by an ALPHA A4 
interferometer (Bruker UK Limited, Coventry, UK) by conjunction with IR. The 
samples can be observed directly without further preparation. A universal attenuates 
total reflectance (ATR) accessory is horizontally equipped with the ALPHA 
interferometer for measuring the solid sample. A small number of samples were putted 
on the surface of the diamond ATR plate and the ATR assembly were clamped to 
ensure good contact. The solution spectra were collected using the same spectrometer 
fitted with a transmission accessory and the Bruker 6500S Circular Aperture liquid cell 
with size of 32 × 3 mm CaF2 window. The path length was 0.05 mm. In each 
measurement, 30 scans were collected per spectrum with a resolution of 2 cm-1 in the 
spectral region of 400 to 4000 cm-1 using OPUS software. All the spectral data were 
collected at an ambient temperature, between 20 to 23°C [183]. 
 
Figure 3. 1 Schematic diagram of Michelson Interferometer. 
3.3.1.1.2 Raman Spectroscopy  
Raman spectroscopy relies on inelastic scattering/Raman scattering of photons by 





Raman spectroscopy is a common analytical equipment for detecting the molecules 
structure, as the vibrational information can be obtained from scattering the radiation by 
the molecules. Raman spectroscopy is specifically relevant to the chemical bonds and 
symmetry of molecules. In Raman system, it is not necessarily for the photons that have 
the same energy as the energy gap between ground state and excited state. The working 
principle of Raman spectroscopy is that variations of polarizability of the molecule in 
the electric field, in which radiation would change the electron cloud around the nuclei 
of a molecule. 
When photons impinge on a sample, majority of the scattering is elastic without loss of 
energy thus no change of frequency, this scattering is known as Rayleigh scattering 
(Figure 3. 2). However, Raman scattering is an inelastic scattering, meaning that the 
energy/frequency of scattering photons is changeable because energy of photons is 
transferred or accepted from molecule of a sample when the molecule vibrated. If the 
incident protons transfer energy to the sample, the incident photon will have a redshift 
(lower frequency), also called stokes shift (Figure 3. 2). In the contrast, if the incident 
proton accepted energy from a sample, it is scattered with a blueshift (higher frequency) 
and referred as anti-stokes shift (Figure 3. 2). In most of cases, stokes scattering is the 
most common type of scattering as only small number of molecules are exited in an 
excited state. Typically, Raman scattering is recorded in the wavenumber ranges of 
100-4000cm-1.  
 




Enspectcter R532® Raman spectrometer (Figure 3. 3) is applied to measure the Raman 
spectra of solid or liquid sample directly without further sample preparation in room 
temperature. This equipment is comprised three parts: (1) 20-30mW an output power 
laser source with a wavelength of 532nm; (2) Czerny-Turner spectrometer; (3) scattered 
light collection and analysis system. The ranges of wavenumber of the spectra is 
recorded from 140 to 6000cm-1, covering the vibration ranges of inorganic and organic 
molecules and photoluminescence visible range. In this study, for solid measurement, 
the parameter of the integration time was 200 milliseconds and each spectrum was 
achieved in an average of 100 scans.  
 
Figure 3. 3 Enspectcter R532® Raman spectrometer 
3.3.1.2 Differential Scanner Calorimetry (DSC) 
DSC is the most used thermal analysis technique applied to determine enthalpy changes 
of a sample, such as melting point temperature, crystalline phase transition temperature 
and glass transition temperature. The fundamental principle of DSC is that when phase 
transformation of the sample occurs, the amount of the heat flow will change for 
maintaining the same temperature of the sample and reference. In an endothermic 
process, more heat need to flow to the sample for increasing the temperature, such as 
the melting of solid into liquid. In contrast, in an exothermic process, less amount of 
heat flow is required for the sample to produce the same temperature of reference, like 
crystallization. The DSC equipment can measure the amount of heat absorbed or 
released during the phase transition by detecting the difference in heat flow between the 





Figure 3. 4 DSC curve [285] 
In this study, the melting point of solids was measured by a PerkinElmer Jade DSC 
(PerkinElmer Ltd., Beaconsfield, U.K.) controlled by Pyris Software. The temperature 
and heat flow of the instrument were calibrated using indium and zinc standards. A test 
sample (8−10 mg) was analyzed in crimped aluminum pan with a pinhole pierced lid. 
Measurements were carried out at a heating rate of 20 °C/min under a nitrogen flow rate 
of 20mL/min [183]. 
3.3.1.3 High Performance Liquid Chromatography (HPLC) 
HPLC is a liquid chromatographic technique to separate mixture sample into the 
individual component to identify, quantify and purify the mixture based on molecular 
composition and structure. HPLC instrumentation consist of a solvent reservoir, 
degasser, pump, sample injector, column, detector and data collection devise. A small 
volume sample (0.1-100μL) is injected into the flow stream of the mobile phase and 
flows through a column with a stationary phase. If a component has stronger interaction 
with stationary phase, then it will move slower than other components thus has longer 
retention time (the time point that specific analyte elutes from the column). There are 
different types of stationary phase including normal phase (silica gel), reverse phase 
(silica gel-C18), ion-exchange (stationary phase contains ion group) and size exclusion. 
In reverse phase HPLC, the stationary phase is non-polar and the mobile phase (mixture 
of water and methanol/acetonitrile) is polar. Therefore, the component with less polarity 
has longer retention time. A chromatography detector, lied at the end of the column, is 
used to detect separated analytes that eluted from the column then convert the 




concentration or identity of effluents. The UV detector is the most frequently used to 
measure the sample that absorb UV light at a specific wavelength (190-400nm) [286]. If 
the wavelength is shorter than 210nm, it is not suitable for HPLC system because every 
organic chemical can absorb when the wavelength is less than 210nm. HPLC technique 
is one of most important techniques which has been used in lots quantitative analysis 
work for cocrystal solubility measurement. In cocrystal system, UV method cannot 
determine the individual concentrations of each components. In contrast, HPLC can 
separate mixture components into individual components hence can determine the 
individual concentration for cocrystal components.  
In chapter 5 and chapter 6, A Perkin-Elmer series 200 HPLC system (PerkinElmer Ltd., 
Beaconsfield, U.K.) equipped A HAISLL 100 C18 column (5μm, 250 × 4.6 mm) 
(Higgins Analytical Inc., Mountain View, CA, USA) was utilized to measure FFA, NIC 
and TP concentration in solution at room temperature. All samples were detected by a 
UV absorption detection. For determining the HPLC methods of FFA, NIC and TP, we 
tried different percentages of mobile phase (Table 3. 2). We found out that the following 
parameters were the best conditions for FFA, NIC and TP. The method that applied for 
detecting FFA was used mobile phase with 15% water (including 0.5% formic acid) and 
85% methanol at 1.5 mL/min flow rate and 286 nm wavelength. Both NIC and TP 
concentrations were identified by an isocratic method with 55% methanol and 45% 
water at 1mL/min flow rate and 265 nm. The injection volume was 20 μL. 
In chapter 7, A HEWLETT PACKARD series 1100 automatic HPLC with a Luna@ 
Omega PS C18 100A LC column (5μm, 150× 4.6 mm) (Phenomenex, Inc., 
Macclesfield, UK) at 40°C was employed. An isocratic method was used to detect FFA, 
NIC and TP concentration. The method with 15% water (including 0.5% formic acid) 
and 85% methanol at 1.5mL/min flow rate and 286 nm wavelength with 50 µL injection 
volume was used for detecting FFA concentration. NIC concentrations were identified 
by a method with 10% methanol and 90% water at 1mL/min flow rate and 265 nm. TP 
concentrations were determined by a method with 40% methanol and 60% water at 




The series of concentrations for building calibration curves of FFA, NIC and TP was 
listed in Table 3. 3. Calibration graphs (Table 3. 4) of FFA, NIC and TP were produced 
using peak areas verse concentration. Three replicated injection of each sample were 
injected into machine. The final peak area was the average of 3 peak areas. Low 
concentration calibration curve was for permeation test and high concentration 
calibration curve was for dissolution test, solubility test and desupersaturated 
experiments. HPLC calibration curves were validated by known concertation standard 
solution of FFA, NIC and TP. The validation results of calibration curve were listed in 
Table 3. 5, showing that all standard deviation (SD: to evaluate the difference between 
real and measuring concentration) less than 5%, meaning the accuracy of all calibration 
curve were high. 
Table 3. 2 HPLC methods 
Components Mobile Phases Flow rate 
(mL/min) 
Detection Wavelength 
(nm) Water (V/V%) Methanol 
(V/V%) 
FFA 50 (with 0.5% formic acid) 50 1.5 286 
 30 (with 0.5% formic acid) 70 1.5 286 
 15 (with 0.5% formic acid) 85 1.5 286 
NIC 50 50 1 265 
 65 35 1 265 
 55 45 1 265 
TP 50 50 1 265 
 55 45 1 265   
Table 3. 3 Concentrations for calibration curve 
Components   Calibration curve range Concentration points (μg/mL) 
FFA 0.1-1(μg/mL) 0.01, 0.05, 0.1, 0.5 and 1 
 1-50(μg/mL) 1, 5, 10, 20, and 50 
NIC 0.1-1(μg/mL) 0.1, 0.2, 0.5 and 1 
 1-50(μg/mL) 1, 5, 10, 20, and 50 
TP 0.1-1(μg/mL) 0.1, 0.2, 0.5 and 1 






Table 3. 4 Calibration curves of FFA, NIC and TP 
Table 3. 5 Validation of calibration curve x: in unit of μg/mL; 𝐶𝑟: validation solution of real 
concentration, μg/mL and 𝐶𝑚: validation solution of measured concentration, μg/mL 









FFA 0.1-1 y=102.57x+0.3811 R2=0.9997 0.8 0.81 1.25 
1-50 y=102.28x+20.987 R2=0.9998 30 29.84 0.53 
NIC 0.1-1 y=25.799x-0.118 R2=0.9999 0.8 0.78 2.50 
1-50 y=25.191x+2.9149 R2=1 30 29.68 1.07 
TP 0.1-1 y=62.48x-0.9908 R2=0.9995 0.8 0.82 2.50 
1-50 y=62.622x+1.235 R2=1 30 29.54 1.53 
3.3.1.4 Atomic Force Microscopy (AFM) 
AFM is a type of scanning probe microscopy, one of the important techniques for 
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at nanoscale. Its first time used in experiment was in 1986 and original commercial 
version was introduced in 1989. 
AFM (Figure 3. 5) comprises several configurations, including cantilever, support for 
cantilever, piezoelectric element, tip, detector of deflection and motion of cantilever, 
xyz driver and sample stage. Practically, an ultra-fine tip (probe) with needle shape 
approaches the sample and scans the surface and the movement (up and down) of the 
tips causes a deflection of the cantilever. Then a laser irradiates on the cantilever at an 
oblique angle and is reflected from the back of cantilever. The incidence angle of the 
laser beam will be altered as a function of the deflection of cantilever. The reflected 
laser beam strikes a position-sensitive photo-detector, which can translate the deflection 
of cantilever into an electrical signal and the intensity of the signal is proportional to the 
displacement of the cantilever. The position of sample needs to be under the tip, 
adjusted by xyz driver.  
AFM operation is classified into three modes based on the way of tip motion: 
non-contact mode, contact mode and tapping mode. Contact mode (static mode) is the 
simplest and most forthright imaging mode. In contact mode, the tip continuously drags 
cross the surface of the sample in a well-defined scan area with a repulsive interaction 
force. The cantilever deflection is directly used as a feedback signal for maintaining the 
cantilever in a constant position which is set by the user. Low stiffness cantilevers need 
to be used for strengthening the deflection signal due to the measurement of static signal 
is influenced by the noise and drift. The lateral force that exerted on the surface is high, 
could damage the surface structure of the sample. Therefore, contact mode is not 
suitable for the sample with soft surface. 
In this study, AFM (Agilent 5420 SPM, USA) measurements were carried out in contact 
mode at room temperature using a J-type piezo-scanner with a standard silicon nitride 
tip (Windsor Scientific Ltd., UK). The resolution of a measurement was 512 × 512 
points (nm × nm) with equal steps along the x and y directions. The images created by 
AFM system software were saved as the deflection mode, which was the derivative 





Figure 3. 5 Diagram of AFM [287] 
3.3.1.5 Optical Light Microscopy (OLM)  
Optical microscopy (light microscopy) is a type of microcopy that employs visible light 
and lenses to magnify image of small samples which cannot be observed by naked eye. 
There are several configurations in an optical microscopy, including eyepieces, 
objective turret, objective lenses, focus knobs (coarse and fine adjustment), sample 
stage, light source, diaphragm and condenser and mechanical stage (moving the sample). 
The principle of the optical microscopy is that the sample will be magnified by an 
objective lens to create a magnified image. The magnified image will be further 
magnified by eyepiece to allow the user to observe the sample. 
In this study, a LEICA DM 750 polarizing microscope (Leica Microsystem Ltd., Milton 
Keynes, U.K.) with a 200× or 100× objective equipped with a version 4.0 studio capture 
for monitoring the FFA crystallization behavior from a supersaturated solution and 
displacement of different faces of a single crystal during dissolution. 
3.3.1.6 X-ray Diffraction (XRD) 
X-rays are electromagnetic waves with very short wavelengths, ranging from 0.001 to 
10 nanometers. The X-rays diffraction can happen in crystal due to several reasons: (1) 
the atoms are periodically arranged in a crystal that can diffracted the X-rays; (2) the 
wavelength of X-rays is similar as the distances between crystal planes. X-ray 
diffraction is a non-destructive and common analytical technique for understanding the 











shines a crystal, the incidence beam will be diffracted into many specific directions by 
crystalline atoms. A three-dimensional X-ray crystallography of the electron density in 
the crystal can be calculated by detecting the intensities of diffracted spots and angles of 
the diffracted beams. The average positions of the atom and chemical bonds within the 
crystal can be measured based on the electron density  
A constructive interference of the diffracted beam can occur when the conditions satisfy 
Bragg’s Law: 
nλ = 2dsinθ (Equ.3-1) 
Where n is any integer, λ is the wavelength of the incidence beam, d is the distance 
between crystal planes and θ is the incidence angle (Figure 3. 6). 
 
Figure 3. 6 Extra distance (2dsinθ) of x-Rays for penetrating deeper into the sample 
The samples used in X-ray diffraction experiments can be single crystal or powdered 
sample. Single crystal X-ray diffraction is used to detect the unit cell, including position 
of the atoms within the crystal and cell dimension. In this diffraction, the intensity of 
diffraction spots is a function of the Miller indices (hkl), which used to determine the 
planes of atoms. In X-ray powder diffraction (XRPD), all possible diffraction directions 
of the lattice can be detected by scanning the powdered sample. The crystalline 
materials can be identified by conversing the diffraction peak into d-spacings according 
to the Bragg’s Law. 
In this study, X-ray powder diffraction pattern of solids was recorded from 5° to 35° at a 








Coventry, UK). Cu-Kβ radiation was used with a voltage of 30 kV and current of 10 
mA.  
3.3.1.7 Nuclear Magnetic Resonance (NMR) Spectroscopy 
NMR is a spectroscopy technique for studying chemical, physical and structure 
information of molecule by absorbing and re-emitting electromagnet radiation in a 
magnate field. In a molecule, all nuclei are charged and some of them have spin. Only 
the atom with odd mass or odd atomic number (such as 1H and 13C), the nuclei will have 
spin.  Practically, a magnetic field is created due to the spin of nucleus. without an 
extra applied magnetic field, nucleus spin in different directions. When nucleus in an 
extra magnetic field, they will be parallel with the extra magnetic field and an energy 
transfer will happen between the ground state and excited state of nuclei. The energy 
gap (between ground state to exited state) of different nuclei is distinct. An energy 
transfer takes place from ground state to exited state by absorbing radio frequency, 
which would be emitted when exited state is back to the ground state. A NMR spectrum 
obtaining based on the emitted frequency, is a plot of intensity of signal as a function of 
emitted frequency.  
Normally, the emitted frequency is converted to chemical shift (ppm) in a spectrum, 
referring to the difference in parts per million between the emitted frequency of the 
evaluated nuclei and frequency of reference. For proton NMR, the chemical shift of 
tetramethysilane (TMS) is 0 ppm, thus it is always used as reference. The chemical shift 
is changed when the electron density is altered around the nucleus. High electron 
density around the nucleus will shield the nucleus and the signal would locate in upfield 
(low chemical shift) and vice versa. There are several factors that impact the chemical 
shift, including electronegative group, magnetic anisotropy of π system.  
In this study, a Bruker AV400 NMR Spectrometer (Bruker UK Limited, Coventry, UK).  
was used to measure the 1H NMR for probing interaction among drug, coformer and 
polymer in a ternary solution. Samples were prepared in deuterated chloroform (CDCl3) 
using standard 5 mm NMR tubes and TMS as an internal standard. For each 1H NMR 




and a time domain of 32k data points. All analyses were carried out using software 
MestReNova V11.0 (Mestrelab Research, Escondido, CA 92027, USA). 
3.3.2 Experimental Methods  
3.3.2.1 Apparent Equilibrium Solubility Test 
Equilibrium solubility test is used to measure the amount of materials that can dissolve 
into a specific solvent to generate a saturated solution under specific temperature and 
pressure. 
In this study, all samples solubility was determined by suspending an excess amount of 
crystalline materials in small vials with 20mL dissolution media. The suspension was 
kept at specific temperature with specific well-defined shaking rate for 24h. The 
supernatant was separated from excess solids in solution by MSE Micro Centaur at 
13000RPM for 1min in a MSB 010.CX2.5 centrifuge (MSE Ltd., London, U.K.). 
Subsequently, the supernatant was diluted, and the concentrations of FFA and coformers 
were determined using HPLC. The solid residues were retrieved from the tests, dried for 
24h at ambient temperature, and analyzed by DSC, FTIR, and XRPD. All experiments 
were conducted in triplicate, and data were reported as an average concentration in 
solution.  
3.3.2.2 Desupersaturation Experiments  
Desupersaturation experiments is used to evaluate the polymers effect on the kinetics of 
nucleation and crystal growth in a cocrystal supersaturated system. Seeded 
desupersaturation experiment is applied for examining the polymers effect on crystal 
growth. A low supersaturation ratio should be used in the crystal growth experiments 
for avoiding secondary nucleation. The overall effect of polymers of crystallization of 
supersaturated solution can be studied by using unseeded supersaturated solution.  
In this study, all supersaturated solutions were generated by solvent shift method. In 
seeded desupersaturation experiments, 50mg of milled FFA I crystal seeds (size ≤ 
250µm) were placed into 50mL dissolution media and reached to FFA equilibrium state 




mg/mL FFA stock solution of pure FFA, FFA-NIC CO or 0.6mL of 2.5mg/mL FFA-TP 
CO into the FFA equilibrium solution. The amount of ethanol added to the medium was 
small and had a negligible impact on the apparent FFA equilibrium solubility. In 
unseeded desupersaturation experiments, a supersaturated solution was generated by 
diffusing 20mL of 500μg/mL FFA stock solution of pure FFA, FFA-NIC CO or 
FFA-TP CO to 80mL of water, resulting in 100 g/mL FFA in the cosolvent of 1:4 
ethanol and water.  
Each sample (1mL) was withdrawn from the solution at six predetermined time 
intervals, i.e. 5, 15, 30, 60, 120 and 240min. The supernatant was separated from excess 
solids by centrifugation at 13000RPM for 1min in a MSE Micro Centaur. The 
supernatant was diluted to determine the concentrations of FFA and coformer of NIC or 
TP by HPLC. The solid residues obtained from the desupersaturation experiments were 
examined by DSC, FTIR and OLM. All experiments were conducted in triplicate and 
data were reported as the average of the experiments. 
3.3.2.3 Cocrystal Solubility Test 
The cocrystals solubility cannot be measured by using the normal solubility test method 
because of their unstable thermodynamic in solution. A method called eutectic point 
measurement is applied to successfully measure the solubility of cocrystal, in which two 
solid phases of drug and cocrystal coexisted in an equilibrium state.  
The transition concentrations of FFA and a coformer in PBS were measured to 
determine the solubility of cocrystal. A series of the coformer solutions with different 
concentrations were prepared. Excess amount of FFA I crystalline materials was added 
into a small vial with 20mL of each of the prepared coformer solutions in a shaking 
water bath at 250RPM shaking rate at 23 ± 0.5 °C for 24 h. The samples were separated 
from excess solids by centrifugation at 13000RPM for 1min in a MSE Micro Centaur. 
The concentrations of FFA and coformers were determined by HPLC and the solid 
residues were analyzed by XRPD, DSC, and FTIR. The transition concentrations (or an 
eutectic point) of a cocrystal were determined in the lowest coformer solution prepared 
where two solid phases of the solid drug and cocrystal coexisted in equilibrium with 




3.3.2.4 Powder Dissolution Test 
The powder dissolution test can be conducted under both in-sink and non-sink condition 
to examine the effect of polymers on dissolution behaviors of drug by analyzing the 
concentration changes of drug with time in dissolution medium. In sink condition, the 
dissolution medium volume should be three to ten times greater than the volume 
required to saturate a drug in solution. For non-sink condition, the needed volume of 
dissolution medium is three to ten times less than the saturation volume of drug. 
Under sink condition, the effect of polymers on the dissolution rate of cocrystals can be 
evaluated. In this condition, the changes of the dissolution rate of cocrystals in different 
polymers solution is relevant to the interaction between the pre-dissolved polymer and 
dissolving crystal surface. Under non-sink condition, the capability of polymers on 
generating and maintaining the supersaturated state of cocrystals would be examined 
during dissolution. Additionally, assessment of the supersaturated system under 
non-sink condition can mimic in vivo conditions in the gastrointestinal tract. 
All samples that used in powder dissolution tests were slightly grinded by a mortar and 
pestle and sieved by a 60mesh sieve (below 250μm) to diminish the influence of particle 
size on the dissolution rates. Dissolution media (400mL) in a flat bottom beaker was 
used in each of the experiments. For sink condition experiments, cocrystal powders with 
equivalent 40mg of FFA I were used. While powders with equivalent 400mg of FFA I 
were used for non-sink condition tests. The dissolution tests were conducted at 23 ± 
0.5°C with the aid of magnetic stirring at 250 RPM. Samples of 1 ± 0.1mL were 
withdrawn from the dissolution vessel at predefined time points of 5, 15, 30, 60, 120, 
and 240min. The supernatant was separated from excess solids by centrifugation at 
13000RPM for 1min in a MSE Micro Centaur. HPLC was used to determine the 
concentrations of FFA and coformers of NIC or TP. Solid residues obtained from the 
non-sink condition experiments were dried at room temperature and analyzed by DSC, 




3.3.2.5 OLM Monitoring Single Crystal Dissolution and Analysis  
OLM with video camera at 200× magnification and version 4.0 of the Studio Capture 
software were used to monitor the displacement of different faces of a single crystal 
during dissolution. The size of single crystals ranges from millimeters to one centimeter.  
A single crystal was horizontally placed inside a Petri dish with one end fixed by blue 
tack and then followed by addition of 20mL of PBS in the absence or presence of a 
200μg/mL pre-dissolved polymer. Data were collected at 0, 2, 4, and 6h. 
The specific faces’ dissolution rates of single crystals (FFA I, FFA-NIC CO and 
FFA-TP CO) were determined by measuring the retreated velocity of the faces. Figure 
3.7 represents a model showing the temporal change in the lateral dimensions of single 
crystals. The retreated rate of the crystal length represents for the dissolution rate of the 
(100) and the retreated velocity of crystal width represents for the dissolution rate of the 
(001). The dissolution rate of (100) and (0-11) for FFA I, (01-1) and (100) for FFA-NIC 
CO and (001) and (100) for FFA-TP CO was monitored by OLM. All experiments were 
repeated in triplicate. 
 
Figure 3.7 Model of dissolving a single crystal 
3.3.2.6 Dissolution and Permeation Measurements  
In order to determine in vitro behavior of a cocrystal formulation, a 
dissolution/permeation (D/P) system was used to evaluate the dissolution and 
permeation behavior of cocrystals simultaneously. The D/P system consists of 
side-by-side chambers with a regenerated cellulose membrane of a MWCO of 6-8 KDa 
(Spectrum Labs, USA) mounted between the donor and acceptor sides as a model 
membrane of the human intestine shown in Figure 3. 8. Each compartment has a 













































area of the membrane. A small amount of crystalline materials (size below 250µm) was 
added into a donor compartment and then 9mL of 0.01M pH 4.5 PBS was filled into the 
receptor cell. Finally, 9mL of 0.01M pH 4.5 PBS without and with a pre-dissolved 
polymer solution was added into the donor cell to start the experiment. The temperature 
of the cells was maintained at 37°C using a circulating water bath. The samples from 
donor was withdrawn using a syringe and immediately replaced the same amount of the 
fresh dissolution media into the donor cell to keep the constant dissolution volume in 
the cell at pre-determined time. The samples from donor need to be separated from 
excess solids by centrifugation at 13000RPM for 1min in a MSE Micro Centaur. The 
sample concentration measurement from donor cell mainly showed the dissolution 
profile. The sample was taken from the acceptor cell using a 100 L Gilson pipette. 
Concentrations measured from acceptor represented the permeation profile. The FFA, 
NIC and TP concentration was determined by an automatic HPLC. All experiments 
were repeated in triplicate. 
 
 


















3.4 Preparation  
3.4.1 Buffer Preparation 
pH 6.8 (0.01M) phosphate buffer solution (PBS) was prepared as a dissolution medium 
according to British Pharmacopoeia 2018. 50mL of 0.2M potassium dihydrogen 
phosphate (KH2PO4) and 22.4mL of 0.2M sodium hydroxide (NaOH) were mixed and 
diluted to 1000mL with double distilled water. 
pH4.5 PBS (0.01M) was used as a dissolution medium in this study, which was 
prepared according to British Pharmacopoeia 2018. 1.361g potassium phosphate 
monobase dissolved in 1L double distilled water and pH value of the solution was 
adjusted using sodium hydroxide solution if necessary  
3.4.2 Cocrystals Preparation 
3.4.2.1 Powdered Cocrystals Formation  
FFA-NIC CO was prepared by a solvent evaporation method. A 1:1 equimolar mixture 
of FFA I and NIC was dissolved in acetonitrile with stirring at 80°C. The solution was 
placed in a fume cabinet overnight for solvent evaporation. FFA-TP CO was 
synthesized by a cooling crystallization method. A 1:1 molar ratio of FFA and TP was 
dissolved in a cosolvent (7:3 acetonitrile and water) with stirring at 90 °C and then the 
solution was placed into an ice bath for 2h until the crystals were separated out from the 
solution. Both FFA-NIC CO and FFA-TP CO were characterized and confirmed by 
DSC, FTIR, and XRPD. 
3.4.2.2 Single Cocrystals Formation  
The single cocrystals of FFA-NIC CO and FFA-TP CO were grown from a saturated 
1:1 equimolar mixture solution of FFA and coformers in cosolvent (7:3 mixture of 
acetonitrile and water) by slow evaporation at room temperature over a period of 3−4 
days. FFA cocrystals were harvested from the mother solutions by vacuum filtration. 




3.5 Calculation Equations 
3.5.1 Solubility Parameter (SP)  
Solubility parameter (SP) is used to compare the relative hydrophobicity of polymers, 
FFA, and coformers in solution. The SP of an organic compound is estimated by Fedors 
[288] as  
SP = δ = √𝛿𝑑




𝛿𝑑 = ∑ 𝐹𝑑𝑖  /𝑉𝑚 
(Equ.3- 3) 
𝛿𝑝 = √∑ 𝐹𝑝𝑖
2  /𝑉𝑚 
(Equ.3- 4) 







where 𝛿 is total solubility parameter, 𝛿𝑑 is dispersion Hansen solubility parameter, 
𝛿𝑝  is the polar Hansen solubility parameter, 𝛿ℎ  is the hydrogen-bonding Hansen 
solubility parameter, 𝐹𝑑𝑖 are the group contributions to the dispersion component 𝐹𝑑 
(the molar attraction constant), 𝐹𝑝𝑖 are the group contributions to the polar component, 
𝐹𝑝, 𝐸ℎ𝑖 is the hydrogen-bonding energy per structural group i, 𝑉𝑚 is the corresponding 
molar volume, M is molecular weight, p is density, The method is based on group 
additive constants; therefore, it requires only knowledge of the structural formula of the 
compounds. The unit of solubility parameter is (MPa)(1/2), representing twice the 
number of (calories per cm3)1/2 [289]. 
Table 3. 6 shows the solubility parameter calculation of FFA. All the values of 𝐹𝑑𝑖, 𝐹𝑝𝑖 




calculations about the SP of TP, NIC PEG, PVP and PVP-VA were listed in Table A2. 
1. 
Table 3. 6 Solubility parameter calculation of FFA. 
FFA 
 
Group Fdi Fpi2 Ehi 
=CH- (8) 1600 0 0 
=C-(4) 280 0 0 
NH (1) 160 44100 3100 
COOH (1) 530 176400 10000 
(1) 
-70 0 0 
(3) 660 -------- -------- 
sum 3160 220500 13100 
















𝛿ℎ = √∑ 𝐸ℎ𝑖/𝑉𝑚 = √
13100
191
 = 8.28 MPa(1/2) 
𝛿 = √𝛿𝑑
2 + 𝛿𝑝2 + 𝛿ℎ
2 = (16.52+2.52+8.282) (1/2) =18.62 MPa(1/2) 
3.5.2 Supersaturation Ratio (SSR)  
Supersaturation is the driving force for crystallization. Supersaturation ratio (SSR) 
defined as the ratio of the supersaturation concentration to is thermodynamic solubility 
in the same medium and temperature. SSR can be calculated using the following 
equation:  
SSR = 𝐶𝑠𝑢𝑝𝑒𝑟𝑠𝑎𝑡𝑢𝑟𝑎𝑡𝑖𝑜𝑛/𝐶𝑒𝑞 (Equ.3- 7) 
where C is the concentration of supersaturation solution and Ceq is the concentration of 
solute equilibrium saturated value respectively. Crystallization will only occur when 




3.5.3 Supersaturation Parameter (SSP)  
Supersaturation parameter (SSP) is used to evaluate the drug precipitation behavior 
from a supersaturated system in comparison to a reference system based on the work by 
Chen et al [291].  
Figure 3.9 shows the concentration-time curves of a supersaturation system in a 
dissolution medium. The reference system (curve 𝑪𝟎𝑪𝑹(𝒕) )) and the investigated 
system (curve 𝑪𝟎𝑪(𝒕) or curve 𝑪𝟎𝑪
′(t) ) were compared. Curve 𝑪𝟎𝑪𝑹(𝒕) represents 
the desupersaturated curve of the pure API supersaturated solution in the absence of 
polymers. The C0 is the initial concentration of the supersaturated solution, which is 
higher than API’s equilibrium solubility. Curve 𝑪𝟎𝑪𝟎(𝒕) represents an ideal situation 
where the drug still dissolved in the medium and no crystallization happens over the 
period of time (t). An integration area of 𝑨𝑪𝟎𝑪𝑹(𝒕)𝑪𝟎(𝒕) can be used to indicate “the 
amount of drug precipitated from the pure API supersaturated solution over time (t)” in 
the absence of polymers. An integration area of 𝑨𝑪𝟎𝑪(𝒕)𝑪𝟎(𝒕) or 𝑨𝑪𝟎𝑪′(𝒕)𝑪𝟎(𝒕) illustrates 
“the amount of drug precipitated from the investigated system over time (t)” in the 
presence of coformers or polymers. An integration area of 𝑨𝑪𝟎𝑪𝑹(𝒕)𝑪(𝒕)  and 
𝑨𝑪𝟎𝑪′(𝒕)𝑪𝑹(𝒕) conceptually considered as “the amount difference of precipitation between 
the reference and the investigated system”. For a supersaturated system with the 
desupersaturation curve of 𝑪𝟎𝑪(𝒕) , the integration area of 𝑨𝑪𝟎𝑪(𝒕)𝑪𝟎(𝒕) is smaller than 
that of the reference system, indicating less drug precipitation. Compared with the 
reference system, a supersaturated system with the desupersaturation curve of 𝑪𝟎𝑪
′(t) 
has more precipitated drug solids because of a larger integration area of 𝑨𝑪𝟎𝑪′(𝒕)𝑪𝟎 (𝒕). 
To quantitatively compare the abilities of different systems on inhibiting the drug 























SSP is a dimensionless parameter. A system with a positive SSP value shows an ability 
to prolong drug supersaturation while a negative SSP value indicates no ability to 
maintain the drug supersaturation.  
 
Figure 3. 9 Illustration of supersaturation parameter 
3.5.4 Dissolution Performance Parameter (DPP)  
Dissolution performance parameter (DPP), was used to evaluate the dissolution profile 
of cocrystal powders in the absence or presence of a pre-dissolved polymer in 
comparison to a reference system. Figure 3. 10 shows the dissolution profiles of 
different solid powders in which Ceq is the equilibrium crystalline API concentration in 
the dissolution medium and specific temperature. The area under the curve (AUC) 
𝑨𝑼𝑪𝑪(𝒕) of a dissolution profile C(t) indicates “the amount of drug dissolved” and is 
maintained over the period of the dissolution time from 0 to t [291]. A higher AUC of 
the dissolution profile indicates a better dissolution performance. A curve 𝑪𝑹(𝒕) is the 
reference dissolution profile of solids R with 𝑨𝑼𝑪𝑪𝑹(𝒕). For solid with a dissolution 
curve C(t), its concentration passes the equilibrium value at Teq  and reaches the 
maximum concentration ( Cmax). The 𝑨𝑼𝑪𝑪(𝒕) is significantly higher than that of the 




























































the solid with a smaller value of  𝑨𝑼𝑪𝑪′(𝒕) dissolved less. In order to quantitatively 














Solids with a positive DPP value show an increased ability to dissolve and to be 
maintained in a dissolution medium, while as a negative DPP value indicates that solids 
have a less ability to dissolve and to be maintained in solution. 
 






































































3.5.5 Flux Rate  
Figure 3. 11 represents a permeation profile. The flux of a drug through a membrane, is 
defined as “the amount of drug crossing a unit area perpendicular to its flow direction 






where J(t) is the flux of a drug; Ct1 is the drug concentration (g/mL) in acceptor cell 
(Figure 3. 8) at t1 (min); Ct2 is the drug concentration (g/mL) in acceptor at t2 
(min); V is the solution volume (mL) in the acceptor cell and A is the area of exposed 
membrane in cm2. Unit of flux rate is μg/(cm2*min). 
 
Figure 3. 11 Illustration of permeation profile  
3.6 Chapter Conclusion  
This chapter introduced the materials, analytical techniques, experimental methods, 
preparation methods and calculation equations used in this study. The name, formula, 
purity and manufacturer of materials were presented. The working principle, application, 


















techniques were shown, including IR, Raman, DSC, HPLC, AFM, optical microscopy, 
XRD and NMR. The experimental methods of solubility tests, desupersaturation 
experiments, eutectic point of cocrystal, powder dissolution and D/P measurement were 
described. Then, the preparation methods of dissolution buffer (0.01M pH 6.8 PBS and 
0.01M pH 4.5 PBS) and cocrystals (single and powdered FFA-NIC CO and FFA-TP 
CO) were described. Finally, the calculation equations that used to calculate SP, SSR, 




Chapter 4 Samples Characterization  
4.1 Chapter Overview  
In this chapter, FFA-NIC CO and FFA-TP CO were prepared by using solvent 
evaporation and cooling crystallization respectively. Different analytical techniques 
were used for confirming the formation of cocrystals by comparing the spectra of 
individual components (FFA I, NIC and TP), FFA-NIC CO and FFA-TP CO, including 
DSC, ATR-IR and XRPD. The results of these analytical techniques show that both of 
FFA-NIC CO and FFA-TP CO were successfully synthesized. The structures of 
FFA-NIC CO and FFA-TP CO were presented in this chapter. 
4.2 Materials and Methods  
4.2.1 Materials 
FFA I, NIC, TP, acetonitrile and double distilled water were used in this chapter and 
detailed introduction of this materials can be found in chapter 3. 
4.2.2 Methods 
FFA-NIC CO and FFA-TP CO were formed by solvent evaporation and cooling 
crystallization respectively. ATR-FTIR, DSC, XRPD and Raman have been used to 
characterize the formation of cocrystals. Details of cocrystals synthesis methods and 
these techniques were described in Chapter 3. 
4.3 Results 
4.3.1 DSC Analysis of FFA I, FFA-NIC CO and FFA-TP CO 
The DSC curve in Figure 4. 1 shows that the melting point of FFA-NIC CO was around 
136.4oC which was higher than the melting points of FFA I (133.5oC) and NIC 
(128.1oC). In contrast, the melting point of FFA-TP CO was 185.6oC which was in the 





Figure 4. 1 DSC thermograms for FFA I, NIC, FFA-NIC CO, TP and FFA-TP CO 
4.3.2 IR Spectroscopy Analysis of FFA I, FFA-NIC CO and FFA-TP CO 
The structures of FFA, NIC, TP, FFA-NIC CO and FFA-TP CO have been studied in 
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The structures of FFA-NIC CO and FFA-TP CO have been confirmed by the measured 
IR spectra in Figure 4. 3 [229, 234]. FFA-NIC CO is formed through an acid-pyridine 
heterosynthon involving FFA and NIC molecules [234]. The IR spectrum of FFA I has 
peaks at 3318 cm-1 and 1651 cm-1, corresponding to N-H and C=O stretching 
frequencies [293]. The spectra of NIC has 2 peaks at 3353 cm-1 and 1592 cm-1, 
corresponding to N-H and pyridine ring C=N stretching [294]. In the spectrum of 
FFA-NIC CO, the frequencies of N-H stretching and C=O stretching of FFA are shifted 
to 3324 cm-1 and 1660 cm-1 while the peaks of N-H stretching and pyridine ring C=N 
stretching of NIC shifted to 1608 cm-1 from 1592 cm-1 and to 3395 cm-1 from 3353 cm-1. 
FFA-TP CO is formed through an O-H∙∙∙N hydrogen bond involving the carboxylic acid 
of FFA and unsaturated N atom of the imidazole ring of TP [295]. The IR spectrum of 
TP has peaks at 3119 cm-1, 1660 cm-1 and 1561 cm-1, corresponding to N-H, C=O and 
C=N stretching frequencies which are shifted to 3068cm-1, 1669 cm-1 and 1558 cm-1 in 
FFA-TP CO spectrum, respectively. In the spectrum of FFA-TP CO, FFA’s N-H 
stretching and C=O stretching frequencies are shifted to 3280cm-1 and 1647 cm-1 
respectively. The summary of IR peak identities of FFA I, NIC, TP and cocrystals are 
shown in Table A1.1 in the appendixes. The summary of Raman results in Figure A1. 1 
and Figure A1. 2, showing new peaks of FFA-NIC CO at 3321 cm-1, 1402cm-1 and 
1158 cm-1 and FFA-TP CO at 3269 cm-1, 3077 cm-1, 1423 cm-1 and double peak (1161 





Figure 4. 3 IR spectrum of FFA I, NIC, FFA-NIC CO, TP and FFA-TP CO 
 4.3.3 XRPD Spectroscopy Analysis of FFA, FFA-NIC CO and FFA-TP CO 
Figure 4. 4 shows the XRPD patterns of individual component of FFA I, NIC, TP, 
FFA-NIC CO and FFA-TP CO. The significant characteristic diffraction peaks of FFA I 
are at 2θ=7.1o, 14.2o, 21.4o and 24.6o. Key characteristic diffraction peaks of NIC are at 
2θ=14.9o and 23.5o. After co-evaporation of FFA and NIC in acetonitrile, the new 
materials of FFA-NIC CO have been formed, showing the characteristic diffraction 
peaks at 2θ=6.7o, 9.6 o, 16.2o, 16.8o and 21.9o ,which are in agreement with those of 
published data [234]. The characteristic diffraction peaks of TP are at 2θ=7.2o, 12.7o 
and 14.5o. Through the cooling crystallization method described in chapter 3, FFA-TP 
CO was generated, indicated by the characteristic diffraction peaks at 2θ=5.9o, 11.3o, 





Figure 4. 4 XRPD spectra of FFA I, NIC, FFA-NIC CO, TP and FFA-TP CO 
4.4 Chapter Conclusion  
In this chapter, samples of FFA I, NIC, TP, 1:1 FFA-NIC CO and 1:1 FFA-TP CO were 
characterized by DSC, IR and XRPD. All characterized results demonstrated that both 
of FFA-NIC CO and FFA-TP CO were formed. Based on DSC spectra, FFA-NIC CO 
and FFA-TP CO has distinct melting point compared to individual components. FTIR 
spectra show the hydrogen bonding formation between FFA with NIC or TP during 
cocrystals formation. XRPD spectra demonstrated new characteristic diffraction peaks 




Chapter 5 Investigating the Influence of Polymers on 
Supersaturated Flufenamic Acid Cocrystal Solutions 
(This work has been published. Citation: Guo, M., et al., Investigating the Influence of Polymers on 
Supersaturated Flufenamic Acid Cocrystal Solutions. Molecular Pharmaceutics, 2016. 13(9): p. 
3292-3307.) 
5.1 Chapter Overview  
In this chapter, it is the first time to carry out a systematic investigation for exploring 
the influence of different polymeric additives in cocrystal formulations to illuminate the 
molecular mechanism of the interplay among the polymer/drug/coformer that impacts 
the cocrystal parent drug crystallization kinetics of nucleation and growth. Chemical 
structures of the model drug, coformers and monomer unit of the polymers are shown in 
Table 5. 1. 
Firstly, equilibrium solubility tests were conducted to assess the effect of polymers in 
changing the apparent FFA solubility in solution. Then, a solvent shift approach was 
used to generate an initial FFA supersaturation condition to study crystallization 
kinetics of both nucleation and growth [296]. OLM was used to determine the induction 
time for quantifying the drug nucleation from a supersaturated solution in the absence 
and presence of different pre-dissolved polymers (PEG, PVP and PVP-VA). Measuring 
the desupersaturation curve in the presence of seeds of pure FFA I crystals for 
evaluating the impact of different polymers on growth. The overall impact of polymers 
on inhibiting FFA crystallization from a supersaturated solution was characterized and 
evaluated by measuring desupersaturation curves in the absence of the crystal seeds. 
SSP in different supersaturated solutions were calculated and compared for quantifying 
a polymer inhibition ability to prolong drug supersaturation [291]. DSC, XRPD, 
ATR-FTIR and OLM was used to examine the solid residuals after the solubility and 
the desupersaturation experiments with and without seeds. To further explore the 
intermolecular interaction mechanisms among a polymer, drug and coformer in solution, 
infrared spectra of the parent drug FFA I and coformers of NIC and TP in combination 




Table 5. 1 Structure and SP values of FFA, NIC, TP, and polymers 























5.2 Materials and Methods 
5.2.1 Materials 
FFA I, NIC, TP, FFA-NIC CO, FFA-TP CO, PEG, PVP, PVP-VA, methanol, ethanol, 
acetonitrile and double distilled water were used in this study. Detailed information of 
these materials can be found in Chapter 3.  
5.2.2 Methods 
5.2.2.1 Preparation of FFA-NIC CO and FFA-TP CO 
FFA-NIC CO and FFA-TP CO were used in this chapter, detailed synthesized methods 
can be found in chapter 3.  
5.2.2.2 Apparent Equilibrium Solubility Determination 
The apparent equilibrium solubility of FFA I, FFA-NIC CO and FFA-TP CO was 
determined in the cosolvent (1:4 ethanol and water) in the absence or presence of 200 
µg/mL of a pre-dissolved polymer (PEG, PVP or PVP-VA). The cosolvent of 1:4 
ethanol and water were used in this study to increase the apparent FFA equilibrium 
solubility and thus avoid immediate crystallization of FFA in media through 
maintaining slower kinetics of nucleation and growth. The detailed solubility test 
method can be found in chapter 3. 
5.2.2.3 Nucleation Induction Time Monitoring by OLM 
Nucleation induction times were determined from desupersaturation experiments 
monitored by a OLM. The FFA stock concentration of pure FFA I, FFA-NIC CO or 
FFA-TP CO dissolved in ethanol was 1mg/mL. Different initial supersaturated solutions 
of 50, 100 and 200µg/mL were generated by adding the appropriate amount of the stock 
solution into a small quartz cell filled with 0.5mL of the cosolvent in the absence or 
presence of 200µg/mL of different polymers. The FFA crystallization behavior from a 
supersaturated solution was monitored by OLM. Data collection started immediately 




determined by observing the onset of the FFA crystal formation. Detailed information 
about the OLM can be found in chapter 3 
5.2.2.4 Effect of Polymers on Supersaturated FFA and Cocrystal Solutions  
To decouple the nucleation process, the inhibition effect of a polymer on the growth of 
FFA crystals was assessed from the seeded experiments by measuring the 
desupersaturation curve of a supersaturated solution of pure FFA, FFA cocrystals in the 
absence and presence of 200µg/mL of a pre-dissolved polymer, either PEG, PVP or 
PVP-VA.  
To evaluate the overall inhibition effect of a polymer on FFA crystallization kinetics 
from a supersaturated solution, unseeded desupersaturation experiments were 
conducted. 
Detailed methods of seeded, unseeded desupersaturated experiments can be found in 
chapter 3. 
5.2.2.5 IR for studying intermolecular interaction  
The investigation of the intermolecular interaction among FFA, NIC, TP and polymers 
(PEG, PVP and PVP-VA) in solution was carried out by solution IR. Methanol was 
selected for the intermolecular interaction study of FFA, NIC and polymers, in which 
concentrations of individual components were 50, 21.7 and 20mg/mL respectively. A 
cosolvent of 1M HCl and methanol at a ratio of 1:6 were selected for the intermolecular 
interaction study of FFA, TP and polymers, in which concentrations of individual 
components were 14.3, 9.14 and 20mg/mL respectively. The detailed setting about IR 
can be found in chapter 3.   
5.2.2.6 Physical Property Characterization Techniques   
HPLC was used to study the solubility and the effect of polymers on supersaturated 
FFA I and FFA cocrystals solutions. DSC, FITR and XRPD were used for 
characterization. The detailed information about these techniques can be found in 




5.2.2.7 Solubility Parameter (SP) and Supersaturated Parameter (SSP) Calculation  
In this chapter, solubility parameter (SP) is used to compare the relative hydrophobicity 
of polymers, FFA and coformers in solution. Supersaturation parameters (SSP) were 
calculated and compared for both seeded and unseeded experiments to quantify 
different polymer inhibition abilities [291]. The equations that used to calculate SP and 
SSP can be found in chapter 3. 
5.3 Results 
5.3.1 Apparent FFA Equilibrium Solubility of FFA I, FFA Cocrystals in Cosolvent 
in the Absence and Presence of Different Polymers 
Figure 5. 1 (a) demonstrates the apparent equilibrium solubility of FFA I, FFA-NIC CO 
and FFA-TP CO in cosolvent media in the absence or presence of predissolved 
polymers of PVP, PEG and PVP-VA at equilibrium after 24 h. In the absence of a 
polymer, the apparent FFA equilibrium solubility of FFA-NIC CO (41.9±2.1µg/mL) 
was slightly higher than those of FFA I and FFA-TP CO which were comparable 
(36.0±0.5µg/mL for FFA-TP CO and 36.8±2.1µg/mL for the pure FFA I). In the 
presence of 200µg/mL polymer, PEG, PVP or PVP-VA, the apparent FFA equilibrium 
solubility of FFA I or FFA cocrystals does not change, indicating that none of the 
polymers changed the solution properties. 
Solid residues collected after the solubility tests were analyzed by DSC in Figure 5. 1b. 
For pure FFA I, the resultant solid residues were the same as the starting materials after 
the solubility test in the absence or presence of polymers, indicated by identical DSC 
thermographs in Figure 5. 1b. Following the solubility tests of FFA-NIC CO and 
FFA-TP CO in presence or absence of polymers, the solid residues were yellow FFA III 
crystals, indicating the cocrystals of FFA-NIC CO or FFA-TP CO had transformed into 
FFA III. This was confirmed by DSC thermographs of the solid residues in Figure 5. 1b, 
in which the same thermal events occurred as that of the pure FFA III. Under DSC 
heating conditions, FFA III melted at 123.1 °C and recrystallized to FFA I, which then 
melted at 134.4°C [297]  However, morphologies of FFA III particles collected from 




FFA-NIC CO tests were needle-shaped, whereas those from FFA-TP CO tests were 
rod/disc-shaped. FTIR data of the solid residues are shown in Figure A2. 1 in the 
appendixes, showing that resultant solid residues had the same IR peak at 1607cm-1, 
1598 cm-1 and 1652 cm-1 as pure FFA I [298]. While the resultant solid residues from 
FFA-NIC CO and FFA-TP CO samples shows same characterized IR peak as FFA III at 
1601 cm-1, 1581 cm-1 and double peaks (1670 cm-1 and 1655 cm-1) [298]. The IR results 
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Figure 5. 1 Solubility test results after 24h: (a) apparent equilibrium solubility; (b) DSC results of solid 
residues; (c) imaging of solid residues: All scale bars were 100μm. 
5.3.2 Effect of Polymers on the Nucleation Induction Time of FFA Crystallization 
in Solution 
According to the measured equilibrium solubility of FFA I in the previous section, the 




values of 1.36, 2.72, and 5.44, respectively. The nucleation induction times in Table 5. 2 
are based on the initial observation times of FFA crystals detectable by OLM. Without a 
predissolved polymer in the cosolvent media, the precipitation of FFA from the pure 
FFA and two cocrystal solutions occurred rapidly at the low SSR of 1.36. The induction 
times of FFA, FFA cocrystals supersaturated solution were significantly distinct in the 
presence of different polymers, PEG, PVP, and PVP-VA. With predissolved PEG in 
solution, its induction times were increased slightly for all test solutions at the low SSR 
of 1.36. No FFA crystals were found for all test solutions in the presence of 200μg/mL 
of predissolved PVP or PVP-VA at an SSR 1.36, indicating that PVP or PVP-VA can 
completely inhibit the crystallization of FFA during the 30min experiment. In order to 
differentiate the inhibition abilities of PVP and PVP-VA, the experiments were 
proceeded with a higher initial degree of supersaturation SSR 2.72. From the recorded 
images, it was observed that dense liquid particles appeared immediately in the 
experiments with the predissolved PVP or PVP-VA and then the formation of the 
crystal nuclei within the dense liquid clusters. It is in excellent agreement with the 
two-step mechanism of nucleation of crystals in solution [299]. In the presence of 
predissolved PVP in solution, the order of the induction times was TFFA‑TP CO < TFFA‑NIC 
CO < TFFA. In contrast, PVP-VA can completely inhibit the crystallization of FFA from 
the three test solutions. Further tests were conducted at the supersaturation level of SSR 
= 5.44 with predissolved PVP-VA. It was shown that the induction times were 
comparable for the two cocrystal solutions, with the longest induction time being 446 s 
for the pure FFA solution. 
Figure 5. 2 shows the images of a representative part of the quartz cell, indicating the 
morphology of the FFA crystals after tests. In cosolvent without a predissolved polymer, 
the needle shape morphology of FFA crystals from both the FFA-NIC CO and pure 
FFA solution was similar. In contrast, the FFA crystals from the FFA-TP CO solution 
were significantly smaller and rod-shaped. In the presence of PEG in solution, the FFA 
crystals precipitated from the three test samples became smaller. In the presence of PVP 
or PVP-VA in solution, all crystals precipitated from three test solutions were a similar 




Table 5. 2 Nucleation induction time (30mins controlled experiments) 








FFA 9± 2(sec) 176 ±37 (sec) No crystal appeared No crystal appeared 
FFA-NIC CO 15±7(sec) 288± 172(sec) No crystal appeared No crystal appeared 
FFA-TP CO 24±10(sec) 218± 161(sec) No crystal appeared No crystal appeared 
 
SSR=2.72 
FFA n.m.1,2 n.m.2 658±47 (sec) No crystal appeared 
FFA-NIC CO n.m. 2 n.m. 2 555±93 (sec) No crystal appeared 




FFA n.m. 2 n.m. 2 n.m. 3 446±73 (sec) 
FFA-NIC CO n.m. 2 n.m. 2 n.m. 3 392± 93(sec) 
FFA-TP CO n.m. 2 n.m. 2 n.m. 3 397± 63(sec) 
1: not measured; 2: Nucleation experiments not measured when SSR=2.72 as the induction time of FFA 
in the absence or the presence of PEG has been detected at SSR=1.36; 3: Nucleation experiments not 











5.3.3 Effect of Polymers on the FFA Crystal Growth in Solution 
Due to the variation of the initial FFA concentrations in the seeded solutions, the 
desupersaturation curve is represented by the normalized value of Cnorm(t) which is 
the ratio of the measured FFA concentration via the initial FFA concentration in 






where C(t) is the measured FFA concentration at sampling time t, C0 is the initial 
FFA concentration in the seeded solution without adding the stock solution and Cstock 
is the FFA concentration of the stock solution.  
Figure 5. 3 shows the desupersaturation curves of the different test samples. The 
gradient of a FFA desupersaturation curve is directly related to bulk growth rate of FFA 
crystals in solution. Without a polymer, the growth rate of FFA crystals of the FFA-NIC 
CO and FFA-TP CO solutions was slower than that of the pure FFA solution, indicating 
the coformer of NIC or TP can inhibit the growth of FFA crystals, with NIC being more 
effective at 12% of SSP. PEG can slightly reduce the growth rate of the FFA crystals in 
the pure FFA solution with 4% of SSP. In contrast, PEG reduced the inhibition ability 
of NIC for the growth of FFA crystals in FFA-NIC CO solution in which SSP was 
reduced to 1% from 12% shown in Figure 5. 3e. Surprisingly, both PVP and PVP-VA 
were ineffective in inhibiting the growth of FFA crystals and instead accelerated the 
FFA crystal growth rates, indicating that the FFA concentrations in solution quickly 
decreased to the equilibrium solubility, shown in Figure 5. 3c, d. With predissolved 
PVP, the SSP dropped to −17% in the pure FFA solution, to −28% in the FFA-NIC CO 
solution and to −12% in the FFA-TP CO solution. In the presence of PVP-VA in 
solution, the crystal growth rates in cocrystal solutions SSP values, −27% in the 
FFA-NIC CO solution, and −24% in FFA-TP CO solution, were faster than that of the 
pure FFA solution, SSP of −13%. DSC thermographs and images of the solids isolated 
from the experiments were the same as that of initial seeds of FFA I, shown in Figure 




collected in Figure 5. 3f, it was found that a shift of the carbonyl peak (1651 cm−1) of 
FFA I was observed in all the experiments, suggesting that a coformer or polymer was 










































































































































































Figure 5. 3 Seeded desupersaturation curves in the absence or presence of polymers: (a) cosolvent; (b) 
Cosolvent with predissolved PEG ;(c) Cosolvent with predissolved PVP; (d) Cosolvent with predissolved 
PVP-VA; (e) Comparison of supersaturation parameters (reference is the pure API in cosolvent); (f) FTIR 

























































5.3.4 Overall Polymer Inhibition Ability on Maintaining FFA Supersaturation 
The overall effect of a polymer on inhibition of FFA crystallization from a 
supersaturated solution was evaluated by unseeded desupersaturation experiments in the 
absence or presence of 200μg/mL of a predissolved polymer of PEG, PVP, or PVP-VA, 
as described in the previous section. The initial FFA concentration was 100μg/mL 
corresponding to SSR = 2.72. Figure 5. 4 shows the desupersaturation curves of the 
different test samples. The FFA concentrations from different test samples decreased 
rapidly in the cosolvent media without a predissolved polymer in Figure 5. 4a. The 
FFA-NIC CO and FFA-TP CO solutions show a comparable performance in which the 
rate of desupersaturation was slower than that of the pure FFA solution. The FFA 
concentrations in all three test solutions were reduced to the same static level of 
42μg/mL within 2h, which was slightly higher than its solubility. In the predissolved 
PEG media, the decreasing rates of the supersaturated FFA concentrations in the 
FFA-NIC CO and FFA-TP CO solutions are significantly slower in comparison with 
that of the pure FFA solution, showing an increased SSP of 13.4% for FFA-NIC CO 
solution, 12.2% for FFA-TP CO, and just 3.2% for the pure FFA solution in Figure 5. 
4b.  Among the three solutions with predissolved PVP, Figure 5. 4c demonstrates that 
PVP is the effective inhibitor for the pure FFA solution as seen by a 15.9% increase in 
inhibition of FFA. Compared with PEG, PVP has a reduced ability on maintaining FFA 
in either the FFA-NIC CO or FFA-TP CO solutions. PVP-VA predissolved in solution 
can significantly reduce the rate of the FFA precipitation from both supersaturated FFA 
and FFA-NIC CO solutions, showing 27.4% and 26.4% increases of SSP values in 
Figure 5. 4d,e. However, there is no difference between PVP and PVP-VA in 
maintaining the supersaturated FFA in FFA-TP CO solution in Figure 5. 4e. The solids 
precipitated from all the experiments were yellow needle-shape FFA III crystals 
confirmed by the DSC results and images in Figure A2. 3 in the appendixes. The FTIR 
data showed that a shift of the carbonyl peak (1655 cm−1) of FFA III at was observed in 
all the experiments, suggesting that a coformer or polymer was coprecipitated in the 













































































































































Figure 5. 4 Unseeded desupersaturation curves in the absence or presence of polymers: (a) cosolvent; (b) 
Cosolvent with predissolved PEG; (c) Cosolvent with predissolved PVP; (d) Cosolvent with predissolved 
PVP-VA; (e) Comparison of supersaturation parameters; (f) FTIR data of solids 
5.3.5 IR Spectroscopic Investigation of Intermolecular Interactions among FFA, 
Coformer, and Polymer in Solution 
Figure 5. 5 shows the comparison of the solution IR spectra of individual components of 
FFA, NIC, TP, and mixtures of FFA and coformers in the absence and presence of 


























































cm−1, indicating C=O stretching [293]. When a component of NIC, PVP, or PVP-VA 
was added in the solution, this FFA characteristic peak was shifted to a smaller 
wavelength number of 1684 cm−1, indicating an intermolecular interaction between 
them in solution. In contrast, there is no change in the FFA C=O peak in the PEG 
solution, suggesting no interaction between these two components. NIC can interact 
with FFA or PVP in solution, demonstrated by a change in the characteristic peak of 
NIC at 1625 cm−1, corresponding to N−H stretching [294], to 1617 cm−1 in the presence 
of FFA and to 1631 cm−1 in the presence of PVP in Figure 5. 5b. Surprisingly there is 
no interaction between NIC with PVP-VA or PEG in solution, confirmed by no change 
in the characteristic peak of NIC at 1625 cm−1. The IR characteristic peak of TP (Figure 
5. 5c) at 925 cm−1, corresponding to N-H symmetric stretching [300], has been shifted 
to a lower wavenumber by inclusion of PVP or PVA-VA and to a higher wavenumber 
by adding PEG or FFA in solution, indicating TP can interact with any of the 





Figure 5. 5 IR spectroscopic investigation of molecular interaction in solution: (a) FFA interaction with 





5.4.1 Effect of a Polymer on the Apparent FFA Equilibrium Solubility of FFA I, 
FFA-NIC CO, and FFA-TP CO in Cosolvent 
There is widespread acceptance that the crystalline nature of pharmaceutical cocrystals 
can offer advantages over amorphous materials to formulate drug compounds with 
limited solubility and bioavailability, due to superior thermodynamic stability and purity. 
Although significant advances in design and discovery have been made, little work has 
been conducted to formulate cocrystals into a drug product. Therefore, the behavior of a 
cocrystal in a formulated product is largely unknown. To offer the most desired in vivo 
performance with the highest bioavailability for many life-saving drugs with poor 
biopharmaceutical properties, a fundamental understanding of critical factors that 
control the dissolution and absorption performance of a cocrystal formulated product is 
required. In this work, the focus was on understanding the parent drug crystallization 
kinetics from a supersaturated cocrystal solution in the presence of a polymeric 
excipient. It aimed to provide the mechanistic understanding of the properties of a 
polymer as a good inhibitor of crystallization for a given drug cocrystal. Two FFA 
cocrystals, FFA-NIC CO and FFA-TP CO, were chosen due to significant differences in 
their physicochemical properties. The low polymer concentration of 200μg/mL used in 
the investigation was based on the rational consideration of a 500mg tablet containing 
250mg of stabilizing polymer, in which 20% of the polymer was released in 250mL of 
the GI tract at the beginning stage of dissolution. According to the equilibrium 
solubility results in Figure 5. 1a, FFA concentrations of FFA I, FFA-NIC CO, or 
FFA-TP CO were constant in solution in the absence and presence of 200μg/mL 
polymer of PEG, PVP, or PVP-VA, indicating that the impact of a polymer on FFA 
supersaturation is due to the stabilization effect on crystallization rather than 
solubilization effect of polymer. Furthermore, due to the low molecular weight of the 
polymer used in the study, the viscosity of the 200μg/mL polymer solution was 
essentially the same as that of the dissolution medium without a predissolved polymer. 
Therefore, the interplay of API-coformer, API-polymer, and coformer-polymer 
elucidated in this study was not affected by the changes of solution bulk properties of 




5.4.2 Effect of Intermolecular Interactions of Drug/Coformer, Drug/Polymer, and 
Coformer/Polymer on Parent Drug Nucleation and Growth Kinetics in Solution 
This study has clearly demonstrated that a cocrystal coformer can interfere with a 
polymer to alter its ability to maintain the parent drug supersaturation in solution. This 
property involves both nucleation and growth through competition of the intermolecular 
interactions of drug/coformer, drug/polymer, and coformer/polymer in solution. 
In the solid state, cocrystals are formed through hydrogen bonding between an API and 
coformer. Once cocrystals are dissolved in solution, they could be regarded as 
completely separate individual molecules. For example, US FDA has elected to classify 
cocrystals within their framework as dissociable “API-excipient” molecular complexes. 
However, in this study it was found that hydrogen bonds between FFA and coformers, 
NIC, or TP, were not broken completely, indicated by changes in their characteristic 
peaks of the solution spectra in Figure 5. 5(a). This API/coformer interaction in solution 
certainly affected the formation of nuclei by hindering the reorganization of a cluster of 
FFA molecules into its ordered structure. Therefore, the coformer of NIC or TP can be 
regarded as a nucleation inhibitor for FFA crystallization, generating slightly longer 
induction time (15s for FFA-NIC CO solution and 24s for FFA-TP CO solution) 
compared with the pure FFA supersaturated solution (9s of induction time) in the 
absence of a polymer, as shown in Table 5. 2.The FFA molecule, shown in Table 5. 1, 
has the very strong hydrogen bond donor of O−H combined with a middle strength 
acceptor of C=O, thus displaying higher hydrophobicity with a low value of SP (18.62 
MPa1/2). Therefore, FFA self-association should be disrupted by a polymer with strong 
acceptor groups that can effectively compete with the acceptor group C=O [301]. 
Indeed, the formation of the hydrogen bonding between the polymer of PVP or 
PVP-VA with FFA in solution was demonstrated by the IR spectroscopic investigation 
in Figure 5. 5a, as both polymers (N−C=O in PVP and N−C=O and O−C=O in PVP-VA) 
have strong acceptors. This suggested that both PVP and PVP-VA were able to act as 
effective nucleation inhibitors, indicated by the significantly increased nucleation 
induction times at different degrees of supersaturation. A higher level of inhibition 
effectiveness of PVP-VA in comparison with PVP was due to the presence of carbonyl 




flexibility to interact with FFA molecules in solution. Therefore, evidence for a 
two-step mechanism of cocrystal nucleation was revealed in the presence of PVP-VA. 
During two-step mechanism nucleation, a droplet of a dense liquid (metastable zone 
with respect to the crystalline state) is formed in the homogeneous solutions prior to 
nucleation. Then clusters order inside the droplet to produce a crystal[299]. The 
precipitated solids in Figure 5. 2 show a lack of birefringence under polarized light and 
no distinct particle morphology, indicating the amorphous nature of the particles was 
due to the integration of PVP or PVP-VA in the FFA crystal structure and/or rapid 
desupersaturation. The amorphous nature of the precipitated particles could be also 
related to liquid−liquid phase separation (LLPS), which was observed in amorphous 
solid dispersion systems (ASDs) in recent publications [302, 303]. The high 
supersaturation generated by ASDs can lead to a two-phase system wherein one phase is 
an initially nanodimensioned drug-rich phase and the other is a drug-lean continuous 
aqueous phase. In those studies, the stronger nucleation inhibitors PVP/PVP-VA 
allowed the system to reach supersaturation levels such that the system underwent 
LLPS. The excess drug then precipitated forming a dispersed, colloidal amorphous 
drug-rich phase, which resulted in the absence of birefringence in the precipitated 
particles. 
The ineffectiveness of PEG as a nucleation inhibitor was probably due to its structural 
rigidity in which the hydrogen acceptor, C−O−C, on the main chain had been prevented 
from interacting with FFA molecules in solution. Thus, no change was observed in the 
characteristic peak of FFA in solution with the predissolved PEG (Figure 5. 5a). The 
limited inhibition ability of PEG may be due to the steric barrier for the formation of 
nuclei via the adsorption of the polymer on the surface of pre-nuclear clusters [304]. It 
has to be stressed that although all three polymers of PEG, PVP, and PVP-VA 
interacted with FFA with different mechanisms, they were all integrated into the FFA 
crystal lattices, showing as a variation of the FFA III characteristic peak, which 
corresponds to its C=O stretching frequency (1655 cm−1) in Figure 5. 4f. The results are 
in good agreement with previous studies, which have shown that multicomponent 




[305, 306]. A change in crystal morphologies, seen in Figure A2. 3 in the appendixes, 
also supported this. 
It was not surprising that the nucleation induction time was reduced for FFA-NIC CO 
solution in the presence of PVP compared to the pure FFA solution because the 
competition between NIC and FFA with PVP weakened the polymer inhibition ability. 
There was no interaction between NIC with PVP-VA in solution shown in Figure 5. 5b. 
Therefore, the nucleation induction time from the FFA-NIC CO solution was almost the 
same as that of the pure FFA solution, in the presence of PVP-VA. As TP can interact 
with both polymers of PVP and PVP-VA in solution, the nucleation induction time 
reduced in the FFA-TP CO solution compared to the pure FFA solution in the presence 
of the polymers, as shown in Table 5. 2. PEG inhibits FFA crystallization using a 
different mechanism in comparison with PVP or PVP-VA, for reasons outlined above. 
The nucleation induction time increased in both the FFA-NIC CO and FFA-TP CO 
solutions in the presence of PEG due to the accumulated inhibition effects of both the 
coformer and polymer on FFA. 
In order to study the effectiveness of the polymers on inhibiting FFA crystal growth 
after nucleation, desupersaturation experiments were conducted including the addition 
of the FFA seeds. A low SSR of 1.27 (based on 36.6μg/mL of the solubility of FFA I 
measured in this study) was used in the growth experiments to avoid secondary 
nucleation. It was observed that polymer effectiveness at reducing crystal growth rates 
was not found to have a similar impact on nucleation. In the nucleation induction time 
study, PVP and PVP-VA were effective nucleation inhibiting agents in the pure FFA 
solution. In contrast, they were poor at inhibiting growth and actually accelerated the 
growth of FFA crystal seeds, as seen by the negative values of SSP in Figure 5. 3e. It is 
known that the alteration of crystal growth by additives can be achieved through 
modifying the step speed or altering the step edge energy, which is classified as step 
pinning, incorporation, kink block, and step edge adsorption mechanisms [307]. To 
occur, the additives must be adsorbed on the surface of the crystals to block active 
crystal growth sites. There are a number of interactive forces responsible for the 




bonding, and hydrophobic interactions. The electrostatic force was not considered 
because of the neutral natures of the solution and drug components used in this study. 
The coformer molecules of NIC or TP in a cocrystal solution were most likely adsorbed 
on the FFA crystal surface due to hydrogen bonding attraction as the growth rate 
inhibitor. This led to moderately increased SSP values of 12% for FFA-NIC cocrystal 
solution and 5% for FFA-TP CO solution, as shown in Figure 5. 3e. In the pure FFA 
solution with the predissolved PEG, hydrogen bonding was not promoted between PEG 
and FFA as shown in the IR spectroscopic investigation in Figure 5. 5a. Therefore, 
hydrophobic interaction was the main interactive force to drive PEG molecules to be 
adsorbed on the surfaces of the FFA crystal seeds. A large difference in their SP values 
in Table 5. 1 suggests a weak interactive force between FFA and PEG in solution. It 
was not surprising that PEG was neither an effective FFA nucleation nor growth 
inhibitor. The decrease in the growth inhibition in the FFA-NIC CO solution in the 
predissolved PEG can most likely be the reduced NIC, being a more effective inhibitor 
in comparison to PEG, when adsorbed on the solid surface due to competition by PEG 
for the same adsorption sites. In the FFA-TP CO solution in the presence of PEG, there 
was no noticeable change in the extent of growth inhibition as both TP and PEG were 
equally effective on an individual basis shown in Figure 5. 3e. 
In the pure FFA solution in the presence of PVP or PVP-VA, acceleration of crystal 
growth occurred, indicated by the negative SSP values of −17% for PVP and −13% for 
PVP-VA. Similar phenomena were found in other studies when one or more surfactants 
were predissolved in the solution in which it was believed that the adsorbed additives 
could lead to a decrease in interfacial tension to be favorable to growth [308]. However, 
in this study the enhanced crystal growth was not likely to be caused by the reduced 
interfacial tension between the crystal and solution due to the polymer adsorption. It is 
known that strong intermolecular hydrogen bonding was occurring between FFA and 
PVP or PVP-VA in solution. When polymer molecules were adsorbed on the surface of 
the FFA seeds, the bound FFA molecules were driven around the FFA seeds, leading to 





In the FFA-NIC CO solution with the predissolved PVP or PVP-VA, acceleration of 
crystal growth was enhanced in comparison to the pure FFA solution in the presence of 
the same polymer. In the FFA-TP CO solution with the predissolved PVP, acceleration 
of crystal growth was reduced in contrast to PVP-VA where growth was promoted. 
These results demonstrated that the combination of PVP or PVP-VA in the presence of 
either coformer (NIC or TP) can either enhance or reduce the rate of the crystal growth. 
Overall, the effect was to accelerate the growth. Thus, rational selection of a polymer is 
required to enhance the inhibition ability in a cocrystal supersaturation solution. 
The comparison of the overall desupersaturation profiles of three supersaturation 
solutions in the absence and presence of a polymer of PEG, PVP, or PVP-VA is given 
in Figure 5. 4. In the absence of a polymer, a cocrystal solution showed a better 
performance to maintain the FFA in solution in comparison to the pure FFA solution 
due to the enhanced combination effects of the nucleation and growth inhibition 
abilities of the coformers. In the predissolved PEG, a cocrystal solution showed an 
increased ability to maintain supersaturation for extended time periods, which was most 
likely due to the enhanced combination effects of the individual nucleation and growth 
inhibition abilities of the coformer and PEG. Clearly the polymer nucleation inhibition 
effect outweighed its growth acceleration ability for FFA in solution, indicating that the 
rate of desupersaturation was reduced dramatically in the presence of PVP or PVP-VA. 
The desupersaturation behavior of FFA cocrystal solutions in the presence of PVP or 
PVP-VA depends on different interaction mechanisms of the polymer and coformer and 
on the competition effect of the polymer and coformer for formation of hydrogen 
bonding with FFA molecules, in which PVP-VA was a good crystallization inhibitor for 
FFA-NIC CO solution. 
It is worth noting that the study has shown the coformers and polymers have been 
integrated in the solid particles recovered from the seeded and unseeded experiments 
based on the measured IR spectra. However, the IR data cannot quantify the relative 
proportion of coformer/polymer coprecipitated in the desupersaturated solids, which 
could be determined by solid state NMR or other techniques. In the meantime, more 
fundamental research is required to guide the selection of polymers in cocrystal 




5.5 Chapter Conclusion  
The development of enabling formulations is a key stage when demonstrating the 
effectiveness of pharmaceutical cocrystals is applied to maximize the oral 
bioavailability for poorly water-soluble drugs. It is important to have a fundamental 
understanding of nucleation and crystal growth for evaluating the inhibition effect of 
polymers on the drug crystallization from cocrystals’ supersaturation. In this study, the 
influence of three polymers PEG, PVP, and PVP-VA on the FFA crystallization in three 
different supersaturated solutions of the pure FFA and two cocrystals of FFA-NIC CO 
and FFA-TP CO has been investigated by measuring nucleation induction times and 
desupersaturation rates in the presence and absence of seed crystals.  
It was found that the competition of intermolecular hydrogen bonding among 
drug/coformer, drug/polymer, and coformer/polymer was a key factor responsible for 
maintaining the supersaturation through nucleation inhibition and crystal growth 
modification in a cocrystal solution. The supersaturated cocrystal solutions with 
predissolved PEG demonstrated effectiveness at stabilizing supersaturated solution 
compared to pure FFA in the presence of the same polymer. In contrast, the two 
cocrystal solutions in the presence of PVP or PVP-VA did not perform as well as pure 
FFA with the same predissolved polymer. The study suggested that the selection of a 
polymeric excipient in a cocrystal formulation should not be solely dependent on the 




Chapter 6 Insight into Flufenamic Acid Cocrystal Dissolution 
in the Presence of a Polymer in Solution: from Single Crystal 
to Powder Dissolution 
(This work has been published. Citation: Guo, M., et al., Insight into Flufenamic Acid Cocrystal 
Dissolution in the Presence of a Polymer in Solution: from Single Crystal to Powder Dissolution. 
Molecular Pharmaceutics, 2017. 14(12): p. 4583-4596.) 
6.1 Chapter Overview 
In this study, the aim is to understand the dissolution mechanisms of cocrystals in 
solution in the absence and presence of a predissolved polymer. We conducted different 
dissolution experiments of both single and powdered cocrystals to evaluate the 
dissolution behaviors at multiple length scales. At the molecular level, we studied how a 
cocrystal surface interacted with a polymer by investigating the changes of the etching 
pattern observed by using AFM. At the macroscopic scale, dissolution rates of 
particular faces of a single crystal were determined by measurement of the physical 
retreated velocities of different faces using optical light microscopy (OLM). In the bulk 
experiments, the concentration of a drug in a dissolution medium in the absence or 
presence of a polymer was measured under both sink and non-sink conditions and the 
dissolution rate was deduced from the evolution of this concentration. Sink condition 
experiments were performed to evaluate the effect of a polymer on the dissolution rate 
of cocrystals, and non-sink condition was to evaluate the ability of a polymer to 
generate and maintain supersaturated drug solutions. Under sink conditions the change 
of a cocrystal dissolution rate during dissolution should be directly related to the 
interaction between the predissolved polymer in solution with the dissolving crystal 
surface. Evaluation of the supersaturating systems benefits from the use of non-sink 
conditions that mimic the in vivo conditions in the gastrointestinal tract. The FFA-NIC 
CO and FFA-TP CO with PEG, PVP, and PVP-VA were selected, with the aim to 
identify the different influences of these polymers on cocrystal dissolution. The 
chemical structures of the model drug, the coformers, and the monomer units of the 




In order to eliminate the effect of viscosity, a low polymer concentration of 200μg/mL 
was used in the study. At this polymer concentration, the equilibrium solubility of FFA 
remained virtually the same as without the presence of the polymers. Because of the 
thermodynamically unstable nature of a cocrystal in solution, the solubility of FFA-TP 
CO and FFA-NIC CO was determined by their eutectic points through measuring their 
solubility curves [309]. The faces of FFA I, FFA-TP CO, and FFA-NIC CO single 
crystals were indexed using X-ray diffraction and nanometer-scale models of their 
morphologies which were created using Mercury 3.9 (The Cambridge crystallographic 
Data Centre, Cambridge, UK). These morphology models were also used to explain the 
properties of each face of a single crystal in the AFM and OLM dissolution experiments. 
In order to quantify the effect of a predissolved polymer on the powder dissolution 
performance, the dissolution performance parameters (DPPs) in different condition 
experiments were calculated and compared. The solid residues after the solubility and 
powder dissolution experiments were examined by DSC, XRPD and IR. 
6.2 Materials and Methods 
6.2.1 Materials 
FFA I, NIC, TP, KH2PO4, NaOH, PEG, PVP, PVP-VA, methanol, acetonitrile, double 
distilled water was used in this chapter. Detailed information about these materials can 
be found in Chapter 3.  
6.2.2 Methods  
6.2.2.1 Preparation of 0.01M pH 6.8 PBS 
The detailed method for preparing 0.01M pH 6.8 buffer can be found in Chapter 3.  
6.2.2.2 Powdered and Single FFA Cocrystals preparation  
Powdered and single FFA-NIC CO and FFA-TP CO was used in this chapter. The 




6.2.2.3 Single Crystal Face Indexing and Morphology Models 
To identify the exposed crystal faces of single crystal during AFM and OLM dissolution 
experiments, representative crystals of each type were mounted on an Oxford 
Diffraction XCalibur diffractometer. Only a few X-ray images were collected for each 
crystal, which allowed determination of the unit cell parameters and the orientation 
matrix. The major faces could then be identified by orienting the crystals in specific 
crystallographic directions on the diffractometer, while observing them through the 
built-in camera. Models of the observed morphologies were created in Mercury 3.9 (The 
Cambridge crystallographic Data Centre, Cambridge, UK) by manually adjusting the 
list of faces and face-to- centroid distances to match those observed experimentally on 
the diffractometer. A summary of these results is given in Figure 6. 1, with the single 
crystal indexing data in Table A3.1 in the appendixes 
6.2.2.4 Apparent Equilibrium Solubility of FFA I 
The Apparent equilibrium solubility of FFA I was determined in 0.01M pH 6.8 PBS 
with or without 200μg/mL of a polymer (PEG, PVP or PVP-VA) in a shaking water 
bath at 250RPM sharking rate and 23 ± 0.5°C for 24h. The detailed information about 
solubility tests can be found in Chapter 3.  
6.2.2.5 Cocrystal Solubility  
For a 1:1 cocrystal of AB without consideration of ionization of each component, its 
solubility is calculated as[309] 
SAB = √Ksp = √AeuBeu 
(Equ. 6- 1) 
where Ksp is the solubility product of the AB cocrystal and concentrations of Aeu and 
Beu  are transient concentrations of drug and coformer where the solution is in 
equilibrium with solid drug and cocrystal. 
To measure transition concentrations of FFA and a coformers of TP or NIC in PBS, a 




solutions and 0.0, 17.8, 57.4, 61.8, 66.2, 71.1, 142.3, and 213.4mmol/L for NIC 
solutions, respectively. The details of the measurement can be found in chapter 3.  
6.2.2.6 Atomic Force Microscopy (AFM) Measurements 
Single crystals with well-defined and visually flat faces were selected for dissolution 
study. The size of single crystal was from millimeters to one centimeter. In order to 
correlate the etching pits with the crystal structure, the axis directions were determined 
by comparing the observed crystal face with the indexed crystal morphology created by 
Mercury 3.9. A single crystal was first mounted onto an AFM sample disk using 
double-sided seal tape, in which the studied face was up. The prepared sample disk was 
then immersed in a Petri dish with 20mL of 0.01M pH 6.8 PBS in the absence or 
presence of a polymer at room temperature for a period of time varying from 2 to 10min 
as shown in Table 6. 1. After a predetermined time interval, the disk was taken from the 
solution and the remaining solution on the crystal surface was removed with filter paper. 
Finally, the sample was air-dried for at least 0.5h before AFM observation. 
The surfaces of single crystals of FFA I, FFA-TP CO and FFANIC CO before and after 
the immersing dissolution tests (Table 6. 1) were observed with an AFM. The detailed 
information and setting of AFM can be found in chapter 3.  
Table 6. 1 AFM measurements. 
Crystal Face Dissolution time (min) 





PBS with pre-dissolved 
PVP-VA 
FFA I (100) 10 10 10 10 
FFA-TP CO (001) 10 10 10 10 




6.2.2.7 Optical Light Microscopy (OLM) Dissolution Monitoring for Single 
Crystals of FFA I and FFA Cocrystals 
In this study, the dissolution rate of specific faces of single crystal of FFAI, FFA-NIC 
CO and FFA-TP CO was monitored by OLM. The detailed information and setting of 
OLM can be found in chapter 3. 
6.2.2.8 Powder Dissolution Tests 
Powder dissolution experiments of FFA I, FFA-TP CO, and FFA-NIC CO were 
performed under both sink and non-sink conditions and conducted in 0.01M pH6.8 PBS 
in the absence or presence of 200μg/mL of a polymer (i.e., PEG, PVP, or PVP-VA). 
The detailed method can be found in chapter 3.  
6.2.2.9 Dissolution Performance Parameter (DPP) 
The equation that used to calculate DPP can be found chapter 3. 
6.2.2.10 Analytical Techniques 
HPLC was applied to determine the solubility and dissolution properties of FFA I, FFA 
cocrystals. DSC, XRPD and AIR was employed for characterization. The details about 
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Figure 6. 1 Crystal morphologies and molecular packings at crystal faces used in experiments.   
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6.3 Results  
6.3.1 FFA I and FFA Cocrystals Characterization, Morphology Prediction and 
Face Indices 
Single cocrystals of FFA-NIC CO and FFA-TP CO were grown using the slow solvent 
evaporation technique described in the chapter 3. The identities of the crystals have 
been confirmed by XRPD, DSC, and FTIR measurements (Figure A3. 1 in the 
appendixes). Single FFA-NIC COs harvested were thin, brick-shaped and single 
FFA-TP COs were chunky, with sizes ranging from millimeters up to one centimeter. 
The single crystals of FFA I from the received materials were plate-like with a wider 
size range from millimeters up to one centimeter. Representative microscopy images of 
these single crystals are shown in Figure 6. 1. Models of the crystal morphologies were 
created using Mercury 3.9 based on the crystal structures of each material obtained from 
the Cambridge Structural Database (CSD refcodes: FPAMCA18 for FFA I; EXAQAW 
for FFA-NIC CO; ZIQDUA for FFA-TP CO, details in Table A3.1 in the appendixes) 
and face indexing of representative single crystals using an X-ray diffractometer (Figure 
6. 1). 
The FFA I structure is formed with hydrogen-bonded dimers between the carboxyl 
groups of two FFA molecules [310]. In the FFA-NIC CO structure, hydrogen-bonded 
rings are formed by two FFA and two NIC molecules. These four-molecule rings are 
linked into infinite tubes by the amide chain motif [234]. Regarding the FFA-TP CO 
structure, TP molecules form a dimer via N−H···O hydrogen bonds involving the 
saturated N atom of the imidazole ring and one of the carbonyl groups. An O−H···N 
hydrogen bond involving the carboxylic acid of the FFA and unsaturated N atom of the 
imidazole ring of TP results in a four- component supramolecular unit [295]. The 
identity of each powdered sample was confirmed by comparison of the measured and 
predicted XRPD patterns shown in Figure 6. 1. The calculated XRPD patterns were in 
good agreement with the experimental data for all crystals. All main XRPD peaks of 
FFA I were predicted accurately. Some mismatched peak positions in the predicted and 
measured XRPD patterns of cocrystals of FFA-NIC CO and FFA-TP CO were found in 




different temperatures of the measurements, i.e., room temperature for XRPD 
measurements and around 100 K for the single crystal data [234, 295]. At different 
temperatures the size of the unit cell will be (slightly) different, leading to the shifts of 
the XRPD peak positions. 
In comparison with the observed single crystal images in Figure 6. 1, the crystal 
morphologies of FFA I, FFA-TP CO, and FFA-NIC CO are represented accurately by 
the models created by the software of Mercury 3.9. Therefore, each surface of a single 
crystal can be assigned through directly comparing the measured image with its 
morphology model. 
Six well-defined planes of a single FFA I crystal were identified, with a pair of major 
faces, (100) and (−100), bounded by two pairs of the less prominent side faces (011), 
(0−1−1), (01−1), and (0−11). The (100) plane could expose either the COOH or the 
CF3 groups (Figure 6. 1). The (0−11) face, on the other hand, exposes the COOH and 
CF3 groups simultaneously, along with the aromatic rings (Figure 6. 1). Based on this 
structural inspection, it is expected that subsequent (100) layers with dominant 
CF3··· CF3 contacts should have lower attachment energy than the (0−11) faces and 
have a slow growth rate normal to the surface, leading to a large face. 
The rectangular shape of FFA-TP CO is formed with a pair of the dominant (001) and 
(00−1) faces, larger side faces (0−10) and (010), and smaller side faces (100) and 
(−100). The (001) face could again have a more hydrophobic nature, because the 
trifluoromethylbenzene rings of FFA are exposed almost perpendicularly out of this 
surface. In contrast, the crystal faces (0−10) and (100) are more hydrophilic, because 
they expose more hydrogen-bond donors and acceptors. 
The dominant pair of FFA-NIC CO faces are (0−11) and (01−1), with less prominent 
faces (011) and (0−1−1) and the smallest pair of (−100) and (100). On the (100) face, 
both COOH groups of FFA and CONH2 groups of NIC are exposed, resulting in a polar 
surface. The (01−1) plane is less polar, carbon, fluorine, and hydrogen atoms are 




6.3.2 Solubility Study 
The apparent FFA I equilibrium solubility at 23°C was 373.3 ± 4.2μg/mL in pH 6.8 
PBS and was comparable of those of FFA I in the presence of 200μg/mL PEG (376.3 ± 
6.7μg/mL), PVP (387.7 ± 5.9μg/mL), or PVP-VA (398.8 ± 2.3μg/mL) shown in Table 6. 
2, indicating that none of the polymers changed the equilibrium solution properties. The 
solid residues collected after the experiments were analyzed by DSC, AIR, and XRPD, 
and indicated that they were the same as the starting materials (Figure A3. 2, 
appendixes). 
The concentrations of FFA and TP after equilibration for 24h when excess amount of 
FFA I was added into each of the prepared TP solutions are shown in Figure 6. 2a. The 
solubility of FFA I initially increased slightly with increasing the TP concentration due 
to soluble complex formation between the two compounds. When the TP concentration 
exceeded 8.9mM, it was found that the apparent solubility of FFA I reached a plateau, 
because the solubility limit of the complex formed was did not change significantly. 
Only an averaged 1.2-fold increase in the apparent solubility of FFA I was observed in 
the presence of TP in comparison to FFA I solubility in PBS alone. Precipitation of the 
FFA-TP CO was observed based on XRPD analysis (DSC and IR results in Figure A3. 
3 in the appendixes) of the solid residues, which indicated the presence of two solid 
phases, FFA-TP CO and FFA I as shown in Figure 6. 2b. Therefore, the measured 
concentrations of FFA and TP in this solution represent the FFA-TP CO transition 
concentration (Table 6. 2). The molar ratio of FFA to TP at the transition point was 
0.26:1, indicating that the system is incongruently saturating. The solubility of FFA-TP 
CO was calculated as 2.99mmol/mL using (Equ. 6- 1), which is a 2.25-fold increase 
compared to the solubility of FFA I alone. 
The apparent concentration of FFA I as a function of NIC concentration is shown in 
Figure 6. 2c, which is similar to a previous work [311]. The apparent solubility of FFA I 
increased with increasing NIC concentration up to 61.8mM, indicating complex 
formation of FFA and NIC in solution. In this region, the solubility limit of the complex 
formed was not exceeded, therefore the solid residues were FFA I alone, confirmed by 




In solutions with a NIC concentration of 66.2mM or above, the solid residues indicated 
the presence of two phases: FFA-NIC CO and FFA I solids, again confirmed by XRPD 
results in Figure 6. 2d (DSC and FTIR results in Figure A3. 4 in the appendix). 
Therefore, the measured concentrations of FFA and NIC in the 66.2mM NIC solution 
represent the FFA-NIC CO transition concentration shown in Table 6. 2. The molar 
ratio of FFA to NIC at the transition point was 0.026:1. The solubility of FFA-NIC CO 
was determined to be 10.4mM, which is 7.83 folds increase compared to the solubility 
of FFA I alone. 
Table 6. 2 Solubility test results. 
 
FFA I equilibrium solubility 
(g/mL) 
In PBS 373.34.2 
In PBS with pre-dissolved PEG 376.36.7 
In PBS with pre-dissolved PVP 387.75.9 
In PBS with Pre-dissolved PVP-VA 398.82.3 
FFA-TP CO transition 
concentration (g/mL) 
FFA concentration in 8.9mM (1600μg/mL) of 
TP solution 
439.92.0 
TP concentration in 8.9mM (1600μg/mL) of 
TP solution 
1028.925.3 
FFA-NIC CO transition 
concentration (g/mL) 
FFA concentration in 66.2mM (8080μg/mL) 
of NIC solution 
474.315.6 
NIC concentration in 66.2mM (8080μg/mL) 










Figure 6. 2 Apparent solubility of FFA I in a coformer solution: (a) FFA and TP concentrations as a 
function of TP concentration; (b) XRPD results of solid residues after the tests in TP solutions; (c) FFA 
and NIC concentrations as a function of NIC concentration; (d) XRPD results of solid residues after the 
tests in NIC solutions. 
6.3.3 AFM Measurements of Single Crystals 
Figure 6. 3 shows the representative AFM images of the faces of single crystals at a 40 
× 40 μm2 scan area after exposure to PBS in the absence and presence of PEG, PVP, or 
PVP-VA. The AFM images at other scans can be found in Figure A3. 5 in the 
appendixes. Before the etching experiments, the surfaces of FFA I and FFA-TP CO 
studied were generally flat and smooth, but with clear defects shown in Figure 6. 3a and 
f. In contrast, the FFA-NIC CO (01−1) face was not smooth but was marked with many 
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After being etched by PBS, clear etching patterns appeared on the FFA I (100) face 
shown in Figure 6. 3b. The pits observed were roughly circular in shape and were 
randomly distributed on the surface. Their diameters ranged from 1 to 10μm with depths 
of up to 0.5μm shown in three-dimensional AFM images in Figure A3. 6 in the 
appendixes. When the FFA I (100) face was etched using PBS in the presence of PEG, 
bigger and deeper pits were obtained in comparison with those etched by PBS alone 
(Figure 6. 3c and Figure A3. 6 in the appendixes). Similar pits were also obtained by 
etching in the presence of PVP, but they appeared at a much smaller in diameter. In 
contrast, the pattern etched by PBS in the presence of PVP-VA was less regular, with 
pits of varied shapes and sizes. 
When the FFA-TP CO (001) face was etched by PBS, many small interpenetrating 
trapezium pits with some isolated pits were formed with diameters of less than 1μm 
(Figure 6. 3g). At the same time, several long ditches were observed, with depth of 
about 1.3μm (Figure A3. 6 in the appendixes). In the presence of PEG in PBS, similar 
etching patterns were obtained to that etched by PBS alone (Figure 6. 3h). The sizes of 
the well-defined separate pits in Figure 6. 3i, etched by PBS in the presence of PVP, 
were much larger than those by PBS alone or in the presence of PEG. The etching 
pattern by PBS in the presence of PVP-VA, shown in Figure 6. 3j, was very different, 
with less clearly defined ditches than in PBS alone. 
The etching patterns in Figure 6. 3l-o on the FFA-NIC CO (01−1) face etched by PBS 
in the absence and presence of PEG, PVP, or PVP-VA were very similar to the original 
surface (Figure 6. 3k), showing striped patterns with lines in the direction of the a-axis. 
However, the roughness of the FFA-NIC CO (01−1) face was different after etching 
dissolution in different dissolution media in Figure A3. 6 in the appendixes. In PBS 
with the predissolved PVP-VA the roughness of the etching surface is pretty much same 
as the original one while the surface is roughest etched by PBS in the predissolved PEG. 
6.3.4 Face Dissolution Rate Determination of Single Crystals 
The temporal change in the lateral dimensions of a single crystal was recorded by 




faces of each single crystal: (100) and (0−11) faces of FFA I, (001) and (100) faces of 
FFA-TP CO, and (01−1) and (100) faces of FFA-NIC CO. 
Representative images of a single crystal during dissolution recorded by OLM are 
shown in Figure 6. 4a (all other images can be found in Figure A3. 7 in the appendixes) 
and the face dissolution profiles of each single crystal are shown in Figure 6. 4b. A 
linear relationship for different faces of both FFA I and FFA-TP CO single crystals in 
PBS in the absence or presence of a polymer was observed in Figure 6. 4b1-b8, 
indicating a constant dissolution rate. The face dependent dissolution rate was 
determined from the gradient of a plot of displacement of the edge of a face versus 
dissolution time. It can be seen in Figure 6. 5 that the dissolution rates of different faces 
for the same crystal are distinctly different. It was found that for the same crystal the 
bigger face had a lower dissolution rate. In the presence of PEG in PBS, the dissolution 
rates of the faces of FFA I or FFA-TP CO increased slightly except the FFA-TP CO 
(100) face, indicating PEG can enhance the crystal dissolution. In contrast, in the 
presence of PVP or PVP-VA, the retreating rates of the faces of FFA I or FFA-TP CO 
decreased, indicating PVP or PVP-VA can retard the face dissolution. 
FFA-NIC CO shows complicated face dependent dissolution behavior in Figure 6. 
4b9-b12. In contrast to FFA I and FFA-TP CO, the dissolution rate increased rapidly on 
both faces in the presence of PVP or PVP-VA in PBS. The variation of the dissolution 
rate on the small (100) face was significantly higher than the big face (01−1). It was 
interesting to note that the predissolved PEG in solution decreased the dissolution of the 
small face (100) and increased the dissolution of the big face (01−1), leading to close to 
isotropic dissolution behavior of FFA-NIC CO faces. Furthermore, FFA-NIC CO faces 
showed good linear dissolution behavior in PBS in the presence of a polymer of PEG. 
In pure PBS, a nonlinear relationship of the crystal displacement vs time data for the 
FFA-NIC CO (01−1) face in Figure 6. 4b9 due to precipitation of FFA III solids on the 
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Figure 6. 3 AFM images of results at a 40x40µm2 scan area.  
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Figure 6. 4 OLM dissolution experiments: a) representative OLM images of single crystal during dissolution; b) displacements of the edge of a crystal face as a 




























































































































































































































































Figure 6. 5 Face dependent dissolution rate of a single crystal in PBS in the absence and presence of a 
polymer 
6.3.5 Powder Dissolution Under Sink and Non-Sink Conditions 
Figure 6. 6 shows the dissolution profiles of FFA I, FFA-TP CO, and FFA-NIC CO in 
the absence and presence of a polymer under sink conditions in which Cequilibrium was 
100μg/mL (based on all the materials dissolved in solution). The gradient of a 
dissolution curve indicates the solid dissolution rate. Without a predissolved polymer in 
solution, FFA-TP CO was shown to dissolve fastest, with 24% increase of AUC in 
comparison with that of pure FFA I solids. FFA-NIC COs dissolved rapidly in the first 
5min, but after that their dissolution rate slowed and became comparable with FFA I, 
indicating that a phase transformation to FFA III occurred. Overall the AUC of 
FFA-NIC COs was 11% higher than that of FFA I. There was no significant change 
(within ±2%) of DPP and dissolution rate of FFA I, FFA-TP COs, or FFA-NIC COs in 
the predissolved PEG solution. With predissolved PVP or PVP-VA, the dissolution 
performance of FFA-NIC COs improved remarkably, i.e., in the predissolved PVP 
solution 75% of solids dissolved within 15 min and AUC increased by 34%, while in 
the predissolved PVP-VA solution 89% of solids dissolved within 15 min and AUC 
increased by 38%. In contrast, both PVP and PVP-VA reduced the dissolution rate and 






Figure 6. 6 Powder dissolution profiles in the absence or presence of a polymer under sink conditions: (a) PBS; (b) 
PBS with predissolved PEG; (c) PBS with predissolved PVP; (d) PBS with predissolved PVP-VA; (e) DPP 
comparison; The DPP of FFA in PBS as reference. 
Figure 6. 7 shows the dissolution profiles of FFA I, FFA-TP CO, and FFA-NIC CO in 
the absence and presence of a polymer under non-sink conditions. Therefore, Ceq was 
the FFA I solubility of 373.3μg/mL measured in this study in Table 6. 2. Teq and Cmax 
values of each test are shown in Table 6. 3 and Table 6. 4. In the presence of a polymer, 




38% reduction of AUC in Figure 6. 7e. There was no supersaturation generated from 
FFA I dissolution in PBS in the absence or presence of PEG, PVP or PVP-VA (Table 6. 
4). FFA-TP COs show an advantage of improved dissolution relative to FFA I solids 
both in the absence or presence of a predissolved polymer. Predissolved PVP can 
modestly increase the DPP of FFA-TP COs, to 40% from 30% in pure PBS, while 
predissolved PVP-VA can slightly decrease its DPP to 24%. A significant increase of 
DPP of FFA-TP COs, to 56%, was observed in the predissolved PEG. Predissolved 
PEG in PBS can increase the dissolution rate of FFA-TP CO, showing a reduced Teq in 
contrast to the slow FFA-TP CO dissolution in the presence of PVP or PVP-VA in PBS 
(Table 6. 3) There was no dissolution advantage observed for FFA-NIC COs in PBS 
alone or in the presence of predissolved PEG. However, in the presence of PVP in the 
solution, the advantage of FFA-NIC COs in dissolution performance was apparent, with 
a 64% increase of AUC (Figure 6. 7e), 50% higher peak solubility (Table 6. 4), and 
faster dissolution rate (Table 6. 3). Similarly, in the presence of PVP-VA in solution, the 
DPP of FFA-NIC COs was increased by 60% and the maximum FFA concentration was 
1.6 times of its solubility. 
Table 6. 3 Teq values of powder dissolution under non-sink conditions. 
Crystal Teq (min) 






PBS with pre-dissolved 
PVP-VA 
FFA I 166 196 >240 186 
FFA-TP CO 50 10 62 87 
FFA-NIC CO 223 196 23 22 
Table 6. 4 Cmax values of powder dissolution under non-sink conditions. 
Crystal Cmax (g/mL) 









FFA I 415.36.0 397.88.40 283.344.8 415.432.8 
FFA-TP CO 497.520.7 527.123.3 538.832.9 539.41.6 
FFA-NIC CO 383.634.1 397.320.7 609.414.0 62910.1 
 
Figure 6. 7. Powder dissolution profiles in the absence or presence of a polymer under non-sink conditions: (a) PBS; 
(b) PBS with predissolved PEG; (c) PBS with predissolved PVP; (d) PBS with predissolved PVP-VA; (e) DPP 
comparison. 
The XRPD results of the solid residues collected after the FFA I dissolution 




indicating that there was no phase transformation for FFA I in solution. The solid 
residues from FFA-NIC CO experiments in the presence or absence of a predissolved 
polymer gave XRPD patterns (Figure 6. 8c) that matched the characteristic features of 
FFA III [226], indicating that FFA III crystals precipitated during dissolution. 
Interestingly, in the presence of PVP or PVP-VA, the solid residues after the FFA-TP 
CO dissolution tests were their starting materials, FFA-TP COs, as shown in Figure 6. 
8b. In contrast, the solid residues after FFA-TP CO dissolution tests in PBS or in the 
presence of predissolved PEG were the mixtures of FFA-TP CO and FFA III solids. The 
DSC and FTIR results of the solid residues are shown in Figure A3. 8 and Figure A3. 9 






Figure 6. 8 XRPD test results of solid residues after dissolution tests under non-sink conditions: (a) FFA I; 




6.4 Discussion  
It is well-known that the dissolution mechanism of cocrystals of poorly water-soluble 
drugs is complex, in which both dissolution of cocrystals and the precipitation of the 
parent drug can occur simultaneously depending on the properties of the parent drug 
and coformer and the experimental conditions [145]. In this study, through rational 
selection of a coformer as well as the dissolution medium in the presence of a polymeric 
additive, we aimed to provide mechanistic insights into the intrinsic relationship among 
dissolution, supersaturation and precipitation for pharmaceutical cocrystals. 
Based on the measured transition concentrations of the parent drug FFA I and coformers 
of NIC and TP, it was shown that FFA-NIC CO increased the FFA solubility by 7.83 
folds, while the increase was 2.25 folds for FFA-TP CO. Discrepancies between 
predicted and observed solubility advantages were significant in the bulk experiments. 
In the powder dissolution experiments FFA-TP CO partially revealed its solubility 
advantage in PBS. Under sink conditions (Figure 6. 6a) it showed 24% increase of AUC 
and under non-sink conditions (Figure 6. 7a) achieved a maximum FFA concentration 
of 497.5μg/mL, which was just 1.33 folds of its parent drug solubility. Despite having a 
higher solubility, FFA-NIC CO dissolved slower than FFA-TP CO in PBS under either 
sink or non-sink conditions (Figure 6. 6a and Figure 6. 7a). However, when PVP or 
PVP-VA was predissolved in the dissolution medium, the expected improvements in 
dissolution rate and apparent FFA concentration were clearly revealed in the bulk 
dissolution experiments of FFA-NIC CO shown in Figure 6. 6c, d and Figure 6. 7c, d. In 
contrast, under non-sink conditions the dissolution rate of FFA-TP CO decreased with 
slightly higher Cmax in the presence of PVP or PVP-VA relative to dissolution in PBS 
without a polymer. 
Based on the crystal structure illustrated in Figure 6. 1 it is shown that the hydrogen 
bonding between the FFA and NIC molecules creates a layer structure of the crystal 
lattice where the NIC molecules form channels among the FFA molecules. Such 
configuration in the crystal lattice allows complete layers of molecules to be easily 
removed from the surface by the solvent medium [312]. Therefore, the etching surface 




as the initial surface Figure 6. 3k. Due to rapid removal of the hydrophilic NIC 
molecules from the surface during dissolution, a local supersaturation of FFA near the 
dissolving surface of FFA-NIC CO was generated, leading to precipitation of the stable 
form FFA solids on the cocrystal particle, indicating changes in the roughness of the 
etching surface (Figure A3. 6 in the appendixes) observed by AFM. Consequently, this 
resulted in reduction of the dissolution rate of FFA-NIC CO. Therefore, the dissolution 
profile of FFA-NIC CO was like FFA I, which was observed in the bulk powder 
dissolution in Figure 6. 7a. It has been reported that FFA has up to nine different crystal 
forms, among which FFA I (white color) and FFA III (yellow color) are the most 
commonly encountered [226]. Below a temperature of 42 °C FFA III is the most stable 
form and has a lower solubility than its metastable form of FFA I, although the 
solubility difference between the two forms is very small with less than 1μg/mL [313]. 
Precipitation of the solid FFA III during dissolution under non-sink conditions shown in 
Figure 6. 8c demonstrated that the supersaturation was first generated by the FFA-NIC 
CO dissolution and then followed by precipitation of the stable form FFA III. 
Furthermore, a nonlinear relationship of the concentration vs time data acquired for the 
FFA-NIC CO (01−1) face in Figure 6. 4b9 also concluded precipitation of FFA solids 
on the dissolving crystal surface. In contrast, no supersaturation was generated by 
dissolution of FFA I crystals, confirmed by the XRPD results in Figure 6. 8a, where the 
solid residues collected after the FFA I dissolution tests were the same as the starting 
materials. 
According to the FFA-TP CO structure shown in Figure 6. 1, an extended chain 
structure formed by a supramolecular ladder network involving both FFA and TP 
molecules with a strong hydrogen bond and interactions of C−H···π and π···π implies 
that the stronger crystal lattice of FFA-TP COs hinders surface dissolution and hence 
impacts the overall solubility. However, each surface of a FFA-TP CO becomes more 
hydrophilic due to inclusion of TP molecules in the crystal lattice in comparison with 
those of FFA I shown in Figure 6. 1, leading to an increased interaction force between 
the faces of FFA-TP COs and aqueous solvent molecules. Therefore, FFA-TP CO has a 
limited ability to improve the FFA solubility by 2.25 folds in Table 6. 2. Similarly, the 
parent drug FFA I, the dissolution mechanism of FFA-TP COs appears to be controlled 




molecules at defect sites have higher mobility to be detached from the surface, a regular 
etching pattern can be formed during etching dissolution, which was observed in the 
AFM etching images of both FFA I and FFA-TP CO faces shown in Figure 6. 3b and 
Figure 6. 3g. Formation of the etching pattern on the crystal surface is determined by 
the crystal interaction network together with the interactions between solvent and 
crystal surface [314]. On the (100) face of FFA I, there are two nonperpendicular 
crystallographic axes: the b-axis and c-axis, in which the COOH or CF3 (see bottom) 
group (Figure 6. 1) is exposed out of the surface. Each molecule is surrounded by six 
neighbors, each attracted through π−π stacking inside the surface, resulting in 
nondirectional force along either the b-axis or c-axis. Therefore, the pits on the (100) 
face of FFA I were circular shape without specific preference of directions shown in 
Figure 6. 3b. Presumably, the size or strain of individual defects on the surface of FFA I 
was different before dissolution, leading to a wide size distribution of the pits. However, 
the situation is different for FFA-TP CO dissolution. When FFA-TP CO dissolves, both 
of FFA and TP molecules detach from the FFA-TP CO lattice from the defect sites on 
the surface. The different etching pattern in Figure 6. 3g in comparison with that on the 
FFA I (100) face in Figure 6. 3b reflects the more anisotropic nature of the interactions 
in FFA-TP CO, with ditches roughly parallel to the strong hydrogen bonds. According 
to the single crystal dissolution experiments, linear dissolution rates were obtained for 
both the FFA-TP (001) and (100) faces, indicating that no solid form conversion 
occurred during dissolution (Figure 6. 4b5) Under non-sink conditions, the precipitation 
of FFA III solids was observed after 50 min (Figure 6. 7a), when the FFA concentration 
in solution was above its solubility. Therefore, a bulk precipitation mechanism is 
proposed for the FFA-TP CO dissolution, where the dissolved parent drug precipitates 
as individual crystals from the bulk solution, in contrast to a surface precipitation 
mechanism for the FFA-NIC CO dissolution, where the parent drug precipitates directly 
onto the surface of the dissolving cocrystals as a coating layer. The strong interaction 
between FFA and TP, along with the smaller difference in hydrophobicity between the 
coformers in FFA-TP CO relative to FFA-NIC CO, suggests that the coformers are 
more likely to remain closely associated in the case of FFA-TP CO. This would then 
lead to a smaller local supersaturation of FFA near the dissolving FFA-TP CO surface, 




When a polymer of PEG, PVP, or PVP-VA was predissolved in the dissolution medium, 
dissolution profiles of FFA-NIC CO or FFA-TP CO changed to significantly different 
extents under either sink or non-sink conditions. In this study, the used polymer 
concentration of 200μg/mL was so low that the solution viscosity remained the same as 
that of the PBS dissolution medium alone. Furthermore, the predissolved polymer had 
no effect on the solubility of FFA I (Table 6. 2). Therefore, the effects of polymeric 
additives on the dissolution of FFA cocrystals are attributed to surface adsorption of the 
polymers through specific interactions with the crystal surface, in particular, hydrogen 
bonding [192, 200, 314-319]. Among the polymers used in this study, PEG, containing 
a high percentage of hydrogen acceptors in the backbone, is the most hydrophilic, while 
PVP-VA, containing 40% acetate side chains in comparison to PVP, is the most 
hydrophobic [183]. 
Based on the dissolution experiment of the single FFA I crystal, the FFA I (100) face is 
more hydrophobic because it has a slower face dissolution rate in Figure 6. 4b1. The 
hydrophilic polymer of PEG with its rigid backbone chains should not be easily 
absorbed on the crystal surface. Therefore, that there was no change of the etching 
patterns of FFA I (100) face in PBS in the presence of predissolved PEG in Figure 6. 3c. 
Bigger and steeper pits observed were most likely caused by an enhanced diffusion rate 
of FFA molecules from the crystal surface attracted by PEG in solution due to less 
hydrophilic environment generated than water around the surface, indicating a slightly 
increased surface dissolution rate in the single crystal dissolution measurement in 
Figure 6. 5. PVP and PVP-VA have oxygen molecules at the side chain positions, 
therefore, there should be no strong steric repulsion for them to form hydrogen bonds 
with the COOH groups of FFA I on the crystal surface. Once the polymers were 
adsorbed onto the surface, they prevented the dissolution medium contacting the crystal 
surface to retard the etching locally, leading smaller and less deep pits in Figure 6. 3d 
and Figure 6. 3e. A lower density of the pits with irregular etching patterns in PBS in 
the presence PVP-VA (Figure 6. 3e) indicated that PVP-VA had more chance to be 
adsorbed on the FFA I crystal surface due to more oxygen molecules at the side chains 




The hydrophobic nature of the FFA-TP CO (001) face was likely to prevent PEG to be 
adsorbed on it; therefore, there was no change of the surface etching patterns in 
comparison with those in PBS alone in Figure 6. 3g, h. With increasing the nonpolarity 
of PVP and PVP-VA, both of the polymers had more opportunities to be adsorbed on 
the crystal surface, affecting the etching patterns of the FFA-TP (001) face in Figure 6. 
3i,j and also causing a reduction of the face dissolution rates in the single crystal face 
dissolution experiments in Figure 6. 5 and decreased DPP values in the powder 
dissolution experiments in Figure 6. 6e and Figure 6. 7e. It has to be stressed that PVP 
or PVP-VA not only decreased the dissolution rates of FFA-TP CO but also prevented 
the precipitation of FFA III when the FFA concentration was above its solubility 
through intermolecular interaction in solution without increasing the solubility of FFA I 
[183], confirmed by the XRPD results of the solid residues where FFA-TP COs were 
the only solid phase in Figure 6. 8b. Consequently, an increased Cmax in Table 6. 4 was 
generated by the FFA-TP CO dissolution. 
In the presence of PEG in PBS, the FFA-NIC (01−1) face dissolution rate increased and 
its (100) face dissolution rate reduced in Figure 6. 4b10, therefore there was no change 
of the overall dissolution performance of FFA-NIC CO in the bulk dissolution 
experiments in Figure 6. 6e and Figure 6. 7e. In contrast, both PVP and PVP-VA were 
easily adsorbed on the FFA-NIC CO surface to slow down the crystal dissolution rate. 
Consequently, precipitation rate of the stable form FFA III solids on the surface of the 
dissolving cocrystals was reduced, showing a similar roughness of the etching FFA-NIC 
CO (01−1) in the predissolved PVP or PVP-VA as the original one prior to the etching 
experiment. Therefore, the advantages of the improved solubility and dissolution rates 
of FFA-NIC CO were observed in the single crystal dissolution experiments in Figure 6. 
4b11, b12 and bulk dissolution experiments in Figure 6. 6e and Figure 6. 7e. It is worth 
re-emphasizing that the precipitation of the stable form FFA III was only partially 
inhibited by the predissolved PVP or PVP-VA in solution, supported by the evidence of 
the nonlinear face dissolution rates in Figure 6. 4 b11, b12 and XRPD results of solid 
residues after non-sink powder experiments in Figure 6. 8c. Except the surface 
roughness, no change of the appearance of the FFA-NIC CO (01−1) face after etching 
dissolution shown in Figure 6. 3l-o, another evidence to support the surface layer 




of FFA-NIC CO, an increasing polymer concentration or new approaches have to be 
developed to completely inhibit the FFA precipitation, which is part of ongoing research 
in our group. 
6.5 Chapter Conclusion 
Understanding the dissolution mechanisms of pharmaceutical cocrystals can lead to 
strategies for improving cocrystal design and its optimum product development. In this 
study, effects of the three polymers, PEG, PVP, and PVP-VA, on the dissolution 
behavior of the cocrystals of FFA-TP CO and FFA-NIC CO were investigated at 
multiple length scales. It has been found that the dissolution mechanisms of FFA-TP 
CO are controlled by the defect sites of the crystal surface and by precipitation of the 
parent drug as individual crystals in the bulk fluid. In contrast, the dissolution 
mechanisms of FFA-NIC CO are controlled by the surface layer removal and by a 
surface precipitation mechanism, where the parent drug precipitates directly onto the 
surface of the dissolving cocrystals as a coating layer. Through controlling the 
dissolution environment by pre-dissolving a polymer, PVP or PVP-VA, which can 
interact with the crystal surface to alter its dissolution properties, the advantages of the 
improved solubility and dissolution rates of the FFA-TP cocrystal and FFA-NIC 





Chapter 7 Investigating Permeation Behavior of Flufenamic 
Acid Cocrystals Using a Dissolution and Permeation System  
7.1 Chapter Overview 
In this work we systematically, for the first time, examined the key processes occurred 
during cocrystal dissolution in the absence and presence of different concentrations of a 
polymer, i.e., the kinetics of drug supersaturation and subsequent drug permeation by 
using side-by-side cell. Cocrystals of FFA-NIC CO and FFA-TP CO along with two 
polymers of PVP and PVP-VA were selected. The molecular structures FFA cocrystals 
and the monomer units of the polymers are shown in Table 7. 1. To gain insight into the 
mechanism of the supersaturated solution and subsequent permeation behavior of the 
parent drug, the atomic-level information of molecular interactions among FFA, 
coformers and polymers was studied by one-dimensional proton nuclear magnetic 
resonance (1H NMR) spectroscopy. Solution 1H NMR is a powerful tool for 
investigating the molecular state of drugs to examine their hydrogen bonding 
interactions and aggregation properties, in which chemical shifts in 1H NMR spectra 
reflect differences in the chemical environment of molecules and peak widths reflect 
molecular mobility [161, 216, 320-327]. 1H NMR studies were conducted in singular, 
binary and ternary components’ solutions of FFA, coformer and polymer to establish 
the possibility of interactions of drug/coformer, drug/polymer and coformer/polymer in 





























7.2 Materials and Methods 
7.2.1 Materials 
FFA I, NIC, TP, PVP, PVP-VA, methanol, ethanol, acetonitrile, KH2PO4, NaOH, CDCl3 
and double distilled water were used in this study. Detailed information of these 
materials can be found in Chapter 3.  
7.2.2 Methods 
7.2.2.1 0.01M pH 4.5 Phosphate Buffer Solution (PBS)  
pH 4.5 PBS (0.01M) was used as a dissolution medium in this study, the detailed 
preparation method can be found in chapter 3. 
7.2.2.2 Powder FFA Cocrystals Preparation  
Cocrystals of FFA-NIC CO and FFA-TP CO were used in this chapter, the detailed 
method can be found in chapter 3. 
7.2.2.3 Apparent Equilibrium Solubility of FFA I, NIC and TP in Solution with the 
Absence and Presence of a Pre-dissolved Polymer 
The apparent equilibrium solubility of individual components of FFA I, NIC and TP 
was determined in 0.01M pH 4.5 PBS with or without different concentrations of a 
pre-dissolved polymer (i.e. PVP or PVP-VA) in a shaking water bath at 150RPM 
shaking rate and 37±0.5°C for 24h. The concentrations of a polymer were 200g/mL, 
500g /mL, 1000g/mL, 2000g/mL, 4000g/mL, 8000g/mL, 12000g/mL and 
16000g/mL, respectively. 
To investigate the effect of a combined coformer and polymer on the FFA I solubility, 
apparent equilibrium solubility of FFA I at different concentrations of a polymer under 
a constant coformer concentration (47.8g/mL for NIC or 71.1g/mL of TP) was also 
determined. A coformer concentration selected in the experiments was based on the flux 
rate experiments where 1.43mg (1mg FFA and 0.43mg NIC) of FFA-NIC CO and 




to 47.8g/mL of NIC and 71.1g/mL of TP in the donor compartment under the 
assumption of completely dissolving of the FFA cocrystals. 
The detailed method for solubility testing can be found in chapter 3. 
7.2.2.4 Dissolution and Permeation Measurements  
The dissolution and permeation properties of FFA I and FFA cocrystals were 
determined by D/P system. One milligram of FFA I or cocrystal powders with 
equivalent 1mg of FFA I were used. All FFA I and FFA cocrystal crystalline materials 
used in the experiments were slightly grounded by a mortar and pestle and sieved by a 
60mesh sieve to control the particle size below 250μm. The concentrations of PVP or 
PVP-VA were 200g/mL, 4000g/mL, and 16000g/mL, respectively. Samples of 
0.5mL were withdrawn from the donor compartment at the predefined sampling points 
of 5, 10, 15, 30, 60, 120 and 240mins and 0.5mL of the sample was taken from the 
acceptor cell at 30, 60, 120 and 240mins. The detailed method can be found in chapter 
3.  
7.2.2.5 NMR Measurement  
1H NMR experiments were used to probe interactions among drug, coformer and 
polymer in solution. Details of the measured samples are shown in Table A4. 1 in the 
appendix, including the singular component solutions of FFA I, NIC, TP, PVP and 
PVP-VA, the binary component solutions of FFA/NIC, FFA/TP, FFA/PVP, 
FFA/PVP-VA, NIC/PVP, NIC/PVP-VA, TP/PVP and TP/PVP-VA, and ternary 
component solutions of FFA/NIC/PVP, FFA/NIC/PVP-VA, FFA/TP/PVP and 
FFA/TP/PVP-VA. Three different concentrations of FFA solutions were prepared, 
including 500g/mL, 1000g/mL and 5000g/mL. In order to mimic a cocrystal system, 
an equal molar concentration of a coformer as that of FFA was prepared in solution, i.e. 
215g/mL of NIC or 320g/mL of TP in 500g/mL of FFA solution, 430g/mL of NIC 
or 640g/mL of TP in 1000g/mL of FFA solution, and 2150g/mL of NIC or 
3200/mL of TP in 5000g/mL of FFA solution. Two different concentrations of a 




in solution to investigate its concentration dependent interactions with FFA and/or a 
coformer of NIC or TP. The details about the NMR setting can be found in chapter 3. 
7.2.2.6 Analytical Techniques  
Automatic HPLC was used to determine the solubility, dissolution and permeation 






7.3.1 Effect of a Pre-dissolved Polymer, Coformer and Combination of a Polymer 
and Coformer on the Equilibrium Solubility of FFA I 
Figure 7. 1 shows the variations of the FFA concentrations in 0.01M pH 4.5 PBS in the 
absence and presence of different concentrations of a pre-dissolved polymer of PVP or 
PVP-VA with or without a fixed concentration of a coformer of NIC or TP at 
equilibrium after 24h. The equilibrium solubility of FFA I at 37°C measured was 9.0 
0.7g/mL. It was observed that PVP had an insignificant solubilization effect on FFA 
molecules in solution. The solubility of FFA I slightly increased with a pre-dissolved 
PVP at a concentration of 500g/mL, reached the maximum of 14.880.98g/mL at the 
PVP concentration of 2000g/mL and then keeps constant with increasing the PVP 
concentration. FFA I solubility started to increase when the pre-dissolved PVP-VA 
concentration was above 1000g/mL and then kept increasing significantly with 
increasing the PVP-VA concentration.  
With a pre-dissolved NIC concentration of 47.8g/mL, the equilibrium solubility of 
FFA I was the same as that in the pure 0.01M pH 4.5 PBS, while as the equilibrium 
solubility of FFA I slightly increased to 10.240.71g/mL with a pre-dissolved TP 
concentration of 71.1g/mL. The equilibrium solubility of FFA I at different 
concentrations of PVP solutions was almost the same as those without the pre-dissolved 
NIC, indicating that PVP was the dominating factor to affect the solubility of FFA I. In 
the presence of 71.1g/mL of pre-dissolved TP in solution, a slight change of the FFA 
equilibrium solubility curve was observed at different PVP concentrations. At a lower 
PVP concentration up to 500g/mL, the solubility of FFA I was constant as that in the 
pre-dissolved TP in the absence of PVP. At the PVP concentration up to 4000g/mL, 
the equilibrium solubility of FFA I was the same as that without the pre-dissolved TP.   
In contrast, the solubilization ability of PVP-VA on the FFA I equilibrium solubility has 
been strengthened significantly due to the pre-dissolved coformer of NIC or TP in 
solution, indicating that the solubility of FFA I significantly increased even at a very 




capable to enhance the solubilization ability of PVP-VA on FFA in solution shown in 
Figure 7. 1. 
 
Figure 7. 1 Apparent equilibrium solubility of FFA I at different concentrations of a pre-dissolved 
polymer with or without a coformer of NIC or TP 
7.3.2 Effect of a Polymer on FFA Cocrystal Dissolution and Permeation  
The molecular weight cut off pore size of the dialysis membrane used in the study was 
6-8 KDa. Thus, FFA, which has a MW of 281, can cross the membrane into the 
acceptor cell while the polymers cannot, i.e. PVP (MW 40,000) and PVP-VA (MW 
51,000). Therefore, the membrane can separate drug molecules associated with 
polymers before they diffuse into the acceptor cell.  
7.3.2.1 Pure PBS 
Figure 7. 2 shows the dissolution and permeation profiles of FFA I and FFA cocrystals 
of FFA-NIC COs and FFA-TP COs in 0.01M pH4.5 PBS without polymers in the D/P 
system. There was no significant difference in the dissolution profiles of the solid 
powders of FFA I and FFA-TP COs in the donor cell, where FFA concentration reached 
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showed a slightly different dissolution profile, where the FFA concentration quickly 
reached its maximum at 5min and after that the FFA concentration started to decline and 
reach its minimum at 120min. The quantitative comparison of DPPs in Figure 7. 5(a), 
based on our previous publication [4], indicated that FFA-TP CO has a comparable DPP 
with FFA I while FFA-NIC CO is the lowest DPP. The FFA concentration profiles of 
the FFA I and FFA-TP COs in the acceptor cell were also the same, showing a linear 
increase with time in Figure 7. 2(b). The FFA concentration in the FFA-NIC COs 
acceptor cell showed a reduced flux rate after 60min. Quantitative comparison of the 
mass flux rates of the systems in Figure 7. 5(b) shows that the FFA mass flux rate of a 
formulation system is proportional to its DDP.  
  
(a) (b) 
Figure 7. 2 Dissolution and permeation profiles of FFA I and FFA cocrystals in PBS in the D/P system: (a) 
dissolution; (b) permeation 
7.3.2.2 PBS in the Presence of a Pre-dissolved Polymer of PVP or PVP-VA 
Figure 7. 3 shows the effect of a pre-dissolved PVP on the dissolution of FFA I and 
FFA cocrystals in the donor cell and its corresponding permeation profiles in the 
acceptor cell. It was found that both FFA-NIC COs and FFA-TP COs showed the 
enhanced dissolution profiles in comparison with the parent drug of FFA I when PVP 
was added into the dissolution media. The dissolution performances of the FFA COs 
were dependent on the PVP concentration. In the dissolution media with a low PVP 
concentration of 200g/mL, a supersaturated state of FFA in solution was observed by 
dissolving either FFA-TP COs or FFA-NIC COs, where the maximal FFA 



















































of FFA concentration was obtained by FFA-NIC COs after 15min. And then the FFA 
concentration was reduced and stabilized approximately to its parent drug solubility for 
both FFA cocrystal systems after 60min. The permeated amount of FFA molecules was 
enhanced by PVP for FFA-TP COs by 1.23-fold or for FFA-NIC COs by 1.17-fold 
shown in Figure 7. 5(b). In contrast, the DPP of FFA I in PBS with PVP was reduced by 
15.4% compared with the pure dissolution medium in Figure 7. 5(a), indicating that the 
pre-dissolved PVP in solution can slow down the drug dissolution and the permeated 
amount of FFA molecules was reduced by PVP for FFA I by 0.90-fold in Figure 7. 5(b). 
At 4000 g/mL of PVP concentration, the maximum FFA concentration in the FFA-TP 
COs donor cell can reach 40g/mL at 15min, which is approximately 4.5-fold of the 
solubility of FFA I, while as it was 23.6g/mL at 15min for FFA-NIC COs, indicating 
FFA-TP COs had a better dissolution performance than FFA-NIC COs. In the FFA-NIC 
CO donor cell the FFA concentration quickly decreased to a constant of 19.5 g/mL at 
30min. In contrast, the FFA concentration in the FFA-TP CO donor cell decreased 
slowly from its maximum and was stabilized at 28.8g/mL after 60min. The FFA-TP 
CO’s DPP was 228% higher than the parent drug of FFA I and it was 128% higher for 
FFA-NIC COs in Figure 7. 5(a). Accordingly, the permeated amount of FFA molecules 
increased significantly by FFA-TP COs with 1.69-fold and FFA-NIC COs with 
1.27-fold in Figure 7. 5(b).  
Increasing the PVP concentration to 16000g/mL in solution, both of FFA-TP CO and 
FFA-NIC CO showed a reduced dissolution performance shown in Figure 7. 3(c5) and 
Figure 7. 5(a), in which the maximal FFA concentration in the FFA-TP CO donor cell 
was 27.5g/mL at 15min and in the FFA-NIC CO donor cell the maximal FFA 
concentration was 19.7g/mL. Unexpectedly it was observed that the permeated amount 
FFA molecules was reduced significantly for the FFA cocrystals in Figure 7. 3(c6) and 
the flux rate of the FFA-TP COs was 0.62-fold of the FFA I in the pure PBS and it was 
0.45-fold for FFA-NIC COs in Figure 7. 5(b). At this polymer concentration, the 
dissolution rate of FFA I became significantly slow in Figure 7. 3(c5), showing 9% 
reduction of DPP in Figure 7. 5(a) and 0.34-fold of the flux rate in comparison with 




The dissolution and permeation profiles of FFA I and FFA cocrystals in PBS in the 
presence of the pre-dissolved PVP-VA in the donor cell are shown in Figure 7. 4. 
Increasing a pre-dissolved PVP-VA concentration in the donor cell, the dissolution 
performance of FFA cocrystals can be enhanced significantly. At a low PVP-VA 
concentration of 200g/mL, a moderate increase of DPP was observed, i.e. 33.8% 
increase by FFA-NIC COs and 42.6% increase by FFA-TP COs in Figure 7. 5(a). At a 
high PVP-VA concentration of 16000g/mL, the DPP can be increased to 460.5% by 
FFA-NIC COs and 409.4% by FFA-TP COs in Figure 7. 5(a) in comparison with FFA I 
in pure PBS. However, the permeated amount of FFA is not proportional to the 
increased DPPs shown in Figure 7. 5(a) and Figure 7. 5(b). The FFA flux rate of FFA I 
and FFA cocrystals reduced with increasing the concentration of a pre-dissolved 
PVP-VA. The FFA flux rates of FFA-NIC COs and FFA-TP COs at the pre-dissolved 
PVP-VA concentration of 200g/mL or 4000g/mL are higher than that of FFA I in the 
pure PBS shown in Figure 7. 5(b). At the highest PVP concentration of 16000g/mL the 























































































































Figure 7. 3 Dissolution and permeation profiles of FFA I and FFA cocrystals in PBS in the presence of a 
pre-dissolved PVP in the dissolution/permeation (D/P) system; The time for dissolution and permeability 








































































































































































Figure 7. 4 Dissolution and permeation profiles of FFA I and FFA cocrystals in PBS in the presence of a 
pre-dissolved PVP-VA in the dissolution/permeation (D/P) system; The time for dissolution and 
permeability tests was 4h. 
  
(a) (b) 
Figure 7. 5 Comparison of dissolution and permeation profiles of FFA I and FFA cocrystals in the absence 
and presence of a pre-dissolved polymer: (a) The DPP results of FFA I, FFA-NIC CO and FFA-TP CO in 
donor cell and (b) the flux rate of FFA I, FFA-NIC CO and FFA-TP CO in the acceptor cell. The time for 
dissolution and permeability tests was 4h.  
7.3.3 NMR Analysis 
1H NMR experiments in Table A4. 1were conducted to investigate the interactions 
among FFA, coformers and polymers in solution. Assignments of the 1H chemical shifts 
of FFA, NIC, TP, PVP and PVP-VA were based on the previous work [325, 328-332]. 
In this work, we focused on examining the characteristic chemical shifts of the protons 
in each of the molecules of FFA, TP, and NIC affected by their hydrogen bonding 
interactions and self-aggregation properties in solution in the absence and presence of a 
polymer of PVP or PVP-VA: i) the chemical shifts of the singlet peak of Hj and two 





















































































































chemical shifts of Ha, Hb, Hc and Hd of TP. The proton details of each molecule can be 
found in Table 7. 1. The full 1H NMR spectra of the experiments can be found in  
Figure A4. 1 in Appendix. 
7.3.3.1 1H NMR Analysis of a Singular Component  
Figure 7. 6(a) shows the 1H NMR chemical shifts of Hj and Hh of FFA at different drug 
concentrations in CDCl3, suggesting that the proton chemical shifts were concentration 
dependent. It is well known that there exists an intramolecular hydrogen bond between 
the NHj group and the C=O of the carboxylic acid of FFA, the chemical shift of Hj is 
impacted by the molecule conformations in solution associated to the dimer formation 
[329]. Increasing FFA concentration, the self-association of FFA occurs through inter 
carboxylic acid hydrogen bonding of two FFA molecules, causing a downfield change 
of the chemical shift of Hh from 8.049ppm at a lower FFA concentration of 500g/mL 
to 8.061ppm at 1000g/mL, and to 8.082ppm at 5000g/mL, due to proton deshielding 
by the hydrogen bonds which lengthens the O-H bond and subsequently reduces the 
valence electro density around the proton of Hh. The intermolecular association of the 
dimer formation of FFAs was induced with increasing FFA concentrations can 
strengthen the intramolecular interaction N-Hj∙∙∙O=C [329], showing an upfield change 
of the chemical shift of Hj from 9.463ppm at a lower FFA concentration of 500g/mL 
to 9.443ppm at 1000g/mL, and to 9.410ppm at 5000g/mL . The self-association of 
NIC in solution occurs through inter-amide hydrogen bonding and does not occur 
through stacking of the pyridine rings [333]. It has been shown that with an increased 
NIC concentration, downfield chemical shifts of Ha and Hb (=0.021 at 430g/mL and 
=0.134 at 2150g/mL for Ha; =0.005 at 430g/mL and =0.041 at 2150g/mL 
for Hb) were observed in comparison with Hc whose chemical shift was almost constant 
(=0.001 at 430g/mL and =0.005 at 2150g/mL) in Figure 7. 6(b). In CDCl3, TP 
self-association occurs through the asymmetric dimer involving hydrogen bonding of 
Hb∙∙∙O of C-CO-N-CHd  and C=N∙∙∙HaN-C [334], showing that all of 
1H chemical shifts 
of Ha and Hb moved to a lower field as the concentration increased (=0.228 at 
640g/mL and =1.034 at 3200g/mL for Ha; =0.007 at 640g/mL and =0.039 
at 3200g/mL for Hb) while as 




changes (=0.003 of Hc and =0.005 of Hd at 640g/mL and =0.013 of Hc and 






  = ℎ𝑖𝑔ℎ 𝐹𝐹𝐴 𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 − 500µ𝑔/𝑚𝐿 𝐹𝐹𝐴  
 
(b) NIC 
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7.3.3.2 1H NMR Analysis of Binary Components   
For clarity, here we only analyzed one set of experiments, i.e. FFA at 1000g/mL, NIC 
at 430g/mL or TP at 640g/mL in the presence of two different concentrations of a 
polymer (PVP or PVP-VA), as an example to discuss the properties of the drug 
self-association and its interaction with the polymer in solution.    
Figure 7. 7 shows chemical shifts of individual components of FFA, NIC and TP in the 
presence of two different concentrations of a polymer of PVP or PVP-VA in CDCl3.   
At a low polymer (either PVP or PVP-VA) concentration of 200g/mL, the chemical 
shift of Hh of FFA changed to downfield, indicating a hydrogen bonding interaction 
between O-H of the carboxylic acid function group of FFA with the carbonyl O group 
of PVP or PVP-VA. Although O=C of the carboxylic acid function group of FFA is not 
involved into the interaction with the polymer, the long backbone chains of polymers 
can affect the confirmation of the FFA molecules to disturb the intramolecular 
interaction of N-Hj∙∙∙O=C, indicating a downfield chemical shift of Hj of FFA in the 
presence of a polymer in solution in Figure 7. 7(a). Increasing the polymer 
concentration to 5000g/mL in solution, the chemical shifts of Hj and Hh peaks moved 
to opposite directions, i.e., an upfield (shielding) shift for Hh, and a downfield shift for 
Hj, suggesting a different interacting mechanism between the FFA and the polymer at 
the high concentration. The upfield shift of Hh peak was probably associated with the 
transition of a solution environment from hydrophilic to hydrophobic with increasing a 
polymer concentration, leading to hydrophobic interaction between FFA and polymer 
molecules [217, 332]. Obviously, the hydrophobic interaction affects the conformation 
of FFA molecules in solution, resulting in the change of the intramolecular interaction 
N-Hj∙∙∙O=C where the downfield shift of Hj peak was observed. Furthermore, broader 
1H NMR peaks of FFA in PVP solution were observed in comparison with those in 
PVP-VA solution, demonstrating that PVP can significantly suppress the mobility of 
FFA molecules in solution.   
The chemical shifts of NIC in Figure 7. 7(b) were not affected by PVP or PVP-VA at a 
lower concentration of 200g/mL, implying that there was no or weak interaction 




hydrogen bonding interactions between NIC and a polymer were formed, observing the 
downfield shifts of 1H NMR peaks of NIC. 
1H NMR spectra of TP are complex, which can be affected by interactions of 
solute-solvent, solute-solute and solute-polymer. In CDCl3, dimerization of TP 
molecules is found to be the dominating factor affecting the 1H chemical shifts of TP 
[334]. Because TPs are good proton donors, PVP or PVP-VA can disrupt TP dimers in 
solution, indicating downfield shifts of 1H NMR peaks of TP at a low polymer 
concentration of 200g/mL shown in Figure 7. 7(c). At a high polymer concentration, 
upfield (shielding) shifts for Hb, Hd and Hc of TP were observed. 
In the solid state of 1:1 FFA-NIC COs, hydrogen bonds are formed by two FFA and two 
NIC molecules, where Hi of carboxyl acid of the FFA and aromatic N of the first NIC 
form a hydrogen bond and the amide Ha or Hb of the second NIC forms a hydrogen 
bond with the carbonyl O atom of the acid of same FFA [234]. It seems that same 
interactions of FFA and NIC are formed in CDCl3, indicating the deshielding of 
chemical shifts of the Hh of FFA and Hc, Ha and Hb of NIC to downfield when equal 
molar FFA and NIC dissolved in CDCl3 in Figure 7. 8(a). Due to formation of a 
hydrogen bond of the carbonyl O atom of the acid of FFA with one NIC, the 
intramolecular N-Hj∙∙∙O=C was disrupted, resulting to the downfield movement of the 
chemical shift of Hj of FFA. 
It is suggested that a dimer of FFA and TP can be formed through Hi of carboxyl acid of 
FFA with N of C-N=CHb of TP [295], therefore, there is a significant chemical shift of 
Hh of FFA to downfield shown in Figure 7. 8(b). Because the C=O atom of the acid of 
the same FFA has not been involved in the intermolecular interaction with TP, the 
intramolecular N-Hj∙∙∙O=C of FFA is not disrupted, showing a constant chemical shift 





(a) FFA  
  = 𝐹𝐹𝐴 𝑖𝑛 𝑝𝑜𝑙𝑦𝑚𝑒𝑟 − 𝐹𝐹𝐴 𝑖𝑛 𝐶𝐷𝐶𝑙3 
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(c) TP  
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TP  = 𝐹𝐹𝐴−𝑇𝑃 − 𝑇𝑃 
 





7.3.3.3 1H NMR Analysis of Ternary Components   
Similar to the above, we only discussed experimental results of the mixtures of FFA at a 
concentration of 1000g/mL with its equal molar concentration of a coformer of NIC or 
TP in different concentrations of a polymer in CDCl3 shown in Figure 7. 9. 
At a low PVP concentration of 200g/mL in CDCl3, characteristic chemical shifts of the 
Hh and Hj of FFA moved to upfield, suggesting that some of hydrogen bonds between 
FFA and NIC have been disrupted due to the interactions of FFA and PVP shown in 
Figure 7. 9(a). In contrast, at the same PVP-VA concentration of 200g/mL in CDCl3, 
characteristic chemical shifts of the Hh and Hj of FFA were almost constant as those 
without the polymer, indicating that the interaction between FFA-NIC was a dominating 
force shown in Figure 7. 9(b). At a higher PVP or PVP-VA concentration of 
5000g/mL, chemical shifts of Hj and Hh peaks moved to opposite directions in Figure 
7. 9(a)-(b), indicating the hydrophobic interaction between FFA and the polymer 
became the dominating force suppressing the hydrogen bonding among FFA, NIC and 
the polymer. 
For a mixture of FFA and TP in CDCl3 in the presence of a lower concentration of PVP 
or PVP-VA of 200g/mL in Figure 7. 9(c)-(d), the chemical shift of Hh of FFA slightly 
moved to upfield while as the chemical shift of Hj of FFA slightly downfield shifts, 
indicating that hydrogen bonds between FFA and TP were disturbed by the polymer. At 
a higher PVP or PVP-VA concentration of 5000g/mL, chemical shifts of Hj and Hh 
peaks moved to opposite directions in Figure 7. 9(c)-(d) similar as those of a mixture of 
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Figure 7. 9 1H NMR spectra of FFA in an equal molar mixture of FFA and NIC or TP at difference 









 In this study, we have demonstrated that the supersaturated drug concentration 
generated by the cocrystal dissolution can be maintained through inclusion of a 
polymeric excipient in formulations, showing the improved dissolution performance of 
FFA-NIC COs or FFA-TP COs by a pre-dissolved polymer of PVP or PVP-VA in the 
donor cell in Figure 7. 5(a) [10, 183, 335]. In the presence of pre-dissolved PVP or 
PVP-VA in solution, the DPP of a FFA cocrystal system was much higher than that in 
solution without a pre-dissolved polymer in Figure 7. 5(a) and it was also proportional 
to the polymer concentration. However, an elevated drug concentration in the donor cell 
did not always improve the flux rate of FFA to the acceptor cell shown in Figure 7. 5(b). 
This erratic drug permeation could lead to poor drug bioavailability, which was 
crucially related to the amount of drug molecules going through the GI membrane. 
Therefore, it is critical importance to explore the interplay of the solubility and 
permeability in a cocrystal based formulation, similar to many other solubility enabling 
formulations, such as surfactants, cyclodextrins, cosolvents, or solid dispersions, where 
an enhanced drug solubility may lead to decrease, remain unchanged and even increase 
the drug permeability [25, 336-338]. The mechanism of the effects of a polymer on the 
dissolution behavior of cocrystals has been explored in our recent publication [335], 
indicating that a pre-dissolved polymer can interact with the crystal surface to alter the 
cocrystal dissolution properties for inhibition of the drug precipitation in solution. The 
discussion here was focused on the mechanistic understanding of the interactions among 
FFA, a coformer of NIC or TP and a polymer of PVP or PVP-VA in the solution which 
affect the maintaining of the supersaturated FFA concentration and subsequent 
permeation to the acceptor cell.         
Both PVP and PVP-VA are water soluble polymers, however, due to differences in their 
molecular structures in Table 7. 1, intermolecular interactions of polymer/FFA and 
polymer/coformer are different, which not only affect FFA nucleation and growth 
kinetics in solution [183] but also the permeation properties of FFA shown in Figure 7. 
5(b). Interestingly, for a given FFA cocrystal formulation of FFA-NIC CO or FFA-TP 
CO at the same polymer concentration, the DPP of the formulation in the presence of 
the PVP-VA was always higher than that of the same formulation in the presence of 




formulation in the presence of the PVP-VA could be higher or lower than that of the 
same formulation in the presence of the PVP, depending on the polymer concentration. 
Furthermore, in the presence of PVP-VA, the FFA flux rate across the membrane for a 
given formulation is in inverse to its DPP while as it is proportional to its DPP in the 
presence of PVP except 16000µg/mL PVP. Therefore, a wrong conclusion could be 
drawn if only the DPP of a cocrystal formulation is considered.     
Based on the solubility results in Figure 7. 1, it was suggested that PVP acted as a 
stabilizing agent in the formulation because the equilibrium solubility of FFA did not 
increase significantly over the whole range of the concentrations studied. The hydrogen 
bonding interaction of FFA and PVP molecules should be a dominant force at a low 
PVP concentration (below 4000g/mL), confirmed by the solution 1H NMR spectra of 
FFA showing the downfield chemical shifts of Hh of FFA in Figure 7. 7(a). Maintaining 
the supersaturated FFA concentration should be achieved through inhibiting FFA 
nucleation by PVP in Figure 7. 3(c1, c3) [183], leading to the increased FFA flux rate 
from the donor cell to the acceptor cell in Figure 7. 3(c2, c4). The flux rate was 
determined by the degree of supersaturation (ratio of dissolved amount of unchanged 
API to its thermodynamic solubility), which was the driving force for transporting the 
drug substance across the membrane [337]. The FFA flux rate achieved by the FFA-TP 
COs is higher than that of FFA-NIC COs because FFA-TP COs can generate a higher 
FFA supersaturation due to the bulk precipitation dissolution mechanism [335]. When 
the PVP concentration was above 4000g/mL, the interaction force between FFA and 
PVP has changed into hydrophobic interactions dominantly due to confined spaces 
between FFA and PVP molecules, showing the upfield chemical shifts of Hh of FFA in 
Figure 7. 7(a). It has to stress that micellization of PVP did not occur due to its rigorous 
backbone structure and there was no significant change of the equilibrium solubility of 
FFA in Figure 7. 1. Consequently, the FFA mobility in solution was reduced at a higher 
PVP concentration, illustrated by a broaden peak of Hj of FFA in Figure 7. 7(a), 
resulting in stabilizing the FFA supersaturated solution in Figure 7. 3 (c3). Reduced 
FFA flux rate at a PVP concentration of 16000g/mL in Figure 7. 5(b) was caused by 
the combined factors of reduced dissolution performance of the cocrystals in Figure 7. 
3(c5) and reduced solute activity coefficient [339]. Although the interaction of FFA and 




1H NMR analysis of binary components in Figure 7. 7 and 1H NMR analysis of ternary 
components in Figure 7. 9, the role of PVP as a stabilizing agent in the formulation did 
not change, supported by the evidence of a minor change of the FFA solubility curves 
with or without pre-dissolved coformer in Figure 7. 1. Therefore, the FFA flux rate to 
the acceptor cell depends solely on the DPP of a cocrystal formulation, where the 
maximal FFA flux rate was obtained by the FFA-TP CO formulation in the presence of 
4000g/mL of PVP.  
Based on the FFA solubility curve in Figure 7. 1, PVP-VA showed a transitional role in 
a cocrystal formulation, depending on its concentration. At a lower PVP-VA 
concentration up to 1000g/mL without a pre-dissolved coformer of NIC or TP, it 
should be treated as a stabilizing agent in the formulation because the equilibrium 
solubility of FFA did not increase in Figure 7. 1. The downfield chemical shifts of Hh of 
FFA in Figure 7. 7(a) indicated the formation of the hydrogen bonding interactions of 
FFA and PVP-VA in solution. Compared with PVP, PVP-VA is more hydrophobic and 
flexible due to the addition of hydrophobic monomer vinyl acetate (VA), leading to 
micellization at a higher concentration [340]. The critical micelle concentration (CMC) 
of PVP-VA was found to be 1000g/mL in absence of coformer in this study. Therefore, 
above 1000g/mL of PVP-VA concentration, the FFA solubility increases significantly 
with an elevated PVP-VA concentration. On the basis of the solution 1H NMR spectra 
of FFA, showing the upfield chemical shifts of Hh of FFA in a higher PVP-VA solution 
in Figure 7. 7(a), it was concluded that encapsulation of FFA in PVP-VA micelles took 
place. The role of PVP-VA has changed to be a solubilization agent in the cocrystal 
formulation. In the presence of a coformer of NIC or TP in solution, a significant 
increase in the solubilization capacity of PVP-VA was observed in Figure 7. 1. It was 
likely the consequence of the association of PVP-VA and a coformer in Figure 7. 
7(b)-(c) to provide an expanded region the inner core for drug solubilization [341]. The 
CMC of PVP-VA was reduced significantly to be around 200g/mL, where the 
equilibrium solubility of FFA started to increase in Figure 7. 1. Therefore PVP-VA 
became a solubilization agent in the cocrystal formulations regardless its concentration. 
Due to increased FFA equilibrium solubility, DPPs of the FFA cocrystal formulations 
are proportional to the PVP-VA concentration in Figure 7. 5(a). From a thermodynamic 




fundamentally different from supersaturation solutions generated in the presence of the 
stabilizing agent of PVP in the formulation. Solubilizing additives increase 
concentration by increasing the equilibrium solubility rather than increasing chemical 
potential, showing a reduction in FFA flux rate across the membrane with an increased 
PVP-VA concentration in Figure 7. 5(b) which is consistent with many other enabling 
formulation studies [25, 336-338]. The maximal FFA flux rate was obtained from the 
FFA-TP CO formulation in the presence of the lowest PVP-VA concentration of 
200g/mL.  
In conclusion, the permeation preformation of a FFA cocrystal formulation is 
determined by the combination of several factors together, including the type of a 
polymer, the polymer concentration and coformer. In particular, the interaction between 
a polymeric excipient with the coformer could play a key role for the improved 
absorption of APIs studied. 
7.5 Chapter Conclusion 
In this work, we examined the dissolution and permeation performances of two 
cocrystals of FFA-NIC COs and FFA-TP COs in the presence of two polymers of PVP 
and PVP-VA in solution using a dissolution/permeation (D/P) system. The study 
showed that the type of a polymer, its concentration and the interaction of the polymer 
with a coformer in solution had significantly effects on the dissolution and permeation 
performances of FFA cocrystals. It was found that the role of PVP as a stabilizing 
agency the formulations has not been altered in spite of the interactions with the 
coformer of NIC or TP in solution, indicating the FFA flux rate from the donor cell to 
the acceptor cell depends solely on the DPP of a cocrystal formulation. Through 
selection of an appropriate PVP concentration in solution, the maximal FFA flux rate 
can be obtained for a given FFA cocrystal formulation. The situation is complicated in a 
cocrystal formulation in the presence of PVP-VA. The role of PVP-VA in the 
formulation can be changed due to the association of PVP-VA and a coformer, 
particularly a transition from a stabilizing agent to a solubilization agent at a very low 
polymer concentration. Therefore, it is found that in the presence of PVP-VA the FFA 
flux rate across the membrane in a given formulation is in inverse to its DPP. The 




of a very low concentration of PVP-VA. Solution 1H NMR is approved to be a powerful 
tool in which the atomic-level information of molecular interactions among FFA, 
coformers and polymers have been revealed. In conclusion, in order to design an 
optimal cocrystal formulation, we need to explore scientific approaches through 
mechanistic understanding of the molecular state of drug molecules among API, 
coformer and plyometric excipients to determine the optimal solubility-permeability 





Chapter 8 Conclusions and Future works  
Conclusions  
This dissertation has focused on investigating the dissolution and permeation properties 
of two cocrystals of FFA-NIC CO and FFA-TP CO in order to design an effective 
cocrystal formulation. The specific goals of the study were to (1) develop a strategy for 
selecting desirable polymers to prevent the recrystallization of FFA in supersaturated 
cocrystals solution; (2) reveal the dissolution mechanism of FFA I and FFA cocrystals 
and explore how the polymers alter the dissolution pattern of FFA cocrystals and (3) 
evaluate the underlying relationship between supersaturated state and permeation 
property of cocrystals during dissolution in presence of pre-dissolved polymers. 
The influence of the three polymers PEG, PVP, and PVP-VA on the FFA crystallization 
in three different supersaturated solutions of the pure FFA and two cocrystals of 
FFA-NIC CO and FFA-TP CO has been investigated by measuring nucleation induction 
times and desupersaturation rates in the presence and absence of seed crystals. It was 
found that the ability of these three polymers on inhibiting the crystallization of FFA is 
different. Furthermore, it was found that the competition of intermolecular hydrogen 
bonding among drug/coformer, drug/polymer, and coformer/polymer was a key factor 
responsible for maintaining the supersaturation through nucleation inhibition and crystal 
growth modification in a cocrystal solution. Supersaturated cocrystal solutions with 
predissolved PEG demonstrated the effectiveness at stabilizing supersaturated solution 
compared to pure FFA in the presence of the same polymer. In contrast, the two 
cocrystal solutions in the presence of PVP or PVP-VA did not perform as well as pure 
FFA with the same predissolved polymer. This study suggested that the selection of a 
polymeric excipient in a cocrystal formulation should not be solely dependent on the 
interplay of the parent drug and polymer without considering the coformer effects. 
Effects of the three polymers, PEG, PVP, and PVP-VA, on the dissolution behavior of 
cocrystals of FFA-TP CO and FFA-NIC CO were investigated at multiple length scales. 
At the molecular level, the interactions of a crystal surface with a polymer by observing 
etching pattern changes using AFM. At the macroscopic scale, dissolution rates of 




retreated velocities of the faces using OLM. In the bulk experiments, the FFA 
concentration in a dissolution medium in the absence or presence of a polymer was 
measured under both sink and non-sink conditions. It has been found that the 
dissolution mechanisms of FFA-TP CO are controlled by the defect sites of the crystal 
surface and by precipitation of the parent drug as individual crystals in the bulk fluid. In 
contrast, the dissolution mechanisms of FFA-NIC CO are controlled by the surface 
layer removal and by a surface precipitation mechanism, where the parent drug 
precipitates directly onto the surface of the dissolving cocrystals as a coating layer. 
Through controlling the dissolution environment by pre-dissolving the polymer, PVP or 
PVP-VA, which can interact with the crystal surface to alter its dissolution properties, 
the advantages of the improved solubility and dissolution rates of the FFA-TP CO and 
FFA-NIC CO can be demonstrated. 
The dissolution and permeation performances of the FFA-NIC CO and FFA-TP CO in 
the presence of two polymers of PVP and PVP-VA were systematically examined using 
a dissolution/permeation (D/P) system separated. The study showed that the type and 
concentration of a polymer and its interaction with a coformer in solution had 
significant effects on the dissolution and permeation performances of FFA cocrystals. 
The role of PVP as a stabilizing agent in the formulations was not altered in spite of its 
interaction with the coformer of NIC or TP in solution, indicating that the FFA flux rate 
into the acceptor cell was proportional to the dissolution performance parameter (DPP) 
of a cocrystal formulation. In presence of PVP-VA, the situation was complex for FFA 
cocrystal. The role of PVP-VA seemed to be changed due to its association with a 
coformer, i.e., PVP-VA transited from a stabilizing agent to a solubilization agent at a 
very low polymer concentration. An inverse relationship of the FFA flux rate and its 
DDP of FFA cocrystals was found in the presence of PVP-VA. The maximal FFA flux 
rate can only be achieved at a very low concentration of PVP-VA. Finally, the 
interactions among FFA, coformers and polymers were analyzed at atomic level to gain 
insight into the mechanism of the supersaturated solution and subsequent permeation 





The future directions can focus on carrying on more fundamental researches on 
selecting suitable polymers in cocrystal formulation system, scale up, animals test and 
finally commercial cocrystal products. 
Cocrystals have been demonstrated that can improve the solubility, increase the 
dissolution rate and create a supersaturated state of poorly water solution drugs. But the 
advantages of cocrystals are reduced because of the recrystallization of stable form in a 
supersaturated solution. This problem is one of the challenges for developing cocrystals 
formulation. Although the pre-dissolved polymers can inhibit the recrystallization of 
API, the mechanism under the effect of polymers on cocrystals has not been fully 
revealed. More efforts should be made to design a model for predicting the effect of 
polymers. 
The other challenge of cocrystals is to find an effective method to scale up the cocrystal 
synthesis. Generally, stirred tanks is a convenient option for scale up crystals, but it is 
not suitable for cocrystals because the harsh requirement of the solubility of cocrystal 
components. Mechanochemical methods of solid-state grinding is difficult to produce 
pure cocrystals. Therefore, it is important to find a way to scale up the cocrystal. 
So far, animal studies on cocrystals’ bioavailability is rare. Only few studies were 
carried on for exploring the pharmacokinetic properties of cocrystals and found out that 
not all pharmaceutical cocrystals can improve the pharmacokinetics compared to the 
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A1 Figures and Tables for Chapter 4 
Table A1. 1 Summary of IR peak identities of FFA I, NIC, TP, FFA-NIC CO and FFA-TP CO 
 
  
Sample Peak position (cm-1) Function group 







Pyridine ring stretching 




-N-H stretching of NIC 
-N-H stretching of FFA 
-(C=O)- stretching of FFA 












-N-H stretching of FFA 
-N-H stretching of TP 
-(C=O)- stretching of TP 
-(C=O)- stretching of FFA 















 peak (cm-1) 
NH stretching 3319 --------- 3321 
CH stretching 3064 3056/309
2 
3060/3082 
C=O stretching ------- 1669 ----- 
Benzene ring stretching coupled with in-plane 
NH deformation and CN stretching. 
1515 ------------ 1513w 
In-plane CH deformation coupling with 






C=O stretching 1397 ------------
--- 
1402 
CN and C=C stretching 1331 ------------
-- 
1327 
In-plane CH deformation, CN stretching 
combined with in-plane NH deformation 
1244 ------------
- 
1246,1256 (double peak) 
pyridine ring stretching ------- 1155 1158 
in-plane C-OH bending 1162 --------- 1158 





In-plane CH blending ------ 1121 1097 
NH2 rock -------- 1092vw 1097vw 
pyridine ring stretching -------- 1041 1029, 1043 (double peak) 
out-of-plane CH bending ------- 832 -------------- 
In-plane ring bending  784 794 
Vibrations of CF3 648, 756 --------- 649,749 
(b) 
 











NH stretching 3319 3122 3269, 3077 
CH stretching 3064 --------- 3077 
C=O stretching ------- 1706, 1663 1710, 1661 
C-C stretching ------ 1611 1613 
Benzene ring stretching coupled with in-plane NH 
deformation and CN stretching. 
1515 ------------ 1520 










CN and C=C stretching 1331 -------------- 1332 
In-plane CH deformation, CN stretching combined 
with in-plane NH deformation 
1244 1249 1258 
in-plane C-OH bending 1162 --------- 1161, 1165 
double peaks 
Antisymmetric CF3 structure 1100 ---------- 
 
1100 
N-CH3 stretching  -------- 1090, 1054 1100, 1051 
CH3 rocking -------- 970  965 
Imidazole in-plane ring deformation  ------- 928 930 
Pyrimidine In-plane ring deformation ------- 662 686 
Vibrations of CF3 648, 760 ------- 651, 746 






A2 Figures and Tables for Chapter 5 
Table A2. 1 SP values of FFA, NIC, TP, and polymers 
NIC 
 
Group Fdi Fpi2 Ehi 
=CH-(4) 800 0 0 
=C- (1) 70 0 0 
 (1) 
290 592900 4500 
-NH2 (1) 280 - 8400 
-N=(1)  164 1750329 1759 








Group Fdi Fpi2 Ehi 
CH3(2) 840 0 0 
=CH (1) 200 0 0 
=C-(2) 140 0 0 
 (2) 
40 2560000 10000 
 (2)  
580 2371600 4000 
-NH- (1) 160 44100 3100 
=N-(1) 164 1750329 1759 








Group Fdi Fpi2 Ehi 
-CH2-(2) 540 0 0 
-O- (1) 100 160000 3000 











Group Fdi Fpi2 Ehi 
-CH2-(4) 1080 0 0 
(1) 
80 0 0 
(1) 
20 640000 5000 
(1) 
290 592900 2000 
Sum  1470 1232900 7000 
Vm=M/ρ=111(g/mol)/1.17(g/cm3)=94.9(cm3/mol) 






Group Fdi Fpi2 Ehi 
-CH3- (1) 420 0 0 
-CH2-(5) 1350 0 0 
(2) 
160 0 0 
(1) 
20 640000 5000 
(1) 
290 592900 2000 
-coo-(1) 390 240100 7000 
Sum 2630 1473000 14000 
Vm=M/ρ=197(g/mol)/1.27(g/cm3)=155.1 (cm3/mol) 








Figure A2. 1 FTIR examining results of solid residuals after solubility test: (a) FFA; (b) FFA-NIC CO; (c) 
FFA-TP CO 































FFA-TP CO IN PVP





Figure A2. 2 Test results of solids collected after the seeded desupersaturation experiments (pictures): (a) 
DSC results: (b) images of solid residuals 
 FFA solution FFA-NIC CO solution  FFA-TP CO solution 
cosol
vent 
   
PEG 
   
PVP 
   
PVP-
VA 






 Initial FFA I seeds 
 
 
 FFA FFA-NIC CO FFA-TP CO 
Cosolvent 
   
PEG 
   
PVP 
   
S-630 






Figure A2. 3 Test results of solids collected after the unseeded desupersaturation experiments: (a) DSC 
results: (b) images of solid residuals 
 FFA solution FFA-NIC CO solution  FFA-TP CO solution 
coso
lvent 
   
PEG 
   
PVP 
   
PVP
-VA 






 FFA FFA-NIC CO FFA-TP CO 
Cosolvent  
   
PEG 
   
PVP 
   
S-630 






A3 Figures and Tables for Chapter 6 
Table A3. 1 Crystal structure data and details of refinements 





































































Figure A3. 2 Characterization of solid residues after FFA I equilibrium experiments in PBS in the absence 






































Figure A3. 5 AFM images 
Crystal Before dissolution  PBS PEG PVP PVP-VA 
FFA 80x80µm2 
     
20x20µm2 
     
FFA-TP CO 80x80µm2 
     
  
  
    





     
FFA-NIC CO 20x20µm2 
     
10x10µm2 
   
  
 
    
    




Figure A3. 6 Three-dimensional AFM images at a 40x40 µm2 scan area 
Crystal Before Dissolution PBS PBS with Pre-dissolved PEG PBS with Pre-dissolved PVP PBS with Pre-dissolved 
PVP-VA 
FFA 
     
FFA-TP CO 










Figure A3. 7 OLM images 
Crystal Polymers Face 
index 
0h 2h 4h 6h 






    
PEG 100 








    
PVP 100 
    
0-11 
    
PVP-VA 100 









    
FFA-TP 
CO 
pH 6.8 001 
 
   
 100 
    
PEG 001 









    
PVP 001 
    
 100 
    
PVP-VA 001 
 










   
FFA-NIC 
CO 
pH 6.8 01-1 
and 100 
 
    
PEG 01-1 
and 100 
    
PVP 01-1 
and 100 
















Figure A3. 8 DSC thermographs characterization of solid residues after un-sink condition dissolution: (a) 












Figure A3. 9 IR results of solid residues after un-sink condition dissolution: (a) FFA; (b) FFA-NIC CO; 











A4 Figures and Tables for Chapter 7 
Table A4. 1 1H NMR samples 




FFA  5000 g/mL, 1000 g/mL and 500 g/mL. 
NIC 2150 g/mL, 430 g/mL  and 215 g/mL  
TP 3200 /mL, 640 g/mL, and 320 g/mL 
PVP 200 g/mL and 5000 g/mL 
PVP-VA 200 g/mL and 5000 g/mL 
Binary 
components 
FFA/NIC  (5000 g/mL FFA, 2150 g/mL NIC), (1000 g/mL FFA, 430 
g/mL NIC) and (500 g/mL FFA, 215 g/mL NIC). 
FFA/TP (5000 g/mL FFA, 2150 g/mL TP), (5000 g/mL FFA, 430 
g/mL TP) and (5000 g/mL FFA, 215 g/mL TP)  
FFA/PVP (5000 g/mL FFA, 200 g/mL PVP), (5000 g/mL FFA, 5000 
g/mL PVP), (1000 g/mL FFA, 200 g/mL PVP), (1000 g/mL 
FFA, 5000 g/mL PVP), (500 g/mL FFA, 200 g/mL PVP), (500 
g/mL FFA, 5000 g/mL PVP) 
FFA/PVP-VA (5000 g/mL FFA, 200 g/mL PVP-VA), (5000 g/mL FFA, 5000 
g/mL PVP-VA), (1000 g/mL FFA, 200 g/mL PVP-VA), (1000 
g/mL FFA, 5000 g/mL PVP-VA), (500 g/mL FFA, 200 g/mL 
PVP-VA), (500 g/mL FFA, 5000 g/mL PVP-VA) 
NIC/PVP (2150 g/mL NIC, 200 g/mL PVP), (2150 g/mL NIC, 5000 
g/mL PVP), (430 g/mL NIC, 200 g/mL PVP), (430 g/mL NIC, 
5000 g/mL PVP), (215 g/mL NIC, 200 g/mL PVP), (215 
g/mL NIC, 5000 g/mL PVP) 
NIC/PVP-VA (2150 g/mL NIC, 200 g/mL PVP-VA), (2150 g/mL NIC, 5000 
g/mL PVP-VA), (430 g/mL NIC, 200 g/mL PVP-VA), (430 
g/mL NIC, 5000 g/mL PVP-VA), (215 g/mL NIC, 200 g/mL 
PVP-VA), (215 g/mL NIC, 5000 g/mL PVP-VA) 
TP/PVP (3200 g/mL TP, 200 g/mL PVP), (3200 g/mL TP, 5000 g/mL 
PVP), (640 g/mL TP, 200 g/mL PVP), (640 g/mL TP, 5000 
g/mL PVP), (320 g/mL TP, 200 g/mL PVP), (320 g/mL TP, 
5000 g/mL PVP) 
TP/PVP-VA (3200 g/mL TP, 200 g/mL PVP0VA), (3200 g/mL TP, 5000 
g/mL PVP-VA), (640 g/mL TP, 200 g/mL PVP-VA), (640 
g/mL TP, 5000 g/mL PVP-VA), (320 g/mL TP, 200 g/mL 
PVP-VA), (320 g/mL TP, 5000 g/mL PVP-VA) 
ternary 
components 
FFA/NIC/PVP (5000 g/mL FFA, 2150 g/mL NIC, 200 g/mL PVP), (5000 




 FFA, 430 g/mL NIC, 200 g/mL PVP), (1000 g/mL FFA, 430 
g/mL NIC, 5000 g/mL PVP),    (500 g/mL FFA, 215 g/mL 
NIC, 200 g/mL PVP) and (500 g/mL FFA, 215 g/mL NIC, 
5000 g/mL PVP). 
FFA/NIC/PVP-VA (5000 g/mL FFA, 2150 g/mL NIC, 200 g/mL PVP-VA), (5000 
g/mL FFA, 2150 g/mL NIC, 5000 g/mL PVP-VA), (1000 
g/mL FFA, 430 g/mL NIC, 200 g/mL PVP-VA), (1000 g/mL 
FFA, 430 g/mL NIC, 5000 g/mL PVP-VA),    (500 g/mL 
FFA, 215 g/mL NIC, 200 g/mL PVP-VA) and (500 g/mL FFA, 
215 g/mL NIC, 5000 g/mL PVP-VA). 
FFA/TP/PVP (5000 g/mL FFA, 3200 g/mL TP, 200 g/mL PVP), (5000 
g/mL FFA, 3200 g/mL TP, 5000 g/mL PVP), (1000 g/mL 
FFA, 640 g/mL TP, 200 g/mL PVP), (1000 g/mL FFA, 640 
g/mL TP, 5000 g/mL PVP),    (500 g/mL FFA, 320 g/mL 




(5000 g/mL FFA, 3200 g/mL TP, 200 g/mL PVP-VA), (5000 
g/mL FFA, 3200 g/mL TP, 5000 g/mL PVP-VA), (1000 g/mL 
FFA, 640 g/mL TP, 200 g/mL PVP-VA), (1000 g/mL FFA, 640 
g/mL TP, 5000 g/mL PVP-VA), (500 g/mL FFA, 320 g/mL 
TP, 200 g/mL PVP-VA) and (500 g/mL FFA, 320 g/mL TP, 
5000 g/mL PVP-VA). 
 
Figure A4. 1 The full 1H NMR spectra of the experiments 



























































































































































































































Journal Publications  
[1] Qiu, S., et al., Role of polymers in solution and tablet-based carbamazepine 
cocrystal formulations. CrystEngComm, 2016. 18(15): p. 2664-2678. 
[2] Guo, M., et al., Investigating the Influence of Polymers on Supersaturated 
Flufenamic Acid Cocrystal Solutions. Molecular Pharmaceutics, 2016. 13(9): p. 
3292-3307. 
[3] Guo, M., et al., Insight into Flufenamic Acid Cocrystal Dissolution in the 
Presence of a Polymer in Solution: from Single Crystal to Powder Dissolution. 
Molecular Pharmaceutics, 2017. 
[4] Investigating Permeation Behavior of Flufenamic Acid Cocrystals using A 
Dissolution and Permeation System. Publication in preparation. 
Conference Publications  
[1] “Understanding the dissolution behaviors of Flufenamic acid cocrystals by 
investigating powder dissolution and single crystal dissolution”, 4th Quality by 
Design Symposium, Leicester.March 2017 
[2] “Investigation of the Effect of Polymers on the Phase Transformation 
Flufenamic Acid Cocrystal”, 4th Int. Pharm. Tech. Conference, Leicester. 
November 2016. 
[3] “Investigation of the Effect of Polymers on the Phase Transformation 
Flufenamic Acid Cocrystal”, 4th Quality by Design Symposium,Leicester. 
March 2016 
[4] “Effects of polymers on solubility of Flufenamic acid-Nicotinamide cocrystal”, 




Oral Presentations  
[1] “Understanding the Effects of Polymeric Excipients on Recrystallization of 
Flufenamic Acid Cocrystals in solution”, East Midlands Universities Association 
(EMUA) postgraduate research student conference; Loughborough University. 
September 2016. 
[2] “Understanding the Effects of Polymeric Excipients on Recrystallization of 
Flufenamic Acid Cocrystals in solution”, Crystal Growth of Organic Material/ 
British Association of Crystal Growth 2016, Leeds University. June 2016.  
[3] “Investigating the role of polymers on solubility and dissolution rates of 
flufenamic acid cocrystals”, Crystal Growth of Organic Material/ British 
Association of Crystal Growth 2015, Queen Mary, University of London.     
June 2015. 
[4]  “Mechanism of Flufenamic Acid Cocrystals Dissolution Behaviors in Presence 
of Polymers”, HLS postgraduate student conference, De Montfort University. 
March 2015. 
 
 
 
 
 
 
